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Abstract 
The heart, the first organ to function in developing vertebrate embryos
1
, is affected by 
congenital defects in roughly 1% of the worldwide human population. These abnormalities 
frequently require treatment for the entire lifespan of the affected individual
2,3
. 
 
microRNAs are an exciting class of non-coding regulatory genes that are known to be 
essential for the heart development of many organisms
4,5
. A miRNA becomes incorporated 
into the miRNA-induced silencing complex, which binds to a target mRNA transcript and 
inhibits its translation. Dysregulation of miRNAs is associated with failing human hearts
6
. 
More than 2,500 mature human miRNAs are currently annotated, and with each miRNA 
predicted to potentially target several hundred transcripts, the further study of these 
molecules is vital for the complete understanding of cardiac biology. 
 
A miRNA expression profile in the chick heart, a model of human heart development, over 
several stages of embryonic development was generated by next generation sequencing. 
Two novel chick miRNAs were discovered, and 31 known animal miRNAs not yet 
annotated in the chick genome were discerned. The predicted targets of three miRNAs 
thought to be essential for heart development, miR-130, miR-138, and miR-499, were 
examined in vitro. Twelve genes were confirmed as targets of at least one of these three 
miRNAs by luciferase reporter assay, including genes in the Wnt signalling pathway which 
is essential at specific stages of heart development
7
. 
 
The roles of miR-1, known to be indispensable for heart formation and function, were also 
studied in the developing chick heart. Two targets of miR-1, FZD7 and RARβ, had been 
identified in vitro
8
. This study showed that inhibition of miR-1 in the HH14 chick resulted 
increased FZD7 and RARβ protein levels, as well as in delayed development, possibly due 
to a loss of inhibition of canonical Wnt signalling in the epicardium. 
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1 Introduction 
1.1 Chick heart development 
During vertebrate development, the heart is the first organ to form and function
1
. An 
estimated 1% of the worldwide population is born with congenital defects to the heart, 
many of whom will require treatment during their entire lifespan
2,3
. Cardiovascular disease 
is a very frequent cause of adult morbidity and mortality in humans, affecting even those 
patients not born with known heart abnormalities
2
. The study of heart development is 
essential to further our understanding of, and leading to prevention of, the factors 
influencing diseases of the heart. The very early heart is a simple contractile tube 
composed of striated muscle, called myocardium, which pumps oxygen and nutrients 
through the developing embryo. Mammalian and chicken embryos share many of the basic 
mechanisms of early heart development
9
 and, like mammals, the fully developed chicken 
heart has four chambers
1
. Along with their relatively short developmental period, the ease 
with which fertilized eggs can be obtained and the many molecular techniques that can be 
used to study heart development in ovo, this similarity makes the use of G. gallus as a 
model organism for heart development very attractive. A summary of incubation times that 
correspond to chick developmental stages, the Hamburger-Hamilton stages of 
development
10
, can be found in Table Apx E.1. This section aims to give a brief overview 
of some of the major events during early chick heart development that were examined for 
miRNA expression by Next Generation Sequencing. 
 
The first microRNA genes identified, lin-4 and let-7, were discovered during studies into 
the effect of loss-of-function mutations which caused notable defects in developmental 
timing in Caenorhabditis elegans
11-13
. The depletion of the miRNA-processing enzyme 
Dicer in mouse embryos resulted in the arrest of development during gastrulation, 
demonstrating that microRNA function is vital for successful early vertebrate 
development
14,15
. The importance of microRNAs during development has further been 
indicated by studies showing that these molecules have essential roles during C. elegans 
2 
 
and D. melanogaster development, both as on-off switches and as fine-tuners of gene 
expression
16
. A study performed in chick embryos by examining the expression patterns of 
microRNAs by locked nucleic acid (LNA) in situ hybridization (ISH) found 75 
microRNAs to be expressed consistently in specific regions and/or cell layers, confirming 
the extent of their role during chick development
17
. 
 
Given the wide-ranging effects of miRNAs during development, this study aimed to 
discover miRNAs that are involved in the early stages of heart development by 
determining a profile of miRNA expression patterns during these early stages in the heart 
and surrounding tissues, and testing the effects of a selected few miRNAs.  
1.1.1 Up to HH4 
The epiblast and the hypoblast are the two cell layers that chick embryos consist of before 
the start of gastrulation. Cardiac progenitors have been identified in the epiblast prior to 
gastrulation, and the first embryonic cells to gastrulate include these progenitors
18
. After 
undergoing an epithelial-to-mesenchymal transformation, cells in the epiblast enter the 
primitive streak and form the mesodermal layer
19
. By HH3 cardiac progenitor cells (CPCs) 
can be found in the rostral half of the primitive streak, from an area caudal to Hensen’s 
node, with at least two discrete subpopulations present that will contribute to either the 
cardiomyocyte or the endocardial cell lineage (Figure 1.1A)
18
. 
 
 
Figure 1.1: A model of a stage HH3 and a HH5-7 chick embryo, showing the position of the cardiac precursor 
cells (CPCs) in the primitive streak (A) and indicating the path they follow when migrating out of the streak (B). 
Hensen’s node is shown in yellow. The relative positions of cell populations that will give rise to the atria, 
atrioventricular canal and left ventricle (blue) and those that will form the right ventricle, conus and truncus 
(red) are indicated
20
. 
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Cells that will eventually form the anterior structures of the heart are located more rostrally 
(Figure 1.1, red) to those that will form the posterior structures (Figure 1.1, blue)
21
. CPCs 
have left the primitive streak by HH4, migrating to form the cardiogenic regions indicated 
in Figure 1.1B. 
1.1.2 HH5 to HH7 
The CPCs have migrated out of the primitive streak into the anterior mesoderm by HH4, 
and the bilateral primary heart fields are established in the splanchnic mesoderm layer 
located directly above the endoderm by HH5 – HH718,19. The primary heart field stretches 
from slightly above Hensen’s node to about a quarter of the length of the primitive streak 
and laterally almost to the edge of the area pellucida at HH4
18,19
. Although specified, CPCs 
are not yet completely committed to a cardiac fate; it has been shown that cells still present 
in the caudal primitive streak at HH5 can form heart tissue if left in contact with the 
anterior endoderm, indicating that cardiac inducing factors arise from the anterior 
endoderm at this stage
18
. Once the CPCs have migrated out of the primitive streak and 
formed the primary heart fields at HH5 (Figure 1.1B), the transcription factor Nkx2.5 is 
expressed in cells that have a ventricular fate
21
. 
 
Between HH6 and HH7, concurrent with neurulation and the formation of the first three 
somites, CPCs become increasingly committed to their fate and by HH7 terminal 
myocardial differentiation markers can be detected in the primary heart fields
18
. Cardiac 
tissue development is strongly inhibited by anterior neural tissue and more weakly 
inhibited by posterior neural tissue. Between HH5 and HH8 small groups of cells 
delaminate from the splanchnic mesoderm and become situated between the developing 
myocardium and the endoderm; these presumptive endocardial cells then migrate to form 
the endocardial heart tubes
18,19
. 
1.1.3 HH8 to HH10 
Between HH7 and HH8 the primary heart field extends up to the level of the first somite 
and by HH8 it is level with the fourth somite
18
. At HH8, just before the bilateral heart 
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fields fuse, pre-migratory cardiac neural crest (CNC) cells are located in the most dorsal 
part of the embryo, between the mid-otic placode and level with the primary heart field at 
the caudal limit of somite 3
18
. The cardiogenic mesoderm, up to now bilateral, starts the 
process of fusing at the midline during HH8 and is fused at the midline by HH9, whilst at 
the same time cardiomyocytes start the process of differentiation
18,19,22
. CNC cells start to 
migrate from the neural crest towards the outflow tract aorticopulmonary (AP) septum and 
towards the pharyngeal arch arteries at HH9 and continue their migration during HH10
18
. 
Outflow tract septation depends on these migrating CNC cells. By HH10 both the 
endocardial tubes and the myocardium have fused, and the heart tube begins to beat despite 
a portion of the outflow tract close to the ventral pharynx still being open
18
. 
1.1.4 HH11 to HH13 
The heart tube continues to lengthen and starts to loop to the right until HH12 as a result of 
inward migration, via the inflow tract (Figure 1.2A, darker blue) and the outflow tract 
(Figure 1.2A, orange), of newly differentiated myocardium
18,19,22
. Once myocardial 
differentiation starts, progenitor cells stop proliferating for some time and therefore growth 
of the heart at this stage results mostly from this inward migration despite the fast cycling 
time of myocardial progenitor cells
22
. At HH12 the late migration of CNC cells into the 
pharyngeal arch arteries starts, eventually resulting in the remodelling of the pharyngeal 
arch artery
18
. 
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Figure 1.2: Adapted schematic drawings of HH14 to HH17 chick embryos.
18
 A: Cardiac progenitors add 
to the looping heart by migrating in through the inflow (darker blue) and outflow (orange) tracts. The migrating 
proepicardial cells, shown in yellow, originate from the proepicardial organ in the splanchnic mesoderm and 
migrate over the myocardium and will eventually cover the heart. B: This lateral drawing of an HH17 chick 
embryo shows cardiac neural crest cells (green) migrating through the branchial arches 3, 4 and 6. The 
proepicardial organ is shown in yellow. 
 
1.1.5 HH14 to HH16 
Further cardiac looping, resulting in the c-shaped heart transforming into an s-shaped heart, 
starts around HH13 with the primitive atria being positioned closer to the outflow tract and 
the primitive ventricular bend moving to a more caudal position relative to the forming 
atria (Figure 1.2A)
18
. Between HH13 and HH15 the dorsal mesocardium, which had up to 
now attached the heart tube to the ventral pharynx, breaks and disappears making this 
movement of the heart tube possible
18,22
. By HH13 CNC no longer produces CNC cells; 
the late migrating CNC cells reach aortic arch 3
18
. At about HH14, once anterograde 
circulation has started, ventricular myocardial cells become proliferative again and as a 
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result the ventricles distend outward
22
. However, myocardial cells in the atrioventricular 
(AV) canal and in the outflow tract do not proliferate in a similar way
22
. Proepicardial cells 
migrate from the proepicardial organ, over the developing myocardium of the heart, to 
form the epicardium as well as smooth muscle cells (Figure 1.2A, B)
18
. The process of 
atrial septation starts at HH16
18
. Additional cardiac looping moves the sinus venosus from 
a position caudal to the atria, to one dorsal to the atria between HH14 – HH1818. 
1.1.6 HH17 to HH20 
By HH17 to HH18 the epicardium, myocardium, cardiac jelly and endocardium layers of 
the heart have formed (Figure 1.3)
18
. The myocardium consists of an outer layer, the 
highly mitotic compact myocardium, and an inner layer, the less mitotic trabeculated 
myocardium
18
. Research has shown that the compact myocardium is necessary for 
myocardial growth; this layer becomes slightly thicker between HH12 and HH21 but a 
second phase of proliferation between HH34 and HH40 increases the myocardial mass 
massively. The signalling molecules responsible for cardiomyocyte proliferation are 
thought to originate in the epicardium, but the patterning of the trabeculated myocardium is 
regulated by the endocardium
18
. 
 
 
Figure 1.3: Schematic drawing of a cross-section through the looping heart, showing the four layers 
formed by HH17 – HH18: the myocardium (red), cardiac jelly (grey), endocardium (pink) and epicardium 
layers (blue)
18
. 
 
The remodelling of the developing heart by apoptosis starts at HH19 and follows the path 
of epicardial coverage, in the tissue bridge between the myocardium and the proepicardial 
organ as well as in the outflow tract
18
. 
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1.1.7 HH21 to HH26 
By HH20 the migrating CNC cells reach the outflow tract, migration of myocardium into 
the outflow tract is finished and cardiac valve formation begins
18
. Cardiac septation and the 
late phase of cardiac looping begins at HH24, and apoptosis is still observed in the outflow 
tract, in the ventricles as well as in the atria
18
. Although a large number of changes still 
occur between this stage and adulthood, such as the completion of valve development, the 
formation of the coronary vasculature and the maturation of the cardiac conduction system, 
for the purposes of this study only these early stages of heart development will be 
considered in detail. 
1.2 Congenital heart diseases 
Despite the frequency of congenital heart defects in the human population, affecting almost 
1% of live births and resulting in the mortality or morbidity of many patients, the genetic 
cause of these defects remain largely unexplained. Current evidence suggests that these 
defects are caused by the improper formation of the heart and vessels as a result of a 
combination of factors
23
. A severe and common form of congenital heart disease arises due 
to a large ventricular septal defect (VSD) which is formed when the conal septum is 
misaligned during development
24
. This disease, Tetralogy of Fallot, occurs in between five 
to seven live human births per 10,000, and generally requires surgical intervention early on 
in life. miR-421 is upregulated in ventricular tissue from human infants with Tetralogy of 
Fallot, and negatively affects a key regulator of the Notch signalling pathway, SOX4. 
SOX4 is required for the formation of the outflow tract and therefore increased expression 
of miR-421 was implicated as one part of the combination of factors that lead to Tetralogy 
of Fallot. 
1.3 Wnt signalling is essential for heart formation and development 
The highly conserved Wnt signalling pathway is central to wide-ranging processes in 
embryonic and adult stages of many organisms
7,25,26
. This signalling pathway is known to 
8 
 
function from the very start of cardiac development, and is essential for patterning the 
heart
7,19,27,28
. This project discovered miRNAs that regulate miRNA-sensing constructs 
containing the 3’ UTRs of several components of the Wnt signalling pathway (Chapter 4), 
strongly suggesting that miRNAs have essential roles during early heart development by 
modulating such components. 
 
The Wnt genes, more than 100 of which have been annotated thus far, regulate many 
developmental processes, determine cell fate, influence differentiation and cell migration, 
and establish polarity in tissues
29,30
. These genes are very widely conserved and have been 
identified in organisms ranging from C. elegans to H. sapiens. The proteins encoded by the 
Wnt genes all contain a signal sequence and a pattern of 23 cysteine residues that does not 
differ greatly between genes. Large families of genes encode the ligands and receptors that 
make up Wnt signalling, giving rise to a very large number of possible interactions. 
Current thinking suggests that all Wnt proteins are secreted and act by binding to receptors 
on the cell surface of the secreting cells or any cells with appropriate receptors nearby. In 
addition, associations of receptors and ligands can cause several different reactions and 
furthermore Wnt ligands can also act to induce other signalling pathways by activating 
intracellular messengers such as c-Jun NH2-terminal kinase (Jnk) and Src kinases
30
.  
 
Four different responses to Wnt-receptor binding are described in literature, although not 
all have been completely characterised. Broadly, these four responses can be divided into 
three categories: binding of a Wnt ligand to a Frizzled (FZD) receptor, to the receptor 
tyrosine kinase (RTK) Ror or to a Ryk RTK. The RTK signalling pathways are 
incompletely understood. Canonical β-catenin / TCF signalling is inhibited when Wnt 
ligands bind Ror2, and Jnk can be activated as a result of this binding, although other 
interaction partners during this process have yet to be identified
30
. Wnt binding to Ryk 
RTK results in activation of Src proteins, and has been studied mostly during neuronal 
development
30
. The cellular response when Wnt binds to FZD can be subdivided into two 
categories, one in which an LRP co-receptor is present and another where possible co-
receptors have not yet been identified. Wnt – FZD signalling is discussed in 1.3.1 and 1.3.2 
below. 
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1.3.1 Wnt / β-catenin pathway 
Canonical Wnt signalling is defined as signalling that disrupts the establishment of the 
body axis in Xenopus embryos along with an increase in the levels of β-catenin and, as a 
result, β-catenin signalling. In this pathway Wnt protein signals on the extracellular surface 
are bound by the 7-transmembrane receptors in the Frizzled (FZD) family, along with their 
LRP co-receptors
26
. In the absence of Wnt a destruction complex associated with LRP, 
consisting of Axin and adenomatous polyposis coli (APC), GSK-3 and Casein kinase, 
binds β-catenin and phosphorylates it leading to the transfer of β-catenin to the proteasome 
and its destruction by the ubiquitin pathway. However, when Wnt binds to FZD the 
binding allows FZD to deactivate the signal transduction protein Disheveled (Dvl), thus 
preventing Dvl from inhibiting the action of glycogen synthase kinase-3 enzyme (GSK-3). 
The inactivation of GSK-3 prevents the degradation of β-catenin, allowing it to travel into 
the nucleus and activate transcription factors from the T-cell factor / lymphocyte enhancer 
factor (TCF / LEF) family, which leads to the activation of Wnt-responsive genes.  
 
At the plasma membrane β-catenin, α-catenin and cadherin proteins can form a complex 
that regulates cell adhesion by its effect on adherens junctions
26
. The canonical Wnt/β-
catenin pathway described above is known to control cell proliferation by the activation of 
cell cycle genes such as c-myc and cyclinD1
7
. 
1.3.2 Non-canonical Wnt pathways 
The planar cell polarity (PCP) and Wnt / Ca
2+
 pathways are non-canonical signalling 
pathways and neither requires the involvement of β-catenin7. These pathways are known to 
inhibit the β-catenin dependent canonical Wnt signalling and in vertebrates, although not in 
flies, Wnt still binds FZD to initiate non-canonical signalling
7
. The binding of Wnt to a 
FZD receptor that is not associated with the co-receptor LRP results in Dvl being allowed 
to form a complex which activates the GTPases Rho and Rac, leading to the activation of 
Rho kinase and Jnk
7
. This in turn causes the activation of Rho-associated kinase (ROCK) 
and results in modifications to the cytoskeleton, or regulation of transcription by the 
activation of Activating Protein 1 (AP1) by Jnk. Furthermore, actin modifications can be 
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caused by Dvl and Rac1 association as a result of Wnt binding
7
. The PCP signalling 
pathway is known to control migration of neural crest cells
31
.  
 
In some cases an increase in the intracellular concentration of Ca
2+
 ions can result when the 
Wnt ligand binds its FZD receptor. In the Wnt/Ca
2+
 pathway this release of Ca
2+
 ions 
causes the activation of calcium-sensitive enzymes such as calcineurin (CaCN), which 
regulates Nuclear factor of activated T-cells (NFAT) and as a result, gene transcription.  
1.3.3 Wnt signalling is context-specific 
Attempts have been made in the past to classify Wnt ligands and FZD receptors as either 
canonical or non-canonical. For example, Wnt5A is known to be a non-canonical ligand as 
it did not induce signalling through β-catenin / TCF when exposed to different mammalian 
FZD receptor that were ectopically expressed in D. melanogaster
30
. However, when 
Wnt5A was recently added to 293 HEK cells that express both FZD4, its receptor, and 
LRP5, canonical signalling was induced. This suggests that the failure of Wnt5A to signal 
in a canonical manner in the early D. melanogaster experiments may have been a result of 
a failure of Wnt5A to recruit a LRP co-receptor. In addition, maternally contributed Wnt11 
acts canonically to increase β-catenin levels, whereas Wnt11 is otherwise known to induce 
non-canonical signalling. Therefore it is possible that Wnt ligands are either canonical or 
non-canonical as a result of the signals and factors locally available.  
 
Furthermore, the cellular responses to Wnt signalling are influenced by the nature of the 
receptor. The extent to which the receptor activates β-catenin signalling is known to 
depend on the C-terminus sequence of the FZD receptor. In D. melanogaster exchanging 
the C-terminal sequence of FZD and FZD2, that induce PCP and β-catenin / TCF 
signalling respectively, has led to a reversal of their signalling
30
.  
 
Evidence has been found in C. elegans that Cell Adhesion Molecule 1 (CAM-1), a Ror2 
homolog, interacts with several Wnt ligands and may act as a sponge to sequester Wnt 
molecules and therefore modulate the range and concentration of secreted Wnts, affecting 
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the balance of signals encountered by the cell and thus adding another point of control over 
the cellular response. 
 
Finally, LRP and Wnt-FZD interactions are prevented by the combined association of the 
transmembrane receptor Kremen and the secreted protein Dkk
30
. When Dkk binds to LRP 
in the presence of Kremen, LRP is transferred into the cell. However, when Dkk is not 
present Krement has the opposite effect, ensuring that LRP is located on the cell surface. 
The effect of these interactions is that Wnt / β-catenin signalling is promoted when Dkk is 
absent and Kremen is present, and inhibited in the presence of Dkk and Kremen.  
 
The factors influencing canonical and non-canonical Wnt signalling discussed above 
illustrate some of the complexity of this signalling pathway. Both canonical and non-
canonical Wnt signalling influences heart development, and a description of signalling in 
the context of specific stages of heart development is discussed in 1.3.4. 
1.3.4 Wnt signalling is essential for heart development 
Canonical and non-canonical Wnt signalling are both known to be essential at certain 
points during cardiogenesis
7
. The requirement for each type of Wnt signalling becomes 
more difficult to elucidate as heart development proceeds and the heart becomes more 
patterned. Broadly speaking, canonical Wnt signalling induces proliferation whereas non-
canonical signalling controls differentiation in some tissues and EMT and migration in 
others (Figure 1.4). Canonical Wnt signalling via Wnt3a is high to induce mesoderm and 
endoderm formation prior to HH3 (Figure 1.4A). To induce specification of cardiac fate in 
cardiogenic mesoderm, non-canonical Wnt signalling is mediated through Wnt5a and 
Wnt11 from HH3 – HH6. Proliferation is induced by canonical Wnt2b once cardiogenic 
precursors have been specified, whereas non-canonical Wnt11 induces terminal 
differentiation from HH7 – HH10. Non-canonical signalling via Wnt11 is still required 
from HH11 to HH15 in the looping heart (Figure 1.4B). As the heart becomes more 
patterned, the roles of canonical and non-canonical Wnt signalling increasingly depend on 
the cell type investigated. Non-canonical signalling through Wnt5a and Wnt11 allows 
EMT and migration of cardiac neural crest cells that will partake in septation of the heart, 
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whereas canonical Wnt signalling induces cardiac neural crest cells to proliferate, through 
Wnt1 and Wnt3a. Canonical Wnt signalling (Wnt2b) is required for primary atrial 
septation, as the genetic knockout of Wnt2a in mice resulted in mutant hearts lacking atrial 
septation. Wnt9a allows canonical Wnt signalling to activate proliferation of endocardial 
cells. 
 
The role of Wnt signalling in the development of the heart is discussed in more detail 
below (1.4). 
 
 
Figure 1.4: A summary of the currently known requirements for canonical Wnt and non-canonical Wnt 
signalling in the developing embryonic heart up to chick stage HH20
7
. A: Canonical Wnt signalling is 
alternately high and low during mesoderm and endoderm formation, specification, proliferation and terminal 
differentiation. B: Non-canonical signalling leads to heart looping, whereas high canonical and high non-
canonical Wnt signalling results in septation. Valve formation proceeds when canonical Wnt signalling is low. 
 
1.4 Factors involved in chick heart development 
The four major milestones of heart development are specification, determination, 
patterning and differentiation. The CPCs that migrate from the rostral half of the primitive 
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streak to the lateral mesoderm between HH3 and HH5 are specified to a cardiac fate and 
will continue on this path even if placed in a neutral environment
18,19
. A higher level of 
commitment to the cardiac lineage is achieved during determination, between HH5 and 
HH7, when the cardiogenic mesoderm cannot be induced to deviate from its fate even if 
placed in an antagonistic environment
18,19,21
. The bilateral heart fields resolve into regions 
with specific fates between HH7 and HH9 during the process of patterning, and the 
expression of molecular and genetic markers that characterise the specific cell type marks 
differentiation, which occurs between HH9 and HH11
19
. 
1.4.1 Specification 
Craniolateral endoderm is the source of most of the factors that facilitate myocardial 
specification, including bone morphogenetic proteins (BMPs), fibroblast growth factors 
(FGFs) and transforming growth factor beta (TGFβ) family members. Canonical Wnt 
signalling has been shown to prevent cardiac specification, whilst non-canonical Wnt and 
Sonic hedgehog (shh) signalling induces it
19,27,28
. 
 
Components of the BMP signalling cascade are expressed together in the bilateral heart 
fields. In chick both the hypoblast and anterior endoderm have been found to express 
Bmp2 and Bmp4, and the cardiac transcription factors Nkx2.5 and Gata4 are upregulated 
in response to Bmp2
19
. Furthermore, when BMP signalling is inhibited by the antagonist 
noggin, cardiogenic mesoderm is not formed. Together these observations strongly suggest 
that myocardial induction is dependent on BMP signalling. 
 
In regions where BMP signalling is present, FGFs cause cardiac specification
21
. FGF8 is 
essential for right ventricle and outflow tract formation, and is expressed in the mesoderm 
during gastrulation, in the pharyngeal endoderm and cardiogenic mesoderm, and in the 
outflow myocardium following specification
19,21
. In the bilateral heart fields Nkx2.5 and 
myocyte enhancer factor 2C (Mef2C) are expressed partly as a result of FGF8 expression 
in the endoderm. 
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A non-canonical Wnt ligand expressed in the endoderm and mesoderm, Wnt11, inhibits 
canonical Wnt signalling and has been shown to induce myocardial differentiation
19,21
. 
When the Wnt molecules in the canonical signalling pathway that bind to Frizzled 
receptors are competitively bound by Wnt-antagonists Dickkopf 1 (Dkk1) and Crescent, 
the canonical signalling pathway is inhibited and myocardial specification is promoted
19
. 
In addition, canonical signalling via Wnt3A and Wnt8 can prevent cardiomyogenesis, 
whereas their inhibition promotes cardiac specification
19,21
. Anterior neural ectoderm 
inhibits cardiac specification more strongly than posterior neural ectoderm by the 
expression of canonical Wnts
18,19
. Along with its function as a repressor of cardiac 
lineages, canonical Wnt signalling also induces endoderm formation
21
. 
 
Although specification of a cardiac fate depends on various factors, the bilateral heart 
fields are characterized by low canonical Wnt signalling and high levels of BMPs, as a 
result of signals originating in the endoderm and mesoderm (Figure 1.5)
21
. 
 
 
Figure 1.5: Origins of cardiac inducing and inhibiting factors
21,32
. A: Schematic drawing of an early stage 
chick embryo with the cardiogenic mesoderm indicated in red and the notochord in green. B: Embryo in A 
viewed cut through the plane indicated by the grey line. The ectoderm, shown in orange, secretes canonical 
Wnt signals that inhibit cardiogenesis. BMP antagonists noggin and chordin are expressed in the notochord 
(green) and also inhibit cardiogenesis in the adjacent mesoderm (pink). The pharyngeal endoderm (blue) 
induces the nearby splanchnic mesoderm (red) to form cardiogenic mesoderm through BMP and FGF8 factors 
as well as the antagonists of Wnt signalling, that act by binding Frizzled receptors, Dkk1 and Crescent
21
. 
Somatic mesoderm and endoderm express non-canonical Wnt11, inducing a cardiac fate in the target 
cells
19,21,32
. 
 
Mesp1 and Mesp2, basic helix-loop-helix (bHLH) transcription factors, are involved in the 
migration of the CPCs from the primitive streak into the anterolateral mesoderm
21
. 
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1.4.2 Determination and heart field formation 
Several transcription factors, including Nkx2.5 and members of the GATA and myocyte 
enhancer factor 2 (MEF2) families, become activated in the bilateral heart field cells which 
results in their determination to a cardiac fate
19
. 
 
In both mice and chicks the NK homeobox gene Nkx2.5 is expressed very early after CPCs 
have migrated to form the bilateral heart fields, and is still expressed in adult hearts
19,21
. In 
mice, Nkx2.5 knockout causes foetal mortality due to outflow and inflow tract 
malformations although cardiac differentiation is not completely abrogated, as evidenced 
by the presence of functional cardiomyocytes in the heart tube
19
. Nkx2.5 regulates the 
expression of a large number of cardiac-specific genes and therefore is essential for 
cardiogenesis, and is expressed in cells at HH5 that eventually form the ventricles of the 
chick heart
21
. A Smad transcription factor binding site, and hence BMP signalling, is 
essential for cardiac-specific expression of Nkx2.5
19
. The Smad transcription factor is 
thought to act together with the GATA4 factor to bring about expression of Nkx2.5 in 
precardiac cells. 
 
Three members of the GATA zinc-finger transcription factor family, GATA4-6, are 
expressed in the developing vertebrate heart. The deletion of GATA4 resulted in a 
reduction in the number of cardiomyocytes as well as cardia bifida in mice, whereas its 
overexpression induced cardiac differentiation in ESCs
21
. Just as GATA4 expression 
induces Nkx2.5 expression, Nkx2.5 expression also upregulates the expression of 
GATA4
21,33
. 
1.4.3 Patterning within the bilateral heart fields 
Fate mapping experiments have traced the origins of cardiac cells but the earliest 
molecular and genetic patterning markers of myocardial progenitors are first expressed 
some time after gastrulation
19
. The bilateral heart fields consist of the primary heart field, 
the anterior heart field, the first heart field and the second heart field. The primary heart 
field differentiates before the anterior heart field, is defined by Fgf8 / Fgf10 expression and 
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forms the inflow limbs of the heart, while the anterior heart field does not express Fgf8 / 
Fgf10 and forms the outflow limbs
19
. The first and second heart fields do not correspond 
exactly with the primary and anterior heart fields and are characterised by Islet1 (Isl1) 
expression. The first heart field forms the outflow limb and a part of the atria whereas the 
second heart field gives rise to the right and left ventricles
19
. Mutation of Isl1 leads to 
disrupted cardiac looping
34
. Additional smaller fields are created within the heart fields by 
the expression of genes such as Tbx1, Tbx5, Tbx20 as well as eHand and dHand
19
. 
1.4.4 Differentiation and heart tube formation 
Cardiomyocyte differentiation markers sarcomeric myosin (MF20) and cardiac troponin-I 
are first expressed at stage HH8 to HH9, in the centre of the heart field and then in the 
heart tube, marking the start of cardiomyocyte differentiation
19
. Cardiomyocytes will 
differentiate even if the heart fields do not join, as evidenced by the formation of two 
beating hearts in cardia bifida. The formation of the foregut, a pocket created when the 
anterior endoderm folds, and the heart tube has been shown to depend on extraembryonic 
endoderm
19
. Heart tube formation has been shown to rely on the expression of the small 
GTPase RhoA, which is highly expressed in HH6-HH9 chick anterior lateral plate 
mesoderm, heart primordia and anterior intestinal portal
19
. 
 
Although the MADS-box protein serum response factor (SRF) is not muscle-specific, it 
associates with the transcription factor myocardin to activate cardiac muscle-specific 
genes. The expression of SRF is regulated by Nkx2.5
21
, which therefore manages growth 
and differentiation in cardiac cells directed by the action of SRF and myocardin. Cardiac 
differentiation gene expression is controlled at HH8 by the coexpression of SRF, GATA4 
and Nkx2.5
21
. 
 
Given the pervasive expression of miRNAs during development, as well as their 
implication as essential regulators of many of the early processes of heart development, 
this work aimed to add to the current knowledge of miRNA expression during the early 
stages of heart development described above. 
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1.5 MicroRNAs 
MicroRNAs (miRNAs) were first discovered during studies into the temporal regulation of 
development in Caenorhabditis elegans (C. elegans) and have since been identified to be 
highly expressed in many model organisms
16
. Although there are several types of small 
RNAs, including small interfering RNAs (siRNAs) and Piwi-interacting RNAs (piRNAs), 
only miRNAs are processed from hairpin structures that contain bulges where the strands 
are imperfectly paired (Figure 1.6)
16
. Despite not being translated into protein, mature 
~20nt miRNAs control the expression of genes post-transcriptionally either by cleaving 
target mRNAs directly, by inducing degradation of the mRNA targets, or by slowing or 
stopping translation of mRNAs. A large number of all eukaryotic protein coding genes and 
most cellular processes are predicted to be controlled by miRNAs
35
. In mammals each 
conserved putative miRNA has an average of 300 conserved predicted targets and more 
than 50% of human 3’ UTRs seem to have conserved miRNA binding sites16. With so 
many predicted targets, the elucidation of the biologically important functions of miRNAs 
is likely to prove essential for a more complete understanding of cellular function and 
development. 
1.5.1 miRNA biogenesis 
MicroRNA genes can be situated within introns of protein coding host genes or within 
intergenic regions. Once transcribed, primary microRNAs (pri-miRNAs) are processed 
inside the nucleus into ~70nt hairpin structures, called pre-miRNAs, by the RNase III 
endonuclease Drosha (Figure 1.6). Some intronic miRNAs do not get processed by Drosha 
but become pre-miRNAs during the splicing process undergone by the host protein coding 
gene
36
. Pre-miRNAs are transported into to the cytoplasm via the exportin5 channel. In the 
cytoplasm pre-miRNAs are cleaved into ~20bp miRNA/miRNA* duplexes with a 2nt 
overhang on each end by Dicer, another RNase III enzyme. One of the mature miRNA 
strands, called the guide strand, is bound to a ribonucleoprotein (RNP) complex by 
becoming attached to the Argonaute protein, thus forming a miRNP complex, and the 
passenger strand is degraded
16,36
. It has been noted that the strand with the less stably 
bound 5’ end is generally the guide strand36. 
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Figure 1.6: The biogenesis of miRNAs. Long pri-miRNA structures are cleaved in the nucleus by Drosha to 
shorter pre-miRNAs that are exported into the cytoplasm by Exportin 5. In the cytoplasm pre-miRNAs are 
cleaved ~20bp miRNA/miRNA* duplexes with a 2bp overhang on either end. One strand is degraded and the 
other is incorporated into ribonucleoprotein complexes called micro-ribonucleoproteins (miRNPs). The miRNP 
complex can induce cleavage of its target mRNA if the miRNA is perfectly complementary to its target, as is 
generally the case in plants. When the miRNA is not perfectly complementary to its target mRNA, translation 
of the target mRNA is repressed.  
 
If the miRNA is perfectly complementary to its target mRNA, the miRNP complex cleaves 
the target mRNA in the centre of the miRNA-mRNA duplex
36
. Most animal miRNAs are 
not perfectly complementary to their targets and their recruitment into miRNP complexes 
results in translational repression or deadenylation of the target mRNA. In the case of 
imperfectly complementary miRNAs, four mechanisms of translational repression are 
currently considered possible. When the miRNP complex binds to its target mRNA during 
protein synthesis, ribosomes are impeded or knocked off the mRNA strand leading to 
slowed translation
37
. Some researchers speculate that miRNP complexes engage as yet 
unknown protease enzymes during translation that then degrade the nascent peptides
36
, 
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although no evidence supporting this degradation has been presented to date. Finally, target 
mRNAs are sent to processing bodies (P-bodies) for storage or degradation as a result of 
the miRNP complex blocking the initiation of translation or inducing deadenylation
36
. 
1.5.2 miRNA targeting principles 
Even though imperfect base pairing of a miRNA to its target mRNA is generally seen in 
animals, nucleotides 2 to 8 at the 5’ end of the miRNA, called the seed region, do have to 
bind in a perfect and contiguous manner for the miRNA to target a specific mRNA
38
. The 
miRNA-mRNA association is further enhanced by perfect pairing of the miRNA nt 12-17 
to its target mRNA
36,38
. Based on modelling the stability of possible complexes Bartel et al 
propose that the miRNA guide strand is bound by Argonaute in a way that forces 
nucleotides 2 to 8 on the 5’ end of the miRNA strand into a position favourable for pairing 
with the target mRNA
16
. Pairing at nucleotides 12-17 then further enhances binding, 
although it is not essential for target recognition. 
 
Several studies have concluded that the most effective miRNA target sites are located in 
the 3’ untranslated region (UTR) of mRNA, specifically about 15 nucleotides downstream 
from the stop codon
36,38
. Better targeting is seen when the miRNA binding site is present 
near either end of the 3’ UTR, especially in longer 3’ UTRs38. The expression of target 
mRNAs with two or more miRNA binding sites is repressed in a non-cooperative manner 
except when two target sites were between 8 and 40 nucleotides apart, suggesting that the 
miRNAs cooperate to increase the amount of repression
38
. 
1.5.3 miRNA regulation of gene expression 
Each microRNA expressed by a specific cell will have a large number of predicted target 
sites complementary to its seed region, in a large number of mRNAs.  Whether any of 
these miRNA-mRNA interactions result in biologically relevant effects will depend on 
many different factors.  Some microRNAs function as on-off switches of target function, 
as when let-7 targets lin-41 during C. elegans development
12
. MicroRNA expression can 
be upregulated in response to an environmental or developmental signal and repress a 
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target that had previously been expressed in the cell to a level more optimal in this new 
state.  Switch interactions can also be the result of a pre-existing microRNA repressing a 
newly upregulated target, as is the case when miR-9a represses senseless in Drosophila 
melanogaster
16
. If a protein should be downregulated by other factors in the cell, such as 
the non-muscle gene Tropomyosin in developing muscle, the continued presence of a 
microRNA, miR-1 in this case, will ‘mop up’ any deviant transcripts and ensure that 
functional levels of this protein are not achieved
16
. The levels of a target can also be fine-
tuned, when miRNA expression reduces the protein expression to a more optimal but still 
functional level.  Neutral miRNA – mRNA interactions do not have observable biological 
effects as the protein levels remain in the optimal range despite the miRNA-mediated 
repression.  MicroRNAs are essential regulators of gene function, and their roles during 
development certainly deserve further elucidation. 
 
This study aimed to expand the current knowledge of miRNA expression during chicken 
cardiogenesis, as well as to further elucidate the effects of a known miRNA, miR-1, on the 
developing heart. In Chapter 3 an analysis of the complete sequencing results, including 
that of sequences not known to be miRNAs, is presented. This includes analysis of the 
quality of the NGS libraries sequenced, as well as an investigation of the top detected 
miRNAs. Following a literature search several miRNAs known to affect heart development 
and function were identified. The fold change patterns of these known miRNAs are 
examined in Chapter 4, to present networks of miRNAs that behave in ways significantly 
correlated to the changes in these known miRNAs. Furthermore, the biological effects of a 
subset of miRNAs on reporter constructs containing 3’ UTRs of several genes are 
summarised in Chapter 4. Novel miRNAs are validated (Chapter 5), and the effect of 
miR-1 dysregulation in ovo is presented (Chapter 6). 
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2 Materials and methods 
2.1 Embryo development 
After laying, eggs were stored at 16
o
C and then incubated at 37
o
C until the desired stage 
had been reached. 
2.2 Dissection of embryos 
2.2.1 For whole mount in situ hybridization (WISH) 
Embryos were dissected into cold DEPC-treated PBS. The extraembryonic regions were 
removed from embryos older than HH12. 4% PFA was added to flattened embryos and 
replaced with cold 4% PFA after 5 minutes, then left at 4
o
C overnight. Embryos were 
washed twice for 5 minutes in PBT, then twice for 5 minutes in MeOH. Embryos were 
stored at -20
o
C in MeOH for no longer than one month.  
2.2.2  For RNA purification 
Depending on the stage, cardiogenic mesoderm or cardiac tissue was dissected under cold 
DEPC-treated PBS. Dissected tissue was transferred into Trizol kept on ice during the 
dissection process; tubes were left at -80
o
C after dissection. 
2.2.3  For protein purification 
Cardiogenic mesoderm or cardiac tissue was dissected under cold DEPC-treated PBS and 
then transferred to tubes containing DEPC-treated PBS and kept on ice. The tubes were 
spun in a microcentrifuge at 2,000 rpm at 4
o
C for 5 minutes. The supernatant was removed 
and cold RIPA buffer added so that x mg tissue equalled x μl RIPA buffer. The tubes were 
vortexed thoroughly, then left on ice for 30 minutes with regular vortexing. Tubes were 
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spun at maximum rpm for 10 minutes and the supernatant was transferred to a new tube. 
Isolated protein was stored at -20
o
C for up to one month. 
2.3 Purification and quantification of DNA, RNA and protein 
2.3.1  Plasmid DNA purification 
Plasmids were purified by QIAprep Spin Miniprep Kit (Qiagen) according to 
manufacturer’s instructions. 
2.3.2  DNA quantification 
DNA was quantified using a standard NanoDrop spectrophotometer; 
260/
280 ratios of 1.8 – 
2.0 indicated good quality DNA. 
2.3.3 Total RNA purification 
Chloroform was added to dissected tissue in trizol to 20% of the trizol volume. The tube 
was gently shaken for 15 seconds and incubated at room temperature for 4 minutes before 
being spun at maximum rpm for 20 minutes at 4
o
C. The clear aqueous phase was 
transferred to a new tube. Isopropanol was added to the aqueous phase to a volume of 50% 
of the original trizol volume and 2μl 15mg/ml Glycoblue was added. The solution was 
incubated at room temperature for 10 minutes and spun at maximum rpm for 15 minutes at 
4
o
C. The supernatant was removed from the pellet and discarded. Freshly prepared 70% 
EtOH was used to wash the pellet by vortexing before spinning at maximum rpm for 5 
minutes at 4
o
C. The supernatant was removed and the pellet dried at 50
o
C. The pellet was 
dissolved in a small amount of nuclease-free water and the quality of the RNA was 
checked by running a small aliquot on a 1% agarose gel. Samples were stored at -80
o
C. 
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2.3.4 RNA quantification 
RNA was quantified using a standard NanoDrop spectrophotometer; 
260/
280 ratios of 1.8 – 
2.0 indicated good quality RNA. 
2.3.5 Protein purification 
Protein was purified from tissue as detailed in 2.3. above. 
2.3.6 Protein quantification 
Protein was quantified by Bradford assay. Fresh dilutions of BSA in deionised water 
ranging in concentration from 2 ng/μl to 10 ng/μl were prepared and used as standards. 
800μl sample was added to 200μl 5x Dye Reagent concentrate and left at room 
temperature in the dark for 5 minutes. Absorbance was measured at 595nm and the 
concentration of protein in each sample was determined. 
2.4 In situ hybridisation 
2.4.1 mRNA probe synthesis 
2.4.1.1 Plasmid preparation 
A small amount of the required DNA glycerol stock was streaked onto a LB agar plate 
containing an appropriate antibiotic and incubated upside down at 37
o
C overnight. A single 
isolated colony was picked and added to 10ml LB medium containing the relevant 
antibiotic, and grown at 37
o
C and 250 rpm overnight. Plasmid was isolated by QiaPrep 
Miniprep kit, according to manufacturer’s instructions. 1μg of purified plasmid was 
linearized using the appropriate enzyme and buffer at 37
o
C for at least 2 hours. A small 
amount of digestion mix was run on a 1% agarose gel next to a small amount of uncut 
DNA to confirm successful digestion. DNA was precipitated from this solution by adding 
0.3M NaOAc and 3 volumes of EtOH, leaving at -80
o
C for 1 hour and spinning at 
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maximum rpm for 30 minutes at 4
o
C. The supernatant was removed and the pellet washed 
with freshly prepared 70% EtOH by vortexing vigorously. The tube was spun at maximum 
rpm for 30 minutes at 4
o
C, the supernatant was removed and the pellet was dried at 50
o
C. 
Once dry, the pellet was resuspended in 8μl water. 
2.4.1.2 RNA synthesis 
1μg linearized DNA, 1x Transcription buffer, 0.5x RNasin, 10μM DTT, 1x NTP-DIG or 
1x NTP-FITC, 0.5x Transcription enzyme (T3, T7 or SP6) and 2μl nuclease-free water 
were mixed and incubated at 37
o
C for two hours. The mixture was purified using the 
Illustra MicroSpin G-25 column purification kit, according to kit instructions. A small 
aliquot of eluate was checked on a 1% agarose gel to confirm successful synthesis; if both 
the RNA and DNA bands were not observed the probe synthesis was considered to have 
failed and the process was repeated. The eluate was left at 80
o
C for 5 minutes to denature 
the RNA, immediately placed into an equal amount of formamide and then added to 10ml 
Hybridisation buffer. Probes were stored at -20
o
C. 
2.4.2 mRNA whole mount in situ hybridisation 
2.4.2.1 Hybridization 
Embryos were washed in 75% MeOH/PBT for 5 minutes, in 50% MeOH/PBT for 5 
minutes, in 25% MeOH/PBT for 5 minutes and then twice for 5 minutes in PBT. Embryos 
older than HH18 were bleached in 6% H2O2/PBT for one hour. Embryos were washed in 
PBT 3 times for 10 minutes each time and left in 4% PFA for 30 minutes, then rinsed twice 
with PBT. Pre-warmed Prehyb buffer at 65
o
C was added to the embryos and replaced with 
more warm Prehyb buffer after 10 minutes. The embryos were left to rock in Prehyb buffer 
at 65
o
C for 2 hours. RNA probe, in Prehyb buffer at a concentration between 100ng/ml and 
1μg/ml, was preheated to 65oC and used to replace the Prehyb buffer covering the embryos 
after two hours. The embryos were left to rock in the probe / Prehyb solution at 65
o
C for at 
least 12 hours. 
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2.4.2.2 Post-hybridization washes 
2x SSC / 0.1% CHAPS and 0.2x SSC / 0.1% CHAPS were pre-heated to 65
o
C. Embryos 
were washed three times in 2 x SSC / 0.1% CHAPS for 20 minutes each time, and then the 
same was repeated with 0.2% SSC / 0.1% CHAPS. Room temperature KTBT was used 
twice to wash the embryos, 10 minutes each time. 
2.4.2.3 Antibody 
Embryos were washed for 3 hours at room temperature in KTBT with 20% goat serum to 
block non-specific interactions. Antibodies were diluted in KTBT with 20% goat serum: 
1/2000 dilution of α-DIG or 1/4000 dilution of α-FITC. Diluted antibody was added to the 
embryos and left to rock at 4
o
C overnight. 
2.4.2.4 Post-antibody washes 
Embryos were washed for 1 hour in KTBT at room temperature, five times. Embryos were 
left to rock in MABT at 4
o
C overnight. 
2.4.2.5 NBT/BCIP detection 
Freshly prepared NTMT buffer was used to wash the embryos, twice for 15 minutes at 
room temperature. The colouring solution was made up by combining 9µl NBT (75mg/ml 
in 70% DMF) and 7µl BCIP (50mg/ml in 100% DMF) per ml NTMT buffer. Embryos 
were washed in this colouring solution, protected from light, until the signal was optimal. 
The colouring reaction was temporarily stopped by rinsing twice with KTBT at room 
temperature and then washing in KTBT until the background colour had been removed. 
Pictures of embryos were taken in KTBT. 
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2.4.3 LNA whole mount in situ hybridisation 
As for mRNA probes (2.4.1), but using a hybridisation temperature set to the LNA probe 
RNA Tm – 30
o
C. LNA probes were pre-absorbed three times in day 10 embryos as 
described in 2.4.2.1 
2.5 Cryosectioning of WISH embryos 
After WISH, embryos were washed twice in PBST for 5 minutes each time before being 
fixed in 4% PFA for 2 hours at room temperature. Embryos were then washed twice for 5 
minutes each time in PBST and left to rock in a 30% sucrose solution at 4
o
C overnight. 
Embryos were placed in sectioning tubes and covered in O.C.T. embedding medium 
(Miles Inc.) for at least 2 hours. After repositioning embryos using needles and forceps, the 
O.C.T. tubes were rapidly frozen in a EtOH dry ice bath and left at -20
o
C overnight. 40μm 
sections were cut at -20
o
C, sections were transferred to Superfrost Plus slides (Fischer 
Scientific) and dried at room temperature. The slides were then washed in dH2O and 
mounted in Hydromount (National Diagnostics). The slides were dried overnight and an 
upright microscope (Zeiss) was used for microscopic analysis. Images were captured using 
AxioVision software. 
2.6 In ovo microinjection into HH14 chick heart 
2.6.1 AntagomiR and RCAS virus injections 
Glass capillaries (1.0mm O.D. x 0.78 mm I.D.; Harvard apparatus, UK) were used to 
prepare microinjection needles on a horizontal Micropipette Puller (P-30, Sutter Instrument 
Co., CA). The closed tip of each needle was removed with fine forceps and 8μl injectant 
was placed in each needle. Custom cholesterol-conjugated and FITC labelled antagomiRs 
supplied by Dharmacon. AntagomiRs were diluted to 0.1mM with RNase-free water 
before injection, whereas resuspended RCAS virus was used without further dilution. After 
removing eggshell to uncover the embryo, the shell membrane was removed and the heart 
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visualised. The needle was positioned using a micromanipulator and the heart tube filled 
with injectant by exertion of pressure. A small amount of PBS containing 0.1% Penicillin 
Streptomycin was pipetted onto the embryo and the hole closed with clear tape. Embryos 
were left at 37
o
C for 24 hours and harvested as described in 2.2.  
2.7 Library preparation for Next Generation Sequencing 
2.7.1 TruSeq library preparation 
2.7.1.1 mirVana small RNA enrichment 
Total RNA was enriched for small RNAs using the mirVana mRNA Isolation kit as per 
manufacturer’s instructions (LifeTechnologies, AM1560). 50 – 100 μg of total RNA was 
mixed with 5 volumes of lysis buffer and 1/10 volume of miRNA homogenate additive 
added. The tube was vortexed thoroughly and left on ice for 10 minutes. 1/3 volume of 
EtOH was added to the mixture and the solution was vortexed. The mixture was pipetted 
onto a Filter Cartridge and centrifuged at 5,000 x g for 1 minute. The filtrate was collected 
and 2/3 volume room temperature EtOH was added; the mixture was vortexed thoroughly. 
The mixture was then applied to a new Filter Cartridge and centrifuged at 5,000 x g for 1 
minute. The filtrate was discarded and the Filter Cartridge washed by applying miRNA 
Wash Solution 1 to the Filter Cartridge and spinning it at 5,000 x g for 1 minute. The 
filtrate was discarded, Wash Solution 2/3 was added and the tube was again spun at 5,000 
x g for 1 minute. This step was repeated for a second time. The tube was spun for 1 minute 
at 10,000 x g before the Filter Cartridge was transferred to a new tube. Elution solution, 
heated to 95
o
C, was added to the Filter Cartridge and left to incubate at room temperature 
for 2 minutes. The tube was spun at 10,000 x g and the eluted RNA recovered. The 
enriched samples were quantified with a Qubit RNA High Sensitivity Assay kit (Life 
Technologies) and the quality of the small RNA-enriched samples was checked with a 
BioAnalyzer PicoRNA assay (Agilent). 
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2.7.1.2 Illumina TruSeq Small RNA library preparation 
Sequencing libraries were generated using mirVana small RNA-enriched samples, 
following the Illumina TruSeq Small RNA library preparation protocol. All incubations 
were done on a thermocycler to ensure precise control of the temperature. The 3’ adapter 
was ligated to small RNA-enriched samples by truncated T4 RNA Ligase 2 at 28
o
C by 
incubating for one hour with ligation buffer and RNase inhibitor. The 5’ adapter was 
ligated immediately by incubating the 3’ ligated mixture, T4 RNA Ligase and ATP at 28oC 
for one hour. The 3’ and 5’ ligated mixture was reverse transcribed at 50oC for one hour by 
adding 1x First strand buffer, 1.25mM dNTPs, 20mM DTT, RNase Inhibitor and 5x 
diluted SuperScript II Reverse Transcriptase. PCR amplification of the cDNA was 
performed using the supplied PCR mix, an RNA PCR primer and an RNA PCR Primer 
Index, specific to each biological sample. 11 cycles of 10 seconds at 98
o
C, 30 seconds at 
60
o
C and 15 seconds at 72
o
C were performed. Each library was purified on its own 1.0mm 
6% Novex TBE PAGE gel; the section between 145 bp and 160 bp was excised and broken 
up into very small pieces by spinning through a 1.5ml Eppendorf tube with three holes 
made in the bottom into a 2.0ml Eppendorf tube at maximum RPM on a benchtop 
centrifuge. 200μl nuclease-free water was added to the gel pieces of each library and the 
slurry was left to rock at room temperature for 24 hours. The gel slurry was transferred 
onto a 5μm filter and spun for 10 seconds at 600 x g. The eluate was left at -80oC. 
2.7.2 Illumina HiSeq Sequencing 
Small RNA libraries were sent to the Oxford Genomics Centre (Wellcome Trust Centre for 
Human Genetics) for 50bp paired end sequencing on the HiSeq 2000 platform (Illumina). 
Each library had been barcoded allowing all samples to be sequenced in a single lane.  
2.8 Bioinformatics analysis 
Some bioinformatic analyses were performed by Dr. Simon Moxon (at the time working in 
Dr Grant Wheeler’s lab). Unless otherwise indicated, all bioinformatic analyses were 
performed by the author. 
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2.8.1 Raw sequence mapping and filtering 
Simon Moxon converted raw sequencing FASTQ files to FASTA format and removed 
adapter sequences with custom Perl scripts. Only reads that mapped perfectly by PatMaN
39
 
to the chicken genome (Galgal4
40
) were retained. 
2.8.2 Profiling of mapped reads to miRBase 
Initially Simon Moxon profiled mapped reads to miRBase
41
 release 19 with the UEA 
Small RNA Workbench tool, miRProf
42
. However, the author subsequently profiled the 
mapped reads to miRBase release 20 using miRProf. All known miRNA analyses done in 
this work were a result of this profiling against miRBase release 20. All normalised reads 
larger than 0 reads per million were retained and used in subsequent analyses. miRProf 
settings were adjusted to return all matching animal miRNAs. Unless otherwise indicated, 
all data handling steps were performed using Microsoft Excel 2007.  
2.8.3 Fold change profiles 
Fold change profiles were generated by dividing the normalised reads per million values 
for each miRNA at each stage by the value recorded at HH5-7. It was considered that the 
HH5-7 sample represented a good baseline of miRNA expression against which to measure 
the levels detected at the remaining stages. Where the level of miRNA at HH5-7 was 0, the 
normalised read of the miRNA at each stage was returned without further division. 
 
Correlations of fold change patterns were performed with GraphPad Prism version 5.01. A 
correlation matrix was generated and r values calculated for every pair of data sets. P 
values were calculated by Pearson’s chi-squared test, assuming a two-tailed distribution at 
a 95% confidence interval. A hierarchical cluster of known heart important miRNAs 
(Figure 4.5) was prepared using the statistical package R by the default Complete Linkage 
method, with the script shown below. 
 
### Read in data frame: 
30 
 
A <- read.csv("Known heart miRs fold change.csv") 
### Indicate rownames and make new data frame with the assigned row names 
rnamesA <- A[,1]                          # assign labels in column 1 to "rnames" 
A_data <- data.frame(A[,2:ncol(A)])  # transform columns 
rownames(A_data) <- rnamesA                  # assign row names  
### Prepare hierarchical cluster 
hc = hclust(dist(A_data)) 
### Load package ape 
library(ape) 
### Set colours for leaves: 
edgecol <- rep('black', 60) 
edgecol[c(1:3)] <- "darkorange2" 
edgecol[c(5)] <- "forestgreen" 
edgecol[c(7)] <- "lightseagreen" 
edgecol[c(10,41)] <- "navy" 
edgecol[c(11:19)] <- "deepskyblue" 
edgecol[c(20:40)] <- "deepskyblue3" 
edgecol[c(42:43)] <- "dodgerblue3" 
edgecol[c(44:50)] <- "darkorchid" 
### Plot basic tree 
plot(as.phylo(hc), edge.width=2,edge.color=edgecol,cex = 0.9, label.offset = 2, 
     tip.color="black",font=1,no.margin=TRUE) 
2.8.4 Novel miRNA prediction 
Simon Moxon predicted novel miRNAs based on their sequence, their genomic location 
and the predicted folded structure of surrounding genomic sequence using the UEA Small 
RNA workbench tool miRCat
42
. 
2.8.5 Novel miRNA target prediction 
Predicted target sites of novel miRNAs discovered in this screen were identified by 
searching for matching 6nt sequences in all the annotated 3’ UTRs of the chicken genome 
(Galgal4), using custom R scripts written by the author. Chromosomes were searched in 
turn with a representative R script shown below. 
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utr3 <- read.DNAStringSet ("Chromosome 1 mart_export.txt") 
P16mer <- vcountPattern ("CGCTCG", utr3) 
P26mer <- vcountPattern ("CCTCTA", utr3) 
P36mer <- vcountPattern ("CATTCA", utr3) 
P46mer <- vcountPattern ("GGCACA", utr3) 
P56mer <- vcountPattern ("ACAGAT", utr3) 
P66mer <- vcountPattern ("CCCTGA", utr3) 
P76mer <- vcountPattern ("GCGCCA", utr3) 
P86mer <- vcountPattern ("AGCCAA", utr3) 
P96mer <- vcountPattern ("CTGATG", utr3) 
P106mer <- vcountPattern ("CCAGAA", utr3) 
P116mer <- vcountPattern ("CATCCC", utr3) 
P126mer <- vcountPattern ("CAGCGC", utr3) 
P136mer <- vcountPattern ("TCTGCA", utr3) 
P146mer <- vcountPattern ("AGCCCC", utr3) 
### Split results by names 
k <- strsplit (names(utr3),"\\ ") 
### Link targets with sequences 
m=c() 
for (i in k) { 
  m=rbind(m,i[1])} 
### Combine search results with columns 
#Targets <- cbind(PutativeOne6mer,m)  
### Combine search results with columns for multiple searches 
Targets <- 
cbind(P16mer,P26mer,P36mer,P46mer,P56mer,P66mer,P76mer,P86mer,P96mer,P106m
er,P116mer,P126mer,P136mer,P146mer,m) 
### Save 
write.csv(Targets, file="Chromosome 1 All putative miRNAs.csv") 
2.8.6 FunDo Disease Ontology analysis 
Genes were analysed by FunDo using the web version
43
 and genes found to be associated 
with diseases were returned. The Disease Ontology and peer-reviewed evidence from 
GeneRIF
44
 was used for the statistical analysis
45
. As for Gene Ontology analysis, Fisher’s 
exact test was used to evaluate the significance of each disease association
46
. 
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2.9 miRNA target selection  
2.9.1 TargetScan target identification 
TargetScan Release 6.2 (June 2012) was searched for conserved and non-conserved targets 
of selected chicken miRNAs. Three lists of targets of the selected miRNAs were generated: 
those that were known to be involved in Wnt signalling, those with known roles in heart 
development following a literature search, and those that were more speculative and were 
targeted by more than one of the selected miRNAs. The final selection of 14 targets were 
made based on the ease with which their 3’ UTRs could be amplified from cDNA. This 
was done as many of the 3’ UTRs of the chicken genome are not well annotated and 
therefore a resistance to PCR amplification could indicate that the 3’ UTR is not correctly 
annotated, belongs to a splice variant expressed at very low levels, or may be too 
challenging to amplify due to high AT-richness. 
2.9.2 GO terms analysis of miRNA targets identified by TargetScan 
gProfiler, an online toolset allowing profiling of gene lists based on Gene Ontology, was 
used to cluster predicted target genes of each miRNA (January 2014). Once targets of 
interest had been selected, the chicken orthologues of these genes were identified using the 
g:Orth function of gProfiler. Any statistical significance assigned to associated GO terms is 
a result of gProfiler analysis. It should be noted that although GO terms analysis is useful 
for trying to predict certain trends, the gene lists are often devoid of context and should be 
accepted with caution. 
2.9.3 Design of primers for 3’ UTR amplification of predicted targets 
Where available, the 3’ UTR sequence of predicted target genes was downloaded from 
ENSEMBL 71 (April 2013; Galgal4) and the predicted target site identified by EMBOSS 
Needle, an online tool that allows sequence alignment of two selected sequences at a time. 
For target genes where a 3’ UTR was not known, or where the predicted target site was 
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located downstream of the end of the annotated 3’ UTR, genomic DNA sequence 
downstream of the last known intron or exon was used to design primers.  
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Table 2.1: A summary of the nature of the 3’ UTR sequences cloned into miRNA sensing luciferase 
constructs.  
Gene Known UTR? 
FZD8 No; used sequence downstream of coding region. 
ATG7 No; used sequence downstream of coding region. 
VANGL2 No; used sequence downstream of coding region. 
QKI No; used sequence downstream of coding region. 
ZEB2 No; used sequence downstream of coding region. 
ENAH Yes 
TCF12 Yes 
PPP3CB Yes 
LEF1 Yes 
ETS1 Yes 
PRKACB Yes 
NFIB Only partly annotated; used sequence downstream of end of annotated 
region. 
NR3C1 Only partly annotated; used sequence downstream of end of annotated 
region. 
ROCK2 Only partly annotated; used sequence downstream of end of annotated 
region. 
 
Primers were designed using Primer3Plus to include the whole known 3’ UTR, or at least 
1,000bp of sequence if not. The restriction site sequence of BglII was added to the 5’ end 
of each forward primer and of NheI to the 5’ end of each reverse primer, to allow 
subcloning of the fragment into a modified pGL3 vector
47
. 
2.10 Experimental evaluation of putative miRNA targets 
2.10.1 PCR of 3’ UTRs 
2.10.1.1 Reverse Transcription 
Total RNA was purified from whole HH18 and HH20 chicken embryos by phenol 
chloroform isoamyl alcohol as described in 2.3.3. cDNA was synthesised from this RNA 
using SuperScript II Reverse Transcriptase (Invitrogen). 
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20μl Reverse transcription reaction mix: 
200ng  Random primers 
2μg RNA 
1μl dNTPs (10mM each) 
4μl RNase-free H2O 
4μl 5x First Strand Buffer 
2μl DTT (100mM) 
1μl RNasin (40U/μl) 
1μl SuperScript II Reverse Transcriptase (200U/μl) 
The reaction mixture was incubated on a thermocycler at 42
o
C for 50 minutes, then 70
o
C 
for 15 minutes before freezing at -20
o
C. Two tubes were prepared for each sample; one 
with Reverse Transcriptase added (RT+) and one without Reverse Transcriptase (RT-) to 
check whether the RNA was contaminated with DNA.  
2.10.1.2 PCR 
Aliquots from both RT+ and RT- tubes were amplified for each sample. cDNA was 
amplified with the Expand High Fidelity PCR System (Roche). 
50μl PCR amplification mix: 
1μl  dNTPs (10mM each) 
37.75μl dH2O 
1.5μl  Forward and Reverse primer mix (10μM each) 
2μl  RT+ or RT- mix 
5μl  10x Expand High Fidelity Buffer with 15mM MgCl2 
2.6U  Expand Enzyme 
The mixtures were amplified as shown below: 
94
o
C 2 minutes 
25 cycles of: 
94
o
C 15 seconds 
57
o
C 30 seconds 
72
o
C 2 minutes 
Then, 
72
o
C 7 minutes 
2.10.1.3 Agarose gel electrophoresis and purification of PCR products 
The PCR products were purified by 0.7% agarose (Melford laboratories). The size of each 
product was evaluated by molecular size marker (Roche). Products were cut from the gel 
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and purified by GeneJET Gel Extraction Kit (Thermo Scientific) according to 
manufacturer’s instructions. None of the RT- control reactions showed any amplification. 
2.10.2 Generating miRNA-sensing luciferase constructs 
2.10.2.1 Ligation into pGEM-T Easy 
Purified PCR fragments were ligated into pGEM-T Easy using the pGEM-T Easy Vector 
System I (Promega). 
10μl Ligation mixture: 
5μl  2x Rapid Ligation Buffer 
37.5ng  pGEM-T Easy Vector 
1μl  T4 DNA Ligase 
3.25μl  Purified PCR product 
Mixtures were left at room temperature for 2 hours. 
2.10.2.2 Transformation into DH5α E.coli competent cells 
75μl DH5α E.coli chemically competent cells were thawed on ice for 30 minutes. pGEM-T 
Easy ligation mixtures were simultaneously cooled on ice for 30 minutes. The entire 
ligation mixture was added to the competent cells and mixed by gentle flicking. Tubes 
were placed in a heat block at 37
o
C for 30 seconds and then left on ice for 2 minutes. 800μl 
LB broth was added and tubes were left shaking at 37
o
C and 200RPM for 60 minutes. 
After incubation tubes were gently spun down at 3,000 RPM for 3 minutes and the pellet 
resuspended in 200μl broth. 40μl 20mg/ml X-gal (Thermo Scientific) and 4μl 1M IPTG 
(Thermo Scientific) was added to the cell suspension and the entire volume was plated 
onto a LB-Agar plate containing carbenicillin and incubated at 37
o
C overnight. A single 
white colony was picked from each plate and cultured overnight in 10ml LB broth, at 37
o
C 
and 200RPM. 
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2.10.2.3 Plasmid purification 
pGEM-T Easy constructs were purified by QIAprep Spin Miniprep Kit (Qiagen) according 
to manufacturer’s instructions. DNA was quantified as described in 2.3.2. 
2.10.2.4 Restriction of amplified 3’ UTRs 
pGEM-T Easy constructs were digested with BglII and NheI restriction enzymes 
(Promega) to release the amplified 3’ UTRs. 
Digestion mix: 
2μg pDNA 
3μl Buffer B 
xμl dH2O to make the reaction up to 30μl 
1μl NheI Enzyme 
1μl BglII Enzyme 
Reaction mixtures were left in a heat block set to 37
o
C for 2 hours. The restricted 3’ UTR 
fragments were isolated by agarose gel electrophoresis as described in 2.10.1.3 and 
quantified as described in 2.3.2. 
2.10.2.5 Ligation into modified pGL3 vector 
A modified pGL3 vector, created by deleting the MCS upstream of the SV40 promoter in 
the pGL3 Control cloning vector (Promega) and inserting a MCS downstream of the 
luciferase stop codon, was cultured and isolated as described in 2.10.2.3. The empty vector 
was digested with BglII and NheI restriction enzymes and purified as described in 2.10.2.4 
and quantified as described in 2.3.2. Purified 3’ UTR fragments (2.10.2.4) were ligated 
into the modified pGL3 vector. 
Ligation mix: 
5μl 2 x Rapid Ligation Buffer 
66ng Linear empty pGL3 vector 
xμl Purified 3’ UTR fragment 
1μl T4 DNA Ligase 
yμl dH2O to make the reaction up to 10μl 
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A ratio of 6 moles of insert to 1 mole of empty pGL3 vector was used. The ligation mix 
was left at room temperature overnight. The entire ligation mix was transformed into 
DH5α E.coli cells and cultured as described in 2.10.2.2, without the use of X-Gal. 
2.10.2.6 Colony PCR identification of constructs containing 3’ UTR inserts 
Seven colonies from each plate were checked for the presence of the specific insert by 
PCR, with the original pGEM-T Easy construct serving as a PCR control. 
20μl PCR mix: 
10μl 2x BioMix Red (Bioline) 
1μl Forward and reverse primer mix used to amplify 3’ UTR (10μM each) 
9μl dH2O 
Cycling conditions: 
94
o
C 4 minutes 
30 cycles of: 
94
o
C 30 seconds 
55
o
C 30 seconds 
72
o
C 1 minute 
Then, 
72
o
C 7 minutes 
Each colony was numbered and transferred to a new LB Agar carbenicillin plate and 
incubated at 37
o
C overnight. PCR products were assessed on a 0.7% agarose gel. One 
colony from each plate, known to contain the insert after PCR, was cultured as described in 
9.2.2 and purified as described in 2.10.2.3. The sequence of the insert was checked by 
Sanger sequencing using pGL3 sequencing primers: 
pGL3 Sequencing primer 1: 
5’-CCTCATAAAGGCCAAGAA-3’ 
pGL3 Sequencing primer 2: 
5’-CTCATCAATGTATCTTATCATGTC-3’ 
2.10.3 Generating pGL3 mutant constructs 
pGL3 mutant constructs were generated using Gibson Assembly which generates a 
construct from PCR products with overlapping regions.  
39 
 
2.10.3.1 Mutagenesis PCR of pGL3 constructs 
A pair of primers placed in the ampicillin resistance gene were used as universal primers in 
all mutagenesis cloning. Primers were designed over the miRNA target site which 
contained mismatched nucleotides chosen to create an enzyme restriction site out of the 
miRNA target site (Figure 2.1). 
 
Figure 2.1: pGL3 Luciferase miRNA-sensing construct. An example of a modified pGL3 vector containing 
an amplified 3’ UTR insert, showing the position of mutagenesis primers. 
The two halves of each pGL3 construct were amplified using Phusion High-Fidelity DNA 
Polymerase (Finnzymes, NEB). 
PCR mix and method: 
2.5μl Forward primer (10μM), 2.5μl Reverse primer (10μM) and 20ng pDNA were 
combined in a PCR tube. 
Mastermix: 
31.5μl dH2O 
10μl 5 x Phusion HF buffer 
1μl dNTPs (10mM each) 
1U Phusion polymerase 
43μl mastermix was added to the primers and pDNA mix by gentle pipetting. 
Cycling conditions: 
98
o
C 30 seconds 
20 cycles of: 
98
o
C 10 seconds 
59
o
C 30 seconds 
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72
o
C X minutes 
Then, 
72
o
C 10 minutes 
4
o
C 2 minutes 
An extension time of approximately 1 minute per 1kb of PCR product was used. 5U DpnI 
restriction enzyme (Promega) was added to the PCR mixture immediately after the final 
PCR step. The mixture was incubated on a thermocycler at 37
o
C for 2 hours to digest any 
remaining pDNA. PCR products were purified on 1% agarose gels as described in 2.10.1.3 
and quantified as described in 2.3.2. 
2.10.3.2 Gibson assembly of PCR products 
The two complementary halves of each plasmid were assembled using Gibson Assembly 
mastermix (NEB). PCR products were combined in a 1:1 molar ratio, with 100ng of the 
larger product being used. 
Gibson Assembly reaction mixture: 
Aμl PCR product A 
Bμl PCR product B 
10μl 2x Gibson Assembly mastermix 
xμl dH2O to make reaction volume up to 20μl 
The Gibson Assembly mixture was incubated on a thermocycler at 50
o
C for 60 minutes. 
2μl Gibson Assembly mixture was then transformed into 150μl DH5α E.coli cells as 
described in 2.10.2.2 and purified as described in 2.10.2.3. A diagnostic digest of the 
purified mutant pDNA was done to confirm successful mutation. 
Digestion mix: 
1μg pDNA 
2μl 10x Restriction buffer 
1μl Restriction enzyme 
xμl dH2O to make reaction volume up to 20μl 
Digestion mixtures were incubated at 37
o
C for 2 hours, and digestion checked on a 1% 
agarose gel.  
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2.10.4 Luciferase assays of miRNA sensing constructs 
2.10.4.1 Cell culture 
Chicken DF1 fibroblast cells were cultured in Dulbecco’s modified Eagle medium 
(DMEM) containing GutaMAX, 1g/L D-glucose and Pyruvate (Life Technologies), with 
10% fetal bovine serum (FBS) (Gibco, Life Technologies) and 1% penicillin-streptomycin 
(Gibco, Life Technologies) added on first use. Cells were passaged every other day by 
treatment with 1ml 0.25% Trypsin-EDTA (Gibco, Life Technologies) for 30 seconds at 
room temperature followed by removal of trypsin and further incubation at 37
o
C for 
approximately 2 minutes. Cells were then transferred to a new flask containing media at a 
1:5 dilution. Cells were maintained in a humidified cell culture incubator at 37
o
C with 5% 
CO2. 
2.10.4.2 Cell transfection 
Cells were detached from the flask surface as described in 2.10.4.1, and counted using a 
haemocytometer. Approximately 6,000 cells were added to each well of a 96-well plate 
and media added to a volume of 100μl. Cells were incubated for at least 12 hours to allow 
re-attachment to the plate surface. The media was removed and replaced with 50μl serum-
free media. A transfection mix was prepared as described below. 
Transfection mix 1: 
100ng pGL3 pDNA 
50nM miRNA mimic 
25ng Renilla pDNA 
xμl Serum-free media to a volume of 25μl 
Transfection mix 2: 
25μl Serum-free media 
0.2μl Lipofectamine 2000 Transfection reagent (Life Technologies) 
Tubes were left at room temperature for 5 minutes. Transfection mixes 1 and 2 were 
combined and left at room temperature for 20 minutes. 50μl of the combined transfection 
mix was added to a well of cells and cells were left to incubate at 37
o
C. After 6 hours the 
media was removed and replaced with media described in 2.10.4.1. but without 1% 
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penicillin-streptomycin. Cells left in humidified incubator for 24 hours. Either miScript 
miRNA mimics (Qiagen) or custom siRNA oligos (Sigma) were used as miRNA mimics. 
Custom siRNA oligos were designed to represent the endogenous miRNA/miRNA* 
duplexes, complete with mismatches. Each construct was evaluated in the presence of the 
putative target miRNA mimic, a control miRNA mimic (miR-140) and without a miRNA 
mimic. Some 3’ UTRs had more than one putative miRNA target; these constructs were 
also evaluated with a mixture of the two putative miRNA mimics. 
2.10.4.3 Luciferase assay 
A Dual-Luciferase Reporter Assay System kit was used to assess luciferase acitivity 
(Promega). This kit allows Renilla Luciferase to serve as an internal control of transfection 
efficiency. 
  
Cells were washed twice with cold PBS and care was taken to remove all PBS. 60μl 1x 
Passive Lysis buffer was added to each well and the plate was rocked gently for at least 15 
minutes. 10μl lysis solution and 50μl Luciferase Assay Reagent II were combined and 
photo emission was measured at 562 nm using a multi-label counter (Perkin Elmer). 50μl 
Stop & Glo reagent was added and the Renilla Luciferase photo emission measured at 562 
nm. 
2.10.4.4 Normalisation of luciferase assay data 
Four biological replicates, each with three technical replicates, were performed. Each 
firefly luciferase assay reading was normalised to its renilla luciferase reading. The 
average activity of the plasmid in the absence of miRNA mimics was set to 100%. The 
activity of the constructs transfected with putative target miRNA mimic(s) and control 
miRNA mimics was normalised to the average activity of the plasmid in the absence of 
miRNA mimics. A student’s t-test using standard deviation values was performed using 
GraphPad Prism version 5.01 for Windows, GraphPad Software, San Diego California 
USA, www.graphpad.com. 
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2.11  Western blotting 
Loading buffer and 1μl 100mM DTT was added to 40μg protein from tissue lysate 
prepared as described in 2.3.5 and quantified as in 2.3.6, and denatured at 70
o
C for 10 
minutes. Samples were loaded onto an 8% resolving polyacrylamide gel with a 5% 
stacking polyacrylamide layer and run at 100V for up to 2 hours.  
 
Samples were then transferred onto a nitrocellulose membrane using a semidry blotter 
(BioRad) at 100V for 90 minutes. Following transfer the membrane was washed in TBST 
for 5 minutes and then blocked in freshly prepared 5% milk in TBST at room temperature 
for 2 hours. The membrane was washed in TBST for 15 minutes and then rocked in a 
1:5,000 dilution of primary antibody in 5% milk in TBST overnight at 4
o
C. After washing 
the membrane four times for 10 minutes each time in TBST, a secondary antibody coupled 
to HRP (Jackson Laboratories) was applied at a 1:1,500 dilution for 1 hour at room 
temperature. Residual secondary antibody was removed by washing with TBST. Protein 
was detected by chemiluminescence subsequent to treatment of the membrane with 
1.25mM luminol (Sigma) and 0.2mM β-coumaric acid (Sigma) in 100mM Tris-HCl pH 
8.5, followed by imaging on a Fujifilm LAS 3000 imager (Fuji Photo Film Co., Ltd).  
 
Membranes were stripped by washing in mild stripping solution. 
Mild stripping solution: 
15g Glycine 
1g SDS 
10ml Tween20 
xml Sterile H2O to 1L after adjusting the pH to 2.2. 
Membranes were washed twice for 10 minutes in mild stripping solution, then twice in 
PBS for 10 minutes and finally twice in TBST for 5 minutes before being put back into 5% 
milk in TBST. 
2.12  Northern blotting 
Total RNA was purified and quantified from whole HH16 and HH20 embryos as described 
in 2.2.2, 2.3.3 and 2.3.4 and probed for microRNAs. 
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2.12.1 Polyacrylamide gel electrophoresis 
A 15% denaturing polyacrylamide gel was prepared by dissolving urea in dH2O and 
combining with other reagents as described below: 
2.1g  Urea 
1.25ml  dH2O 
1.85ml  40% Acrylamide solution 
500μl  5x TBE 
50μl  10% APS 
2.5μl  TEMED 
2x loading dye was added to 50μg total RNA and denatured at 90oC for 30 seconds before 
placing on ice. 
2x loading dye mix: 
50μl 0.5M EDTA 
0.2g 2% Bromophenol Blue 
0.01g Xylene cyanol 
9.5ml Formamide 
Samples were run at 100V for approximately 1 hour in 0.5x TBE running buffer. 
2.12.2 Semi-dry transfer and cross-linking 
RNA was transferred onto a membrane (Hybond NX, Amersham Biosciences) by semidry 
blotter at 300mA for 1 hour, and then crosslinked. 
Crosslinking mix 1: 
10ml  dH2O 
122.5μl 12.5M 1-methylimidazole 
10μl  HClconc 
Crosslinking mix 2: 
10ml  Crosslinking mix 1 
0.373g  EDC 
2ml  dH2O 
The membrane was placed on top of Whatman filter paper that had been soaked in 
crosslinking mix 2, sealed with clingfilm and left rocking at 60
o
C for 2 hours. The 
membrane was then washed in dH2O twice for 5 minutes at room temperature. 
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2.12.3 Probing 
2.12.3.1 Pre-hybridisation 
ULTRAhyb-Oligo Hybridization Buffer (Life Technologies) was warmed to 37
o
C before 
being added to hybridisation tubes containing RNA membranes. Membranes were washed 
in hybridisation buffer in a HB-1000 hybridisation oven (UVP) at 37
o
C for 2 hours. 
2.12.3.2 γ32P-ATP end labelling of complementary oligonucleotides 
γ32P-ATP labelled probes were generated by a T4 Polynucleotide Kinase (NEB) reaction. 
Reaction mix: 
2μl 10μM Complementary oligo 
2μl 10x Reaction Buffer A 
12μl Nuclease-free H2O 
1μl T4 Polynucleotide Kinase 
3μl  γ32P-ATP 
The mixture was incubated in a heat block at 37
o
C for an hour and unincorporated 
nucleotides were removed by centrifugation (MicroSpin G25 columns, Illustra). Sterile 
H2O was added to the probe to a final volume of 50μl, added to the hybridisation tubes 
containing the RNA membranes and left rotating overnight at 37
o
C. The membranes were 
washed with washing solution at 37
o
C. 
Washing solution: 
500μl 20x SSC pH 5 
500μl 10% SDS 
49ml dH2O 
The membranes were vigorously rinsed in washing solution, then washed twice for 20 
minutes at 37
o
C and finally rinsed again with washing solution before being wrapped in 
clingfilm and exposed on a phosphorimaging plate (Fujifilm BAS cassette 2025). Plates 
were developed using a phosphorimager (Molecular imager FX pro plus, BIORAD). 
Membranes were stripped by washing twice in boiling 0.1% SDS for 20 minutes. 
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2.13 Image J quantification of Western and Northern blots 
Relative intensities of Western and Northern blot bands were calculated using ImageJ 
software
48,49
. The Rectangular Selections pane was used to draw a rectangle around the 
normalising band (Actin for Western blots and U6 for Northern blots). Once the selection 
was confirmed a second, identically sized rectangle was used to surround the target band 
(FZD7 or RARβ for Western blots, miR-130 for Northern blots). The software 
automatically calculated the intensity of the coloured pixels in the identically sized areas 
and allowed the normalisation of target to loading control. This value was then expressed 
as a percentage and a comparison made between adjacent lanes. A student’s t-test was 
performed on the Western blot results using GraphPad Prism version 5.01 for Windows, 
GraphPad Software, San Diego California USA, www.graphpad.com and P values 
reported. 
2.14 Fold 
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3 Small RNA sequencing of chick cardiac and cardiogenic 
tissue 
3.1 Introduction 
A summary of the sequencing strategy employed in this project, along with bioinformatic 
analysis of the known animal miRNAs identified in the samples is presented in this 
chapter. Apart from removal of adapter sequences and removal of reads that did not map to 
the chicken genome, all work was performed by the author. Simon Moxon performed the 
adapter removal and the mapping as described in 2.8.1. 
3.1.1 Dissection of tissues for heart tissue-enriched miRNA sequencing 
In order to investigate the miRNA expression profile of the chick embryo during 
cardiogenesis, cardiac and cardiogenic tissue was dissected from embryos over a range of 
stages that represent many of the major early events in heart development (Table 3.1).  
  
48 
 
Table 3.1: A summary of the events taking place during heart development between stage 5 (HH5) and 
stage 23 (HH23) in the chicken embryo.  
Period Major heart development events 
HH5-7 Cardiac progenitor cells migrate from the primitive streak, forming the bilateral heart fields. 
Terminal differentiation markers can be observed by HH7. 
HH8-10 The heart fields fuse. 
Cardiomyocytes start to differentiate. 
Cardiac neural crest cells start to migrate from the neural crest to the outflow tract. 
HH11-13 The heart tube loops from a C- to an S-shape. 
Growth during this time is mainly from migration of cells. 
The cardiac neural crest cells migrate into the pharyngeal arch arteries. 
HH14-16 Myocardial cells proliferate in the ventricles, causing them to balloon out. 
The epicardium and smooth muscle cells start to form. 
Atrial septation starts. 
HH17-20 The four layers of the heart (myocardium, cardiac jelly, endocardium and epicardium) have 
formed. 
The cardiac neural crest cells reach the outflow tract and valve formation begins. 
HH21-23 Valve formation continues. 
Ventricular septation begins. 
 
During the early stages of development (HH5 to HH7), cardiogenic mesoderm migrates 
from the primitive streak to form the bilateral heart fields (Figure 3.1A). Between stage 
HH8 and stage HH10 the bilateral heart fields fuse and the heart tube is formed (Figure 
3.1B). During these early stages it is difficult to separate cardiogenic and cardiac tissue 
from other surrounding tissues and therefore the dissected area was chosen to include all 
forming heart regions but also contained other developing tissues. From stage HH14 
onwards the heart projects away from the rest of the embryo, and it becomes more feasible 
to dissect only heart tissues. During these later stages the cardiac neural crest cells migrate 
towards the forming heart (Figure 3.1C). To capture these migrating cells, tissue indicated 
in the blue region of Figure 3.1C was dissected and labelled “NT”; these samples contain 
many different tissue types, including neural tube and head mesenchyme, in addition to 
cardiac neural crest cells.  
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Figure 3.1: Tissue dissection performed prior to small RNA enrichment. A: A schematic of a typical chick 
embryo between stages HH5 and HH7, with the migrating cardiogenic mesoderm indicated in blue and red. 
The dissected area is shown in the red box. B: A ventral view of a HH9 chick embryo. By HH9 the heart fields 
have fused and a heart tube has formed. C: A lateral view of an embryo past HH14. Dissected heart tissue is 
shown outlined in red, and a second sample containing migrating neural crest and other tissues, designated 
“NT”, is outlined in blue. 
 
In total, nine samples were enriched for small RNA and used to prepare Illumina TruSeq 
indexed libraries: HH5-7, HH8-10, HH11-13, HH14-16 Heart, HH14-16 NT, HH17-20 
Heart, HH17-20 NT, HH21-23 Heart, and HH21-23 NT. These libraries were sequenced 
by 50bp paired-end Illumina HiSeq 2000 sequencing. 
3.1.2 Next Generation Sequencing technologies 
The Human Genome Project was initiated in 1990 and aimed to sequence the entire human 
haploid genome by automated Sanger sequencing
50
. Despite the increase in sequencing 
throughput that resulted from improvements in automation, the Sanger sequencing method 
still relies on polymer separation of fluorescently labelled DNA fragments, limiting the 
number of samples assayed in parallel and thus limiting throughput
51
. The need for 
improvement drove the development of several Next Generation Sequencing (NGS) 
platforms, able to produce large amounts of sequencing data by a variety of different 
strategies
50,51
. 
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Table 3.2: Summary of the capacities of the most widely used sequencing platforms. Comparison of 
Illumina GAIIx
52
, Illumina HiSeq 2000
52
, Life Technologies 5500W
53
 and Roche 454 FLX+ platforms
54
. The 
approximate total number of GAIIx, HiSeq 2000, Roche 454 and ABI SOLiD machines in the world
55
 is 
indicated to give perspective on the popularity of the different NGS platforms. 
Platform Illumina 
GAIIx 
Illumina 
HiSeq 2000 
LifeTechnologies 
SOLiD 5500W 
Roche 
454 FLX+ 
Template 
preparation 
Solid-phase PCR Solid-phase PCR Solid-phase PCR Emulsion PCR 
NGS chemistry 
Reversible 
terminators 
Reversible 
terminators 
Ligation Pyrosequencing 
Read length 2 x 150bp 2 x 150bp 75bp + 25bp 700bp 
Run time 10 days 11 days 7 days 1 day 
Gb per run 30 600 160 0.7 
Machines 
worldwide 
500 826 ~324 364 
Bp: base pairs; Gb: gigabases. 
 
Although not without their limitations
51
, these new technologies are rapidly being 
improved to increase throughput, reduce errors and decrease cost. Several platforms are 
currently in development
56
, and many benchtop machines are now available for smaller-
scale use
57,58
. Three platforms are most commonly used for larger sequencing projects: the 
454 sequencer by Roche, Life Technologies’ SOLiD system as well as the Illumina GAIIx 
and HiSeq systems (Table 3.2). In addition, improvements in reagents chemistries and 
machine optics have allowed for steady gains in sequencing output and flexibility. For 
example, the Illumina HiSeq 2500 can be used for either rapid runs (600x10
6
 reads per run, 
2 x 150bp reads), or for high output runs (4x10
9
 reads per run, 2 x 125bp reads)
59
. 
3.1.3 Techniques for assessing microRNA expression 
Three methods are currently used to assess expression of miRNAs: microarrays, 
quantitative PCR (qPCR) and NGS. Microarrays involve the hybridisation of labelled 
small RNAs to oligonucleotide probes on a solid surface
60
. The design of microRNA 
probes is often constrained by the short length of miRNAs, which can lead to inclusion of 
the entire mature miRNA sequence in the probe and therefore a large variation (>20
o
C) in 
the melting temperatures (TM) of the different probes
61
. Such a large variation in TM then 
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results in cross-hybridisation and loss of specificity. This problem, along with difficulties 
in distinguishing between different members of a miRNA family, which can vary by as 
little as a single nucleotide, have been overcome by allowing the increase in hybridisation 
temperature as a result of the inclusion of Locked Nucleic Acid (LNA) nucleotides in the 
probe. Data analysis of microarray data is simple and well established, and for profiling 
experiments microarrays have much to offer. However, novel miRNAs cannot be readily 
detected by microarray.  
 
qPCR for miRNAs can be done by preparing cDNA with a stem-loop primer, followed by 
either TaqMan or SYBR Green assays with a universal primer complementary to a portion 
of the stem loop sequence and a miRNA-specific forward primer
62
. The TM of the forward 
primer can be adjusted by adding a tail, the length of which will depend on the TM of the 
mature miRNA
62
, or by adding LNA nucleotides
63
. The design of miRNA-specific qPCR 
primers can be costly and it is often necessary to assay several genes in order to identify 
good normalisers for each experiment
61
. As with microarrays, qPCR cannot be used to 
discover novel miRNAs. 
 
Sequencing of miRNAs, in contrast, does not require knowledge of the miRNA and 
therefore can be used to detect novel miRNAs. However, the preparation of samples for 
sequencing involves ligation and PCR amplification steps and at the moment is still 
plagued by biases introduced by these steps
61,64
. Finally, extensive computational 
knowledge is required to perform bioinformatic analyses on NGS data, although increasing 
numbers of user-friendly tools have recently become available
42
. 
 
NGS was selected for this project as it represented the technology that offered the ability to 
both profile the expression of known miRNAs and to detect previously undiscovered 
miRNAs. The Illumina HiSeq 2000 platform was chosen for its accuracy, its sequencing 
yield and its flexibility which allowed all nine samples to be sequenced in a single lane. 
The High-Throughput Genomics Group at the Wellcome Trust Centre for Human Genetics 
in Oxford performed the Illumina HiSeq sequencing. 
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3.1.4 NGS Library preparation and sequencing 
The general workflow from biological sample to sequencing result is similar for all three 
major NGS systems (Table 3.2): nucleic acid isolation, library preparation, template 
preparation, sequencing, and bioinformatic analysis. It is essential that pure DNA or RNA 
of good quality is used as an input into the library preparation process and to this end 
sample quality must be assessed. Library preparation involves the generation of a pool of 
DNA, the length of which will vary depending on the platform and the application, with 
sequencing primers ligated to each end of every strand. A small amount of this library is 
then immobilized either on beads, in the case of SOLiD and 454, or on a sequencing slide, 
in the case of both Illumina platforms
50
. Once immobilized, the library is amplified and 
then sequenced by extending primers by synthesis
51
.  
 
Small RNA library preparation for the HiSeq platform comprises the ligation of a 
sequencing adapter to the 3’ end of a small RNA-enriched sample followed by ligation of a 
different sequencing adapter to the 5’ end of the sample (Figure 3.2A). cDNA synthesis 
and PCR amplification, with primers complementary to the ligated adapters, follows. The 
amplified products are then separated on a polyacrylamide gel allowing the isolation of the 
library, double stranded DNA copies of adapter ligated small RNA. 
 
Once the library has been validated to contain a pool of the correct size DNA fragments by 
checking the size distribution of the library by fluorescent capillary gel electrophoresis on 
a BioAnalyzer machine , template preparation can begin. The double stranded DNA library 
is first denatured and then flowed over a solid surface, the flow cell, covered with primers 
covalently attached to the flow cell surface and complementary to the adapters ligated onto 
the library (Figure 3.2B). 
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Figure 3.2: A brief overview of Illumina TruSeq small RNA library preparation and paired end 
sequencing. A: Proprietary adapters are ligated onto the 3’ ends and then the 5’ ends of small RNA-enriched 
samples. After ligation a specific RT primer is used to make cDNA, which is then amplified with primers 
complementary to the ligated adapters. For barcoded libraries, indexed primers are used during the PCR step 
that add a six nucleotide sequence into the adapter sequence. Each sample is amplified with a different 
indexed primer, thus barcoding each biological sample. B: The indexed small RNA library is washed over the 
flow cell, which is covered with primers covalently attached to the flow cell surface, allowing library strands to 
attach to the flow cell. Sequencing is initiated by the binding of a sequencing primer complementary to the 
adapter sequence, and sequencing by synthesis follows. Once the sequencing reaction is complete, the 
synthesized strand is melted off of the template strand and washed away. At this point a primer 
complementary to the universal portion of the index is added, allowing the index to be sequenced. The 
synthesised strand is then again melted off. The template is flipped over and becomes attached to the flow cell 
surface by its formerly free end, allowing a sequencing primer complementary to the second adapter to bind 
and initiate another sequencing by synthesis reaction. 
 
The library will bind to these complementary primers and because the concentration of the 
library fragments added to the flow cell is closely controlled, several free primers will 
surround each bound library strand. The bound library strands will form a bridge by 
attaching to a neighbouring primer complementary to the second adapter on its free end. 
When a mix of unlabelled nucleotides and enzyme is flowed over the flow cell, library 
strands are copied. The DNA on the flow cell is then denatured and the original library 
strand is washed away, leaving only the copy of the library strand which is covalently 
attached to the flow cell surface. The flow cell is then treated to disrupt the bridge of single 
stranded DNA on one side only, and several cycles of bridge amplification PCR is 
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performed resulting in “monoclonal” clusters of DNA generated from a single parent 
library strand. The different clusters cover the flow cell, which will be used to sequence the 
template library. 
 
The template library on the HiSeq platform is sequenced by a method involving cyclic 
reversible terminators. A mixture of fluorescently labelled nucleotides, that have been 
chemically modified at their 3’ end to prevent the addition of further nucleotides, is flowed 
over the flow cell
50
. This allows DNA polymerase to incorporate a nucleotide 
complementary to the template strand. The excess nucleotides are then washed away and 
the flow cell is imaged to detect which nucleotide was added. As the flow cell is covered in 
clusters from a single parent strand, the signal from a single cluster should be the same for 
each incorporation, therefore allowing the detection of the fluorescent signal. After the 
imaging step both the fluorescent dyes and terminating groups are cleaved off and washed 
away, and the cycle is repeated. The HiSeq platform is currently able to complete at least 
150 cycles, although improvements are rapidly being made. Once 150 cycles of nucleotide 
incorporation has been completed, the DNA on the flow cell is denatured and each 
molecule is flipped over to become covalently attached to the flow cell by the adapter 
previously left free. Another 150 cycles of sequencing can then be done, giving results 
from both ends of the template strand. This is called paired end sequencing. Generally, 50 
base pair (bp) paired end runs are more commonly used for small RNA sequencing. 
 
Every flow cell contains eight separate lanes that allows the generation of up to eight 
separate template libraries. Furthermore, adapters can be made library-specific by the 
inclusion of a small identifying oligonucleotide that indexes each library
65,66
. These 
barcodes allow concurrent sequencing of templates generated from multiple libraries in a 
single flow cell lane, and can therefore greatly reduce the cost of a sequencing project. 
Once sequencing is complete, base calls are converted into sequence information 
corresponding to the library strand. The sequencing reads can then be aligned to a known 
reference genome, if one exists, and further analyses can be done to extract biologically 
relevant information. 
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3.1.5 Previous sequencing experiments 
Chicken microRNA expression has been scrutinized by NGS in whole embryos at E11 
(~HH37)
67
, in embryonic skeletal muscle at E10 (~HH36)
68
, in chicken liver at E15 
(~HH41) and E20 (~HH45)
69
, in developing chicken adipocytes in vitro
70
, and in chicken 
embryonic fibroblasts in vitro
71
. Furthermore, NGS of somites from 3- to 5-day old 
chicken embryos affirmed the importance of tissue-specific sequencing in determining 
which microRNAs are highly expressed in such tissue, possibly indicating an important 
role in that tissue, and giving a starting point for the examination of the functions of the 
highly expressed microRNAs
72
. Although some highly expressed miRNAs such as miR-1 
and miR-208 have been found to be essential for heart development or function, the NGS 
library preparation method is vulnerable to sequence-dependent ligation and PCR bias 
(discussed further in 3.3.5). This work focussed on comparing expression profiles across 
different samples, as the ligation and PCR bias is most likely constant for each miRNA. 
 
An Illumina GA NGS profiling experiment conducted in 2009 suggested that the 18 most 
highly expressed miRNAs in adult murine heart tissue account for more than 90% of 
cardiac miRNAs
73
. A summary of this profile, with the same miRNAs from different loci 
combined to simplify, is presented in Figure 3.3. In adult mouse hearts miR-1 was 
reported to be the most sequenced miRNA, taking up more than a third of all reads. Several 
of the miRNAs shown in Figure 3.3 are known to be essential for heart development and 
function including miR-1
4
, miR-126
74
, miR-133
4
, miR-143
75
, and miR-208
6
. 
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Figure 3.3: Known miRNA profile in adult mouse hearts show a few miRNAs dominate sequencing 
space. Summary of the percentage normalised reads taken up by the 12 most highly detected miRNAs in 
male and female adult mouse hearts, as determined by a sequencing study conducted by another group of 
researchers
73
. 
 
However, very little is currently known about the specific miRNA expression profiles 
during the major events of early heart development, and elucidation of such a profile 
would assist in discovering miRNAs that may play an important role in forming the early 
heart. 
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3.2 Results 
3.2.1 Illumina TruSeq libraries were enriched for 22-nucleotide RNAs 
Simon Moxon converted raw sequencing FASTQ files to FASTA format and removed 
adapter sequences with custom Perl scripts. Only reads that mapped perfectly by PatMaN
39
 
to the chicken genome (Galgal4
40
) were retained. The vast majority of reads had a length 
of 22 nucleotides (Figure 3.4), indicating that the prepared libraries contained a fraction of 
RNA corresponding to miRNAs in size. A further peak, smaller but broadly around 33 
nucleotides, most probably contains Piwi-interacting small RNAs (piRNAs)
76
 that appear 
to be more highly expressed in the early stages of chick development (Figure 3.4). 
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Figure 3.4: Size distribution of sequenced small-RNA enriched total RNA. A: The peak at 22 nucleotides 
corresponds to mature miRNA length. A second, broader but much smaller peak at 33 nucleotides is most 
probably Piwi-interacting RNAs
76
. B: The percentage ratio of 22nt reads compared to 33nt reads for each 
sample shows the the relative peak size of the 33nt fraction is much larger in the HH5-7 and HH8-10 samples. 
 
A comparison of the contribution of 22nt reads versus 33nt reads for each sample shows 
that 33nt sequences are more abundant in the early stages of chick development (Figure 
3.4B). This profile is similar to that seen in the literature
77
, confirms that libraries 
containing mostly miRNA-sized sequences were successfully generated, and implicates 
Piwi-interacting RNAs in processes occurring between HH5 and HH8 in the chicken 
embryo (3.3.1). 
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3.2.2 Many animal miRNAs are expressed during chick cardiogenesis 
Initially existing miRNAs from miRBase
41
 release 19 were profiled across the 
developmental time series with the UEA Small RNA Workbench tool, miRProf
42
, by 
Simon Moxon. Subsequently, trimmed reads were profiled against existing miRNAs from 
miRBase release 20 by the author (2.8.2). miRProf searches for perfect matches to all 
animal miRNAs, allowing the identification of miRNAs that have yet to be annotated in 
some model organisms. The miRNA results from analysis of these NGS data with miRProf 
were compared to a list of known chicken miRNAs using a custom R script
78
 written by 
the author, which resulted in the discovery of 31 known animal miRNAs not yet formally 
identified as chicken miRNAs in miRBase (Table Apx A.1). Three of these (miR-143, 
miR-182 and miR-363) were highly expressed in one or more samples (see 3.2.5 later). A 
list of the number of animal miRNAs that have not yet formally been added to miRBase as 
chicken miRNAs is given for each sample in the final column of Table 3.3. 
 
Table 3.3: Breakdown of the total number of distinct miRNAs matched to animal miRNAs in miRBase 
release 20 by sample. The total number of known chicken miRNAs is shown in column three, with the 
percentage of the total number of known chicken miRNAs represented in each sample indicated in column 
four. miRBase release 20 contains a total of 636 known chicken miRNAs. Column five shows the number of 
miRNAs that match perfectly to miRNAs known in other animals that have not yet been added to the list of 
known chicken miRNAs. 
Sample miRNAs by 
miRProf 
Gga miRNAs % of 636 known 
Gga miRNAs in 
sample 
Non-Gga 
miRNAs in 
sample 
5-7 183 165 26% 18 
8-10 282 264 42% 18 
11-13 327 309 49% 18 
14-16 Heart 355 333 52% 22 
14-16 NT 385 363 57% 22 
17-20 Heart 375 351 55% 24 
17-20 NT 357 336 53% 21 
21-23 Heart 342 321 50% 21 
21-23 NT 332 311 49% 21 
 
The discovery of conserved animal miRNAs expressed in the chicken embryo not 
previously annotated adds several miRNAs that can be added to the miRBase chicken 
miRNA database. As discussed in 3.3.2, two of these miRNAs are known to be essential 
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for heart development (miR-143) and are upregulated in failing human hearts (miR-182), 
making their discovery in the chicken embryo very interesting. 
3.2.3 A large fraction of known chicken miRNAs are expressed from gastrulation 
The total normalised reads in the miRNA-sized fraction of each sample was mostly 
assigned to known animal miRNAs (Figure 3.5A), apart from the 51% of reads not 
assigned in sample HH5-7. Only 26% of the 636 known chicken miRNAs were expressed 
during early development (HH5-7, Table 3.3). However, the percentage of total chicken 
miRNAs increased rapidly with development to reach a peak of 57% in the HH14-16 NT 
sample. This increase in the number of miRNAs detected as development proceeds has 
subsequently been found by other researchers
77
, and indicates that a large number of 
known chicken miRNAs are already expressed in HH5-7 embryos. 
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Figure 3.5: Known miRNAs account for most of the reads from the miRNA sized fraction of almost all 
the samples, and many known chicken miRNAs were detected. A: The percentage of normalised reads 
from the miRNA sized fraction that were found to be due to known animal miRNAs is shown in grey, with the 
remaining unlabelled reads shown in blue. B: The percentage of known chicken miRNAs detected in each 
sample. Early in development (HH5-7) only 26% of the 636 known chicken miRNAs were detected. However, 
the fraction of known chicken miRNAs detected soon rose to a maximum of 57% (HH14-16 NT). A small 
portion of miRNAs were detected in only one of the nine samples at low levels, as indicated by the red caps 
on the appropriate bars. 
 
A small number of miRNAs were detected at only one time point, always at less than 1 
read per million (Figure 3.5B). The average number of reads for miRNAs detected at more 
than one time point ranged from 1,418 (median 4.19) to 2,587 (median 1.95) reads per 
million. The percentage of miRNAs only present in one sample varied from 0% in HH5-7 
to 2.4% in HH17-20 Heart. A complete list of miRNAs detected at single time points, 
along with their raw reads numbers, can be found in Table Apx A.2. In total 63 miRNAs 
were detected at single time points. Although the detection of these miRNAs at specific 
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stages could indicate that they have functions particular to those stages, only five were 
found to be conserved in humans and therefore further investigations were focussed on 
miRNAs that could be profiled over several stages (3.3.3). 
3.2.4 Samples cluster according to their known animal miRNA expression 
To determine whether miRNA expression profiles across all stages assayed showed 
gradual changes, the correlation of samples based on their known animal miRNA 
expression profiles, as matched by miRProf
42
 to miRBase
41
 release 20, was assessed using 
a custom R
78
 script written by the author and is displayed as a heatmap in Figure Apx A.1. 
 
Early samples (HH5-7, HH8-10 and HH11-13) clustered together, and were more closely 
related to other slightly older stages (HH14-16 Heart, HH14-16 NT and HH17-20 Heart) 
than to the oldest stages. The later heart sample, HH21-23 Heart, clustered together with 
the older “neural tube” samples (HH17-20 NT and HH21-23 NT). This indicates that most 
miRNA levels changed gradually as development proceeded, as was expected from the 
mixed temporal nature of the dissected tissues. 
 
Sorting miRNAs by normalised read size gives a summary of the levels at which most 
miRNAs were detected (Figure 3.6). Many miRNAs were detected at quite low levels 
between 0 and 0.001 reads per million, particularly at the earliest time point (HH5-7, 38%). 
More than 25% of miRNAs were detected at between 0.001 and 5 reads per million, while 
between 6% (HH5-7) and 16% (HH17-20 Heart) of miRNAs had levels ranging from 
1,000 and 600,000 reads per million. 
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Figure 3.6: Representation of five ranges of known animal miRNA normalised reads. The percentage of 
total miRNAs detected broken down by their normalised read numbers. Less than 17% of miRNAs detected 
had normalised read numbers in excess of 1,000 reads per million. The largest fraction (more than 25% in all 
samples) had normalised reads between 0.001 and 5 reads per million. White: 0 to 0.001 reads per million. 
Yellow: 0.001 to 5 reads per million. Orange: 5 to 50 reads per million. Red: 50 to 1,000 reads per million. 
Black: 1,000 to 600,000 reads per million.  
 
Previous sequencing experiments on adult mouse hearts found that 18 miRNAs represent 
90% of the total sequencing reads. As discussed in 3.3.5 this abundance of very few 
miRNAs may be a result of ligation and PCR bias that greatly influenced earlier 
sequencing experiments, and has not been eliminated yet. Since the detected normalised 
read levels of a miRNA may be influenced by ligation or PCR bias, it is difficult to draw 
conclusions of function based on such reads. A better strategy comprises focussing on 
patterns of change over several time points, as the bias should remain constant for each 
miRNA. However, an analysis of the top expressed miRNAs (3.3.5 and 3.2.6) highlighted 
several predicted targets that are common to different miRNAs found to be highly 
expressed. 
3.2.5 miRNA expression is dominated by two miRNAs 
Ranking known animal miRNAs by normalised read number revealed a single miRNA 
filled a large fraction of the sequencing space of each sample. A distinct change in miRNA 
expression pattern was observed between HH11-13 and HH14-16. 
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Figure 3.7B shows that during early stages in samples HH5-7, HH8-10 and HH11-13, 
miR-92 represented between 66% and 43% of the total known animal miRNA reads. 
Initially 84% of the total known miRNA reads were taken up by only seven miRNAs, but 
in HH11-13 this decreased to 70%. However, from HH14-16 miR-10 became the most 
ubiquitous miRNA in both heart and non-heart tissue samples (Figure 3.7C and Figure 
3.7D), with miR-92 relegated to second or third place. Although miR-10 was the most 
sequenced miRNA in the HH14-16 H and HH14-16 NT samples, taking up about 25% of 
the total known animal miRNA reads, the increase in its expression was much larger in the 
non-heart tissue samples (Figure 3.7F). Investigations into known miR-10 functions 
revealed its intimate involvement in vasculogenesis and angiogenesis, processes that occur 
in both developing cardiac and neural tissue (3.3.5), explaining the large upregulation of 
this miRNA observed here.  
 
miR-130 is dysregulated in diabetic mouse hearts
79
 and consistently featured in the top 10 
miRNAs by normalised expression in the early samples and in the later heart samples, 
although not in the later NT samples. Therefore this miRNA was selected for further 
biological investigation as described in 4.2.7.  
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Figure 3.7: miRNA expression was dominated by two miRNAs and three miRNAs were consistently 
expressed at a very high level in all nine samples. A: The top miRNAs detected in samples HH5-7, HH8-
10 and HH11-13 were dominated by miR-92. B: Although the total number of reads for miR-92 increases 
across these stages, the reads as a percentage of total miRNA reads decreased indicating that miRNA 
expression increased during these stages of development. C,E: miRNA-10 dwarfed the expression of other 
miRNAs in later heart and neural tube samples (HH14-16, HH17-20 and HH21-23 Heart and NT). D,F: 
miRNA-10 expression increased across these stages, especially in the NT samples where it eventually 
accounted for 68% of the total miRNA reads in the HH21-23 NT sample. 
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3.2.6 Enrichment of predicted target genes of top expressed miRNAs 
Although the top ten miRNAs expressed in each sample stay mostly constant, an analysis 
was done to check whether any miRNAs not common to all the samples are still predicted 
to target the same genes. The overlap of predicted target genes of the top expressed 
miRNAs unique to three groups of samples, early development (HH5-7) and later 
development heart (HH14-23 H) and other tissues (HH14-23 NT), was assessed by 
comparison using custom R scripts written by the author. 
 
The majority of top expressed miRNAs found in samples taken during the early stages of 
development (HH5-7, HH8-10, HH11-13) were common to all three samples. 
 
Table 3.4: Comparison of predicted target genes of top expressed miRNAs for samples HH5-7, HH8-10 
and HH11-13.  
Samples compared HH5-7 HH8-10 HH11-13 
Number of predicted targets of top 10 expressed miRNAs  3,081 3,342 3,278 
Number of top miRNAs unique to sample 1 0 2 
Number of predicted targets of top miRNA(s) unique to sample 16  410 
Genes targeted by unique miRNA(s) only 5  68 
% Genes covered by other top expressed miRNAs 69%  83% 
 
 
HH5-7 had one unique top expressed miRNA not found in the other two samples: miR-
2954. miRBase release 20 contains only two entries for this miRNA, one for chicken and 
one for zebra finch. However (Table 3.4) shows that 69% of the predicted target genes of 
miR-2954 were also covered by the remaining top miRNAs, which were common to HH8-
10 and HH11-13. Two top expressed miRNAs in sample HH11-13, miR-10 and miR-148, 
were not found in the top 10 miRNAs of either other sample. These miRNAs were 
predicted to target 410 genes, 83% of which were also targeted by the other common top 
miRNAs (Table 3.4). 
 
During later stages of heart development one unique top expressed miRNA could be found 
in each of the three samples assayed (HH14-16 H, HH17-20 H and HH21-23 H). 
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Table 3.5: Comparison of predicted target genes of top expressed miRNAs for samples HH14-16 Heart, 
HH17-20 Heart and HH21-23 Heart.  
Samples compared HH14-16 H HH17-20 H HH21-23 H 
Number of predicted targets of top 10 expressed miRNAs  3,480 3,046 3,379 
Number of top miRNAs unique to sample 1 1 1 
Number of predicted targets of top miRNA(s) unique to sample 112 6 28 
Genes targeted by unique miRNA(s) only 37 1 11 
% Genes covered by other top expressed miRNAs 67% 83% 61% 
 
Even though miR-22, miR-126 and miR-100 were not common to all three samples, 
between 61% and 83% of their predicted target genes were also predicted to be targets of 
the mostly highly expressed miRNAs common to all three samples (Table 3.5). 
 
Overall non-heart samples HH14-16 NT, HH17-20 NT and HH21-23 NT each showed 
high expression of a single unique miRNA, miR-22, miR182 and miR-100 respectively. 
 
Table 3.6: Comparison of predicted target genes of top expressed miRNAs for samples HH14-16 NT, 
HH17-20 NT and HH21-23 NT.  
Samples compared HH14-16 NT HH17-20 NT HH21-23 NT 
Number of predicted targets of top 10 expressed miRNAs  2,895 3,522 2,771 
Number of top miRNAs unique to sample 1 1 1 
Number of predicted targets of top miRNA(s) unique to sample 112 1121 28 
Genes targeted by unique miRNA(s) only 36 567 11 
% Genes covered by other top expressed miRNAs 68% 49% 61% 
 
Although these miRNAs were unique when the top detected miRNAs of these three 
samples were compared, miR-22 is also a top expressed miRNA of sample HH14-16 H 
and miR-100 was also highly expressed in sample HH21-23 H. Table 3.6 confirms that as 
in the matched heart samples (Table 3.5), more than 61% of the genes predicted to be 
targeted by miR-22 and miR-100 were also predicted targets of the miRNAs common to all 
three NT samples. Almost half of the predicted target genes of miR-182, a top expressed 
miRNA in sample HH21-23 NT only, were also predicted to be targeted by the remaining 
top expressed miRNAs found in all three samples. This suggests that the top expressed 
miRNAs may be functioning in concert to ensure the repression of a core set of targets. 
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A comparison of the ten most highly detected miRNAs in all nine samples revealed that 
three miRNAs were common to all the samples (Figure 3.8A). Just over 40% of the 
predicted target genes of two of these common miRNAs, miR-26 and miR-92, were 
predicted target genes of one or both of the other two common miRNAs (Figure 3.9). 
However, almost four fifths of the predicted target genes of the third common top 
expressed miRNA, miR-30, were not common to miR-26 or miR-92. This analysis 
suggests that miR-26 and miR-92 may function redundantly to ensure the repression of 
their overlapping targets, whereas miR-30 does not (3.3.6). 
 
As noted in 3.2.5, miR-10 rapidly dominates the sequencing space from HH14-16 (Figure 
3.8B). The overlap between predicted target genes of the three common highly expressed 
miRNAs and those of miR-10 is very low (Figure 3.9), ranging from 3% to 5%. 
 
 
Figure 3.8 Three top expressed miRNAs are common to all samples and miR-10 expression increases 
rapidly during development. A: Venn diagram showing that three top miRNAs were common to all samples. 
B: Percentage of total reads by the three top miRNAs that were common to all samples: miR-26, miR-30 and 
miR-92. miR-92 initally dominated with 66% of total miRNAs in HH5-7, but quickly dropped to below 15% in 
older embryos. miR-26 and miR-30 both maintained relatively constant expression levels across all stages. 
miRNA-10 was rapidly upregulated from HH11-13. 
 
As discussed in 3.3.5, miR-10 is likely functioning to ensure normal vasculogenesis and 
angiogenesis in both cardiac and neural tissue and the rapid increase in its expression 
reiterates its importance in these tissues.  
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 miR-26 miR-30 miR-92 
Total predicted target genes 354 1,357 504 
Unique predicted target genes 203 1,125 293 
% overlap of predicted target genes 43% 17% 42% 
% genes also targeted by miR-10 3% 3% 5% 
 
Figure 3.9: Analysis of predicted target genes of the three top expressed miRNAs common to all nine 
samples. A large portion of the predicted target genes of miR-26 are also predicted to be targeted by miR-92 
and vice versa. However, only 17% of the predicted target genes of miR-30 are targeted by either miR-26 or 
miR-92.  
 
The predicted target genes of miR-26, miR-30, miR-92 and miR-10 were filtered by genes 
known to be expressed in the human heart
80
. The Pattern Gene Database (PaGenBase) 
contains 7,187 genes known, collected from 26 array and NGS experiments, to be 
expressed in the human heart. Although the number of predicted target genes of miR-26, 
miR-30, miR-92 and miR-10 was more than halved, the extent to which targets of miR-26 
and miR-92 were covered by one or more of the others remained very similar to that seen 
before filtering the predicted genes (Figure 3.10B, row 3). The percentage of shared 
targets between miR-10 and any of miR-26, miR-30 or miR-92 was very low (Figure 
3.10B, row 4) after only considering predicted target genes known to be expressed in the 
heart.  
 
 
 
 miR-26 miR-30 miR-92 
Total predicted target genes 128 409 166 
Unique predicted target genes 80 333 100 
% overlap of predicted target genes 38% 17% 39% 
% genes also targeted by miR-10 1% 2% 2% 
 
Figure 3.10: A large fraction of the predicted targets of miR-26 and miR-92 that are expressed in the 
human heart are also predicted targets of the other two highly detected miRNAs. The overlap in 
predicted targets seen between miR-26, miR-30 and miR-92 remains of a similar size whether all predicted 
genes (Figure 3.9) or just those predicted genes known to be expressed in heart are considered (row three). 
A very small percentage of the predicted target genes of miR-26, miR-30 and miR-92 are also predicted target 
genes of miR-10 (row four).  
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A full list of the overlapping predicted targets that are also expressed in the human heart is 
shown in Table Apx A.3 and Table Apx A.4. A core of 14 genes were found to be 
predicted targets of miR-26, miR-30 and miR-92. However, A GO terms analysis of these 
14 genes did not return any significant associations confirming that the overlapping 
targeting of these genes is not connected to a single pathway or developmental process. 
3.2.7 Unique predicted target genes of top expressed miRNAs 
Many of the predicted target genes of the top expressed miRNAs miR-26, miR-30 and 
miR-92 were found to be targeted by at least two of these miRNAs. In order to assess 
whether these miRNAs target any unique genes or pathways, an analysis was performed on 
the predicted target genes unique to each of these three miRNAs. 
  
To determine which target genes or pathways were targeted uniquely by top expressed 
miRNAs at each stage, the predicted target genes and their significant Gene Ontology 
(GO) terms
81
 of the top ten sequenced miRNAs for each of the nine samples were 
identified. Custom R scripts written by the author were used to isolate those GO terms 
unique to three groups of samples: HH5-13 (HH5-7, HH8-10, HH11-13), HH14-23 H 
(HH14-16 H, HH17-20 H, HH21-23 H), and HH14-23 NT (HH14-16 NT, HH17-20 NT, 
HH21-23 NT). 
 
Table 3.7: Significant GO terms unique to three groups of samples: early stages (HH5-7, HH8-10, HH11-
13), later stages heart tissue (HH14-16 H, HH17-20 H, HH21-23 H) and later stages non-heart tissue (HH14-
16 NT, HH17-20 NT, HH21-23 NT). The genes associated with the GO term are also shown. 
Samples Significant GO term Genes 
HH5-13 Signalling by TGFβ (REAC:170834) SKI, SMAD2, SMAD6, SMAD7, SMURF1, TGFBR2, 
ZFYVE9 
HH14-23 
Heart 
Congenital malformation of the 
great arteries (HP:0011603) 
ABCC9, ADAMTS18, BCOR, CD96, CHD7, COMT, 
DHCR24, DTNA, EP300, FANCF, FBN1, FBN2, FOXF1, 
GATA6, GJA1, GLI3, GPC3, KAT6B, MED13L, MYH11, 
NFIX, NPHP3, NSD1, PTPN11, RAB23, SALL1, SLX4, 
SMAD3, SOX2, TBX1, TP63, VANGL1, ZEB2, ZIC3, 
ZMPSTE24 
HH14-23 
NT 
Positive regulation of cardiac 
muscle hypertrophy (GO:0010613) 
EDN1, IGF1, AKAP6, MTPN, CAMK2D, PDE5A, ADRB1, 
IL6ST 
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Although there is large overlap between the targets of the top expressed miRNAs across all 
the sample groups, three unique and interesting significant groups of targets were 
identified from the short list of significant GO terms unique to each group (Table 3.7). The 
unique targets of the early stages group are involved in TGFβ signalling, whereas those of 
the later stages heart group have been associated with congenital malformations of the 
great arteries. Finally unique predicted target genes in the later stages non-heart tissue 
group have a significant association with positive regulation of cardiac muscle 
hypertrophy. Insulin-like growth factor 1 (IGF1) causes cardiac hypertrophy as a result of 
the activation of the phophoinositide 3-kinase (PI3K) / AKT pathway, which is normally 
repressed by phosphatase and tensin homolog (PTEN)
82
. The effect of IGF1 is mediated 
through Parkinson protein 7 (PARK7) – induced inhibition of PTEN phosphatase in 
skeletal muscle
83
. Furthermore, Muscle A-kinase anchoring proteins (mAKAPs) are 
encoded by the AKAP6 gene. Following their binding to calcineurin, NFATc3 is 
dephosphorylated and the resulting activation of NFAT transcriptional activity leads to 
cardiac myocyte hypertrophy
84
. Additionally, pathological hypertrophy has been linked to 
Ca
2+
 / calmodulin-dependent protein kinase 2 delta (CAMK2D) and interleukin-6 signal 
transducer (IL6ST) function
85,86
, and endothelin 1 (EDN1) variations have been associated 
with an increased risk of developing left ventricular hypertrophy
87
. 
 
This analysis of the most highly detected miRNAs during chick embryonic development 
has highlighted several essential roles played by these miRNAs, reinforcing their 
importance and generating a profile of their expression in the developing embryo not 
previously known (3.3.6). The most exciting finding relates to the large amount of overlap 
of predicted target genes of these highly expressed miRNAs, suggesting that these 
miRNAs may function to redundantly repress a core set of targets. 
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3.3 Discussion 
3.3.1 Illumina TruSeq libraries were enriched for 22-nucleotide RNAs 
RNA sequencing libraries were successfully prepared from samples enriched for sequences 
22nt long, containing mature miRNA transcripts (Figure 3.4A). A second broad peak 
around 33nts in size is consistent with sequencing results from other experiments
77
 and is 
most likely due to piRNAs. Piwi-interacting RNAs are not processed by Dicer during their 
biogenesis and are largely known for their roles in epigenetic changes and maintenance of 
the gonads and germ cells of vertebrates
77
. The number of reads recorded at 33nts in the 
least developed samples, HH5-7 and HH8-10, are more than 33% of that recorded in the 
22nt miRNA fraction, suggesting that the tissues captured at these stages express piRNAs 
at a high level. The focus of this work is the miRNA expression profile of the sequenced 
tissues, but this dataset could be probed for information on piRNA expression during the 
early stages of heart development in the future. 
3.3.2 Many animal miRNAs are expressed during chick cardiogenesis 
The miRNA-sized fraction of almost all the samples contained mostly known animal 
miRNAs (Figure 3.5A), suggesting that most of the miRNAs expressed in the developing 
chick have been identified in at least one other animal. However, more than half of the 
reads in this miRNA-sized fraction in sample HH5-7 were not identified. At this stage it is 
not clear whether these unidentified sequences are novel miRNAs or fragments of 
degraded RNA. An assessment of the secondary structure of these sequences and their 
genomic surroundings may allow better classification of the unidentified sequences. 
However, the novel miRNA prediction performed by Simon Moxon (Chapter 5) did not 
suggest that this sample contain a large number of novel miRNAs and therefore it was 
considered unlikely that these sequences would be of interested in this study. 
 
miRProf matching of the normalised reads from this dataset to all the animal miRNAs 
contained in miRBase release 20 revealed a total of 31 animal miRNAs not currently 
known in chick. Two of these, miR-143 and miR-182, are very highly expressed in the 
73 
 
developing chick embryo (Figure 3.7). miR-143 is known to play an important role during 
heart development in zebrafish
75
 and miR-182 is upregulated in human patients with 
coronary artery disease
88
. Although not formally annotated yet, these 31 animal miRNAs 
match perfectly to those described and will be submitted for inclusion into the miRBase 
database. 
3.3.3 A large fraction of known chicken miRNAs are expressed from gastrulation 
During the earliest stages profiled only 26% of the 636 known chick miRNAs available in 
miRBase release 20 were expressed, but this number rapidly increased to around 50% in 
the older samples (Figure 3.5B). These results are consistent with an increase in miRNA 
expression as development progresses which has been reported in the chick
77
, where small 
RNAs from repetitive elements were found to be more abundant than miRNAs before 
gastrulation. A small fraction (63 out of 636) of these miRNAs were detected at single time 
points, always at low levels, and only 5 are conserved in Homo sapiens. This implies that 
these miRNAs have limited biological roles, specifically in the context of discovery of 
potentially important human heart development regulators. 
3.3.4 Samples cluster according to their known animal miRNA expression 
The normalised reads of the known animal miRNAs identified from miRBase release 20 
were used to prepare a clustered heatmap in R (Figure Apx A.1). An analysis of the five 
ranges of normalised reads values represented as different colours on the heatmap showed 
that many miRNAs were detected at less than 0.001 reads per million, particularly at the 
earliest time point (HH5-7) where 38% of detected miRNAs fell into this lowest 
expression range (Figure 3.6). Few miRNAs (6% to 16%) had levels in the highest range 
of 1,000 to 600,000 reads per million. The largest fraction of miRNAs in each sample had 
levels between 0.001 and 5 reads per million, suggesting that the majority of miRNAs are 
expressed at low levels during the early stages of chick development. Based on normalised 
reads per million, the nine samples clustered into three groups: the early stages (HH5-7, 
HH8-10, HH11-13), and two later stages (HH14-16 H, HH14-16 NT, HH17-20 H and 
HH17-20 NT, HH21-23 H, HH21-23 NT). Interestingly the most developed heart tissue 
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sample was more similar to the older non-heart tissue samples than the younger heart tissue 
samples. This suggests a change in miRNA expression that might be very relevant to the 
developmental changes exclusive to this range of stages. For instance, during the earlier 
stages the cardiac progenitors are specified and start to differentiate whereas valve 
development and ventricular septation is known to take place in the heart from HH21 to 
HH23. The similarity in miRNA profiles of the HH14-16 and HH14-16 NT samples may 
be due to the contribution, as discussed in 4.2.3, of the cardiac neural crest which migrates 
through the tissue dissected in the HH14-16 NT sample (Figure 1.2B).   
3.3.5 miRNA expression is dominated by two miRNAs 
Two miRNAs were found to dominate over all other known animal miRNAs, with a 
distinct change in dominating miRNA observed between HH11-13 and HH14-16. In the 
early stages (HH5-7, HH8-10, HH11-13) miR-92 is the most abundant miRNA detected, 
taking up between 43% and 66% of the total known miRNA reads (Figure 3.7A, B). 
However, at HH14-16 miR-92 moves down to the second or third place, replaced by miR-
10 as the most sequenced miRNA (Figure 3.7C, D, E and F). Although miR-10 is the 
most detected miRNA is all the older samples, it was found to increase more rapidly in 
non-heart NT samples than in heart samples. In the oldest samples, HH21-23 H and HH21-
23 NT, miR-10 occupies 41% and 68% of the known miRNA reads respectively. miR-10 
has known roles in the regulation of blood vessel formation, which takes place in the tissue 
dissected in Heart and NT samples.  
 
Blood vessels are formed by either vasculogenesis, whereby the mesoderm gives rise to 
blood vessels following differentiation of cells into the endothelial lineage, or by 
angiogenesis, wherein new blood vessels form from existing vessels by proliferation
89
. 
VEGF signalling is essential for neurovascular development, during which blood vessels 
ingress into the neural tube
90
, as well as during vasculogenesis
89
. miR-10 is  upregulated in 
hematopoietic stem cells
91
 and has pro-angiogenic functions in zebrafish and human 
endothelial cells through its effects on Vascular Endothelial Growth Factor (VEGF) 
signalling
92
. Finally, the confirmed targets of miR-10 have four significant GO terms 
associated with vasculogenesis and angiogenesis: vasculature development (GO:0001944), 
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blood vessel development (GO:0001568), blood vessel morphogenesis (GO:0048514) and 
angiogenesis (GO:0001525). Given that vasculogenesis and angiogenesis are such essential 
parts of heart development and that miR-10 is intimately involved in regulating both 
processes, it is not surprising that miR-10 was found to be expressed at such a high level 
during these stages of embryonic development.  
 
Interestingly a miRNA known to be dysregulated in diseased mouse hearts
79
, miR-130, 
was detected in the top 10 miRNAs by normalised expression in the early samples (HH5-7, 
HH8-10, HH11-13) and in the later heart samples (HH14-16 H, HH17-20 H, HH21-23 H). 
Although the effect of miR-130 on heart development is unstudied in current literature, this 
study suggested several tantalising targets of this miRNA when assayed by reporter assays 
(Figure 4.13C, D, G, H, I, L). The potential impact of miR-130 on these targets during 
heart development is discussed in 4.3.7. 
 
Similarly to a sequencing experiment conducted on adult mouse heart tissue previously
73
, a 
few miRNAs were found to dominate the sequencing space in all nine embryonic samples. 
In this study the contributions of the top seven miRNAs were found to total between 84% 
(HH5-7) and 65% (HH17-20 H) of the total normalised reads of all known animal miRNAs 
identified in the samples (Figure 3.7B, D and F). However, the identities of the highly 
expressed miRNAs differed from those published previously, with only 4 highly expressed 
miRNAs in common between the studies: miR-143, miR-22, miR-26 and miR-30. miR-
208, highly detected in the adult mouse heart, has not been annotated in the chicken 
genome and no exact match to this miRNA was discovered by miRProf in the developing 
chick tissues. This miRNA is currently thought to be the only heart-specific microRNA
93
, 
and has been shown to play a role in cardiac stress response as well as in repressing the 
expression of skeletal muscle genes in the postnatal heart, rather than in the development 
of the heart
6,94
. In keeping with the current literature
94
 that points to miR-208 being 
expressed after birth, miR-208 was not detected at any of the time points assayed.  
 
In theory, the abundance of a specific microRNA in a sequencing library should be similar 
to the abundance of that microRNA in a biological sample
95
. However, proprietary 
Illumina adapter ligation has been shown to be biased
64,96
, and since only adapter ligated 
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molecules can be sequenced any bias in their ligation will give a skewed view of miRNA 
expression. The preference of truncated T4 RNA ligase 2 (Rnl2), used to ligate pre-
adenylated adapters to the 3’ ends of RNA molecules, for double stranded nucleotides 
upstream and single stranded nucleotides downstream of ligation sites is well known
64,97
. 
After ligation of the 3’ adapter, a 5’ adapter is added by T4 RNA ligase 1 (Rnl1), which 
favours single stranded substrates
64,97
. A recent literature search failed to reveal other 
published Illumina HiSeq profiles of miRNA expression in heart, but it is possible that the 
profiles of most frequently detected miRNAs obtained in the current study reflect an 
improvement in library construction protocol, compared to the profile obtained in adult 
mouse heart during the very early stages of Illumina GAII sequencing
73
, which has lead to 
a decrease in sequencing bias, possibly by modest changes to adapter sequence or ligation 
conditions
64,97
. 
3.3.6 Enrichment of predicted target genes of top expressed miRNAs 
Further analysis of the top expressed miRNAs in the nine samples was done by splitting 
the samples into three groups: early (HH5-7, HH8-10, HH11-13), late heart (HH14-16 H, 
HH17-20 H, HH21-23 H) and late non-heart (HH14-16 NT, HH17-20 NT, HH21-23 NT). 
The majority of the top expressed miRNAs in samples corresponded to those expressed in 
the other members of the group as summarised in Table 3.4, Table 3.5 and Table 3.6. In 
order to assess whether the miRNAs unique to samples when compared with the other 
members of the group had different or similar roles to the common miRNAs, predicted 
target genes of the unique miRNAs were evaluated. It was shown that the vast majority of 
predicted target genes of the unique miRNAs were also predicted target genes of the 
common miRNAs, suggesting that the top expressed miRNAs in each group act together to 
affect essential targets. It is likely that these miRNAs play many essential roles during 
these stages of development, and further bioinformatic analysis of the shared targets might 
give a plausible starting point in unravelling their many functions. 
 
Three miRNAs were consistently expressed at very high levels in all nine samples assayed: 
miR-26, miR-30 and miR-92 (Figure 3.7G, H). Components of the miR-17-92 cluster 
have been shown to be essential for cardiomyocyte proliferation in adult mice
98
, miR-26 
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has important functions as a regulator of potassium current changes in mice
99
 and 
hypertrophy
100
, and miR-30 is pro-angiogenic in zebrafish embryos
101
 whereas miR-17 and 
miR-20 repress angiogenesis
102
. An analysis of the predicted target genes of these three 
miRNAs showed that more than 40% of the predicted targets of miR-26 and miR-92 are 
also predicted target genes of the others (Figure 3.9). However, only 17% of the predicted 
target genes of miR-30 are also targeted by either or both of miR-26 and miR-92. Analysis 
of the shared predicted target genes revealed a large number of significant, though broad, 
GO terms including cell differentiation (GO:0030154), nervous system development 
(GO:0007399) and cardiovascular system development (GO:0072358), confirming the 
many and varied essential roles these miRNAs are known to play during development and 
in the adult organism.  
 
The degree of overlap of all the predicted targets of miR-26, miR-30 and miR-92 was 
maintained when only genes known to be expressed in human heart tissue were considered 
(Figure 3.9B, Figure 3.10B). This strongly suggests that miR-26 and miR-92 are working 
in concert to target a core set of genes. A FunDo analysis of the overlapping genes known 
to be expressed in the human heart (Table Apx A.3, Table Apx A.4) revealed 25 genes 
significantly associated with disease (2.8.6, Table Apx A.5). Two of these diseases affect 
the heart (Table 3.8). Atherosclerosis, the hardening of the arteries, can lead to further 
pathology and death in diseased hearts
103
.  
 
Table 3.8: Overlapping predicted target genes, known to be expressed in the heart, of at least two of 
miR-26, miR-30, and miR-92 are significantly associated with disease of the heart, amongst other 
diseases.  
Disease Overlapping predicted target genes of miR-26, miR-30 and miR-92 
Atherosclerosis PDE4D (miR-26 & miR-30) 
ATXN1 (miR-30 & miR-92) 
CACNA1C (miR-26, miR-30 & miR-92) 
BDNF (miR-10 & miR-30) 
Heart failure ADRB1 (mir-30 & miR-92) 
LOX (miR-26 & miR-30) 
 
This analysis has identified five genes known to be expressed in the heart and predicted to 
be targeted by at least two of miR-26, miR-30 and miR-92, suggesting that the regulation 
of these five genes may be essential for normal heart function. 
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miR-10 is initially not found in the top 10 miRNAs by normalised read count, but 
dominates from HH14-16, especially in non-heart samples (Figure 3.7C, E and H). 
Although it is not in the top 10 most highly expressed miRNAs in the early stages, it is still 
highly expressed at around position 15 in these samples. The predicted target genes of 
miR-10 not shared with the three common top expressed miRNAs (miR-26, miR-30 and 
miR-92) return only three significant GO terms, all related to nerve development: 
glossopharyngeal nerve development (GO:0021563), glossopharyngeal nerve 
morphogenesis (GO:0021615), and nervous system development (GO:0007399). The non-
heart NT samples do contain the developing neural tube, but also contain many other cell 
types including the migrating cardiac neural crest, that will eventually form part of the 
heart, and cervical somites, that will develop into skeletal muscle. Therefore it is possible 
that in addition to its known roles in vasculogenesis and angiogenesis
91,92
, miR-10 may 
function to counteract factors promoting neural development in non-neural cells. 
 
The extent to which predicted targets of miR-10 overlapped with predicted targets of miR-
26, miR-30 or miR-92 known to be expressed in the heart was very low (less than 3%) 
(Figure 3.10B), similar to the low values of overlap seen when all the predicted target 
genes were compared (Figure 3.9B). Interestingly, only a single gene associated with a 
disease in the heart was a predicted target of miR-10: BDNF, which was also found to be 
targeted by miR-30 (Table 3.8). 
3.3.7 Unique predicted target genes of top expressed miRNAs 
Finally, all the predicted target genes unique to each of the three groups of samples (early, 
late heart and late non-heart) were examined (Table 3.7). The unique predicted target 
genes of the early samples (HH5-7, HH8-10, HH11-13) were found to be significantly 
associated with signalling by TGFβ (REAC:170834). The TGFβ cytokines are involved in 
early heart development, during the formation of the endocardial cushions, in 
vasculogenesis, and in the development of the myocardium in ventricles
104
. In the older 
heart group (HH14-16 H, HH17-20 H, HH21-23 H) predicted target genes unique to this 
group were significantly associated with the GO term for congenital malformation of the 
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great arteries (HP:0011603), suggesting that miRNAs unique to this group function to 
ensure normal development of the great arteries and providing a shorter list of potentially 
very important miRNA:target gene interactions to evaluate in the context of normal heart 
development. The older non-heart group (HH14-16 NT, HH17-20, HH21-23 NT) had 
unique predicted target genes significantly associated with the positive regulation of 
cardiac muscle hypertrophy (GO:0010613). It is possible that this analysis reduced the 
thousands of predicted target genes of the top expressed miRNAs to a few interactions that 
could be essential for tissue development at these stages, simplifying future experimental 
investigations. 
 
The most abundant miRNAs identified in nine chick embryo samples play essential roles 
during early development, and an attempt has been made to focus on some possibly novel 
functions by the bioinformatic analysis of the sequencing data obtained from these 
samples. 
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4 Evaluation of miRNAs important during heart development 
4.1 Introduction 
Following on from the summary of the sequencing strategy employed in this project (3.1) 
and the bioinformatic analysis of the known animal miRNAs detected in the samples 
assayed by NGS (3.2), this chapter focuses on bioinformatic analyses of miRNAs that are 
known to play roles in heart development. Adapter sequences and non-mapping reads were 
removed by Simon Moxon (2.8.1), but all subsequent analyses performed in this chapter 
were performed by the author. 
4.1.1 miRNAs are essential for heart development and function 
The vital role of microRNAs during heart development and in heart function was 
illustrated by two studies that generated the conditional knockout of Dicer after deletion by 
the Cre recombinase enzyme under the transcriptional control of two heart-specific 
promoters
4
. Dicer has been conditionally deleted in the heart by placing Cre under the 
control of an early heart-specific promoter, α-Myosin Heavy Chain (αMHC), which is 
expressed in mice from as early as E14.5
15
. The researchers observed postnatal lethality as 
well as dilated cardiomyopathy (DCM) that resembled the most common form of 
cardiomyopathy associated with human heart failure. The early conditional deletion of 
Dicer in mice by an Nkx2.5-promoter-driven Cre, active from E8.5, lead to embryonic 
lethality in mutant mice; developmental heart defects were observed on autopsy
5
. 
Furthermore, Dicer levels were observed to be much reduced in human patients with hearts 
failing from dilated cardiomyopathy, compared to patients with non-failing hearts
4,15
. 
Treatment of patients with failing hearts by fitting Left Ventricular Assist Devices 
(LVADs) resulted in Dicer levels being returned to levels similar to those detected in non-
failing hearts
15
. Microarray results from several studies of hypertrophic or failing hearts 
show dysregulation of an assortment of microRNAs
6
. 
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Deletion of the Egfl7 gene in mice resulted in animals with vascular malformations
105
. 
However, current evidence points to these abnormalities being a result of the deletion of 
miR-126, which is hosted by the Egfl7 gene
105
. This suggests that other disease phenotypes 
observed by targeted deletion of coding genes in model organisms may be a result of the 
inadvertent removal of their hosted miRNAs. 
4.1.2 miRNAs influence proliferation and differentiation 
Several miRNAs have been shown to affect proliferation and differentiation in embryonic 
and adult hearts. Both miR-1 and members of the miR-17-92 cluster promote 
differentiation of cardiomyocytes
6,106-108
. However, miR-133 inhibits differentiation and 
stimulates proliferation of myoblasts
4
. The miR-15 family were shown to work in concert 
to repress several cell cycle regulators which lead to suppression of proliferation of 
cardiomyocytes
106
, and miR-101 inhibits the proliferation of cardiac fibroblasts
109
. miR-21, 
miR-24 and miR-499 have been shown to inhibit apoptosis, whereas the miR-15 family are 
linked to the induction of apoptosis
106
. 
4.1.3 MicroRNAs involved in vasculogenesis and angiogenesis 
miRNAs are essential for the proper development of the blood vessels. In vascular smooth 
muscle cells (VSMCs) miR-143 and miR-145 reduce proliferation and promote 
differentiation
106
, in contrast to miR-221 and miR-222, that induce proliferation at the 
expense of differentiation
74
. miR-18a, miR-19 and miR-30 are pro-angiogenic, whereas the 
miR-17-92 cluster is associated with reduced angiogenesis
101,106
. miR-126 is essential for 
blood vessel development in mice and zebrafish by directly targeting sprouty-related 
protein EVH1 domain containing 1 (SPRED1) and phophoinositol-3 kinase regulatory 
subunit 2 (PIK3R2), repressors of the vascular endothelial growth factor (VEGF) 
pathway
74
. However, miR-126 has also been shown to negatively affect proliferation and 
to increase apoptosis of endothelial cells
74
.  
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4.1.4 miRNAs involved in patterning the heart 
miR-126 is required, in the outflow tract and in the endocardial cushions, for valve 
formation by repressing the inhibitors of the VEGF signalling pathway
110
. The expression 
of miR-138 during early cardiac looping is essential for patterning in the zebrafish heart
111
. 
4.1.5 Other miRNAs 
miR-208 is located in introns of the αMHC gene, Myh6, and the βMHC gene, Myh7. 
Although it is expressed exclusively in the heart and slow skeletal muscle
93
, deletion of 
this miRNA during development did not result in any apparent developmental defects
94
. 
miR-208 is currently thought to play a role in cardiac stress response as well as in 
repressing the expression of skeletal muscle genes in the heart, rather than in the 
development of the heart
6,94
. The induction of hypertrophy in diabetic mouse hearts 
resulted in the downregulation of miR-130
79
 (Figure 4.1A). Normal zebrafish heart 
development has been shown to depend on miR-138 expression in ventricles
106,111
, which 
is transcribed from intergenic regions of chromosome 2 and 11 in the chick (Figure 4.1B). 
It has been suggested that miR-499, located in an intron of Myh7B (Figure 4.1C), is also 
cardiac and slow skeletal muscle-specific due to its co-expression with Myh7b
6,93
.  
 
Figure 4.1: The mature sequence and genome location of miR-130 (A), miR-138 (B), and miR-499 (C) in 
the chick.  
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In the mouse, overexpression of miR-24 resulted in embryonic lethality whereas 
overexpression of miR-214 did not cause any defects
6
. miR-195 is upregulated in 
hypertrophic human hearts and in mouse models of cardiac hypertrophy, and its 
overexpression in vitro in rat cardiomyocytes resulted in hypertrophic growth
6
. 
Hypertrophy was also induced within weeks of birth in mice overexpressing miR-195 in 
cardiac muscle; eventually the elevated levels of miR-195 resulted in dilated 
cardiomyopathy and heart failure. miR-21 levels were increased after chemical induction 
of hypertrophy in vitro and following surgical intervention leading to hypertrophy in 
vivo
106
. The miR-144 / 451 cluster has been shown to increase survival of cardiomyocytes 
in vitro after chemical treatment to mirror ischemic damage, although the direct targets of 
these miRNAs have yet to be identified in this context
112
. Furthermore, miR-451 is known 
to promote erythroid maturation by targeting the 3’ UTR of GATA-binding protein 2 
(GATA2) in Zebrafish
113
. 
 
MicroRNAs clearly have many and diverse roles both during development and after birth, 
in many organs including the heart. The effects of microRNA dysregulation observed 
during in vitro experiments are often not seen in vivo, and differences between transient 
and permanent knockdown of microRNAs in vivo also exist
114
. The chick remains an 
excellent model species for embryonic experiments and despite a large number of 
microRNAs being expressed during chick embryogenesis
115
, the functions of the vast 
majority of microRNAs during development have yet to be established. 
 
A miRNA profile specific to heart tissue samples (HH14-16, HH17-20, HH21-23) was 
generated by subtraction of the contributions of miRNAs in NT samples from their 
contributions in Heart samples (4.2.2). Furthermore, this chapter serves to highlight the 
expression in these samples of known miRNAs identified as important during heart 
development and function (Table 4.4). The fold change patterns of all detected miRNAs 
over their levels at HH5-7 were determined and miRNAs that were greatly upregulated 
during development were identified (4.2.1). Following a review of current literature 26 
miRNAs known to play roles in heart development and function were identified. The fold 
change profiles of these 26 miRNAs were determined (4.2.3). A further analysis of the 11 
most interesting heart miRNAs identified in this literature search exposed significant 
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correlation between these 11 miRNAs and several miRNAs not currently known to 
function in heart development (4.2.6). 
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4.2 Results 
In this chapter bioinformatic analyses were focused towards miRNAs that are known to 
have roles in the development or function of the heart. An overview of these analyses is 
presented in Figure 4.2, as they are reported and discussed in each section below. 
 
 
Figure 4.2: Overview of analyses performed in Chapter 4. Several analyses were performed in Chapter 4 
ranging from generation of a fold change profile for all known miRNAs (1) to target validation of three selection 
miRNAs (7). 
4.2.1 Few miRNAs have large increases in expression 
In order to identify miRNAs that undergo large changes in expression during the 
developmental time period assayed and to create a profile of the pattern of change in the 
levels of miRNA expression, the fold change of known animal miRNAs in normalised 
reads per million was determined relative to the least developed sample, HH5-7. This 
allowed identification of the extent to which the largest group of miRNAs changed across 
all the samples, establishing that most miRNAs do not have large changes in expression 
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(Figure 4.3). In addition, it allowed the identification of the few miRNAs that did show 
large spikes in expression, pointing to their massive upregulation at specific stages of 
development (Table 4.1). 
 
Samples and miRNAs were clustered based on miRNA fold change using custom R scripts 
written by the author (Figure Apx A.2). A breakdown of miRNAs by their fold change at 
each stage (Figure 4.3) shows that most of the 423 known animal miRNAs detected are 
expressed at a similar or lower level compared to that established at HH5-7, ranging from 
49% (HH11-13) to 64% (HH21-23 NT). The remaining miRNAs show a modest 
upregulation over HH5-7 levels, with from 3% (HH8-10) to 16% (HH17-20 H) of miRNAs 
having a 1 to 10 fold increase in expression. Fewer than 2% of miRNAs have the most 
extreme increase of between 100 and 300 fold at some point during the developmental time 
series assayed. This shows that most miRNAs are expressed at lower or nearly constant 
levels as development progresses, with very few miRNAs dramatically upregulated. 
 
 
Figure 4.3: The fold change of normalised reads per million for each known animal miRNA detected in 
the nine samples compared to reads at HH5-7. Only miRNAs detected in more than one sample were 
considered. The percentage of miRNAs detected broken down by their fold change over HH5-7 levels. Many 
miRNAs were found to decrease between 2 and 130 fold from their HH5-7 levels. Most miRNAs that were 
upregulated were less than 10 fold increased over their HH5-7 levels. Very few (14) miRNAs were found to 
have levels 100 fold increased over their HH5-7 levels. White: Not detected. Light green: 1 to 130fold down. 
Dark green: 1 to 10 fold increased. Red: 10 to 100 fold increased. Black: 100 to 300 fold increased.  
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Table 4.1: A few miRNAs have levels more than 100 times increased over their levels at HH5-7: 
Fourteen miRNAs were found to have an increase in normalised read numbers more than 100 times that 
detected at HH5-7, in at least one of the nine samples assayed. Six of these miRNAs have known roles in 
heart development and function (underlined). 
miRNAs with a fold change larger than 100 in at least one sample 
miR-1 miR-126 miR-187 miR-451 miR-9 
miR-10 miR-145 miR-199 miR-490 miR-99 
miR-100 miR-1451 miR-449 miR-499  
 
Only 14 miRNAs were found to have fold change values of more than 100 over their HH5-
7 values (Figure 4.3, Table 4.1). Six of these miRNAs are known to play roles in heart 
development and function
74,92,106,110,116
, but have fold change patterns very different from 
one another (Figure 4.4). Three of these miRNAs (miR-126, miR-451 and miR-499) show 
a peak in upregulation in the HH17-20 heart tissue sample, whereas only miR-145 showed 
a large spike in expression in the heart at HH21-23. 
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Figure 4.4: The fold change patterns of six of the 14 miRNAs with a larger than 100 fold increase over 
their reads detected at HH5-7 in at least one sample. These miRNAs have all been implicated in heart 
development and function. A: miR-1
106
. B: miR-10
92
. C: miR-126
74
. D: miR-145
106
. E: miR-451
116
. F: miR-
499
106
. 
 
As discussed in 4.3.1 the timing of the upregulation of these miRNAs suggests that they 
may function during some of the important milestones of cardiovascular development, 
such as valve formation (HH17-20). 
4.2.2 Creating a profile of miRNAs in Heart by subtraction of NT sample values 
A profile of miRNAs in the later heart samples (HH14-16 H, HH17-20 H, HH21-23 H) 
was generated by subtracting the fold change values of each miRNA in NT samples from 
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the corresponding Heart samples. This analysis filtered out miRNAs involved in processes 
common to both Heart and NT samples and generated a profile of miRNAs that may be 
essential for heart development. 
 
Table 4.2: Breakdown of the profile generated when subtracting miRNA fold change values in NT from 
those of the corresponding Heart samples. The bulk of miRNAs in the HH14-16, HH17-20 and HH21-23 
samples were found to have 1 to 10 fold higher fold change values in Heart samples than in NT samples, as 
shown in row three. 
Change % miRNAs 
HH14-16 
% miRNAs 
HH17-20 
% miRNAs 
HH21-23 
>10x higher in Heart 1 11 8 
1 – 10x higher in 
Heart 
42 43 51 
Unchanged 15 13 11 
1 – 10x lower in Heart 30 20 12 
>10x lower in Heart 3 4 2 
Undetected 8 9 16 
 
More than 40% of the 292 known miRNAs detected in at least one of the HH14-16, HH17-
20 and HH21-23 time points had fold change values 1 to 10 fold higher in the Heart 
sample than in the corresponding NT sample (Table 4.2). Very few (between 1% and 
11%) of miRNAs were found to be more than 10 fold higher in Heart samples (Table Apx 
A.6). Similarly, less than 5% of miRNAs had fold change levels more than 10 fold lower in 
Heart samples. As Table Apx A.6 shows, 10 of 27 miRNAs known to be important for 
heart development and function were identified as being more than 10 fold increased in 
these Heart samples. Of the remaining 28 miRNAs, 20 are conserved in humans and may 
have as yet undiscovered functions during heart development. 
 
An increase in miRNA expression in Heart samples suggests that such miRNAs may be 
involved in repressing targets to shape the forming heart. In addition, profiles that resemble 
the H – NT profiles of known heart important miRNAs may identify miRNAs essential for 
heart development during these later stages. Therefore an analysis of this expression 
profile was conducted to identify miRNAs that have patterns of H – NT expression similar 
90 
 
to known important heart miRNAs in an attempt to identify as yet undiscovered miRNAs 
that have roles in heart development. A literature search revealed 26 miRNAs that have 
roles in heart development and function
74,101,106,109,110
. A correlation between the H – NT 
profile of each of these 26 heart miRNAs and the remaining miRNAs detected in the 
HH14-16, HH17-20 and HH21-23 samples was performed (Table 4.3). In addition miR-
130, which was consistently identified as very highly expressed in later Heart samples 
(Figure 3.7C), was correlated against the remaining miRNAs identified in this screen. 
miR-92 did not have any significant correlations, and is therefore excluded from the table. 
 
Table 4.3: Breakdown of numbers of miRNAs that correlate to 26 known heart miRNAs based on a H – 
NT fold change profile established for the HH14-16, HH17-20 and HH21-23 samples. Some of the heart 
miRNAs correlated significantly to other heart miRNAs, as shown in column three. The numbers of miRNAs 
that correlate to each heart miRNA that are also conserved in humans are shown in column four. Significant 
correlations were determined by two-tailed P values in GraphPad prism, using a 95% confidence interval. 
Heart 
miRNAs 
Total correlated 
miRNAs 
Correlated heart 
miRNAs 
Correlated miRNAs 
conserved in humans 
miR-1 29 4 8 
miR-10 1 0 0 
miR-101 14 1 4 
miR-125 2 1 1 
miR-126 14 2 9 
miR-128 14 0 4 
miR-130 15 0 3 
miR-133 19 2 12 
miR-138 4 0 1 
miR-143 17 4 7 
miR-145 1 0 1 
miR-15 3 0 1 
miR-16 15 1 7 
miR-17 8 1 6 
miR-18 15 0 3 
miR-181 6 2 3 
miR-19 9 3 5 
miR-20 14 0 3 
miR-21 7 1 7 
miR-221 13 1 7 
miR-222 9 3 5 
miR-24 7 1 3 
miR-30 1 0 0 
miR-31 6 0 3 
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miR-363 26 4 8 
miR-499 8 1 5 
 
A summary of the numbers of correlating miRNAs, of correlating heart miRNAs, and of 
correlating miRNAs that are conserved in humans is shown in Table 4.3. Detailed lists of 
the correlating miRNAs can be found in Table Apx A.7, Table Apx A.8, and Table Apx 
A.9. 
 
This analysis has identified miRNAs conserved in humans that correlate by H – NT profile 
to known heart miRNAs, highlighting networks of miRNAs that may share similar 
functions during heart development. 
4.2.3 miRNAs with a role in heart development and function were detected 
A literature review identified 26 miRNAs known to play various roles in heart 
development and function
74,101,106,109,110
 (Table 4.4). A hierarchical clustering of the fold 
change values of the 26 miRNAs was performed using a custom R script written by the 
author in order to identify similarities between the expression patterns of these heart 
important miRNAs. This served to identify the closely related expression patterns of miR-
126 and miR-499, well known and relative unstudied miRNAs respectively. Further 
examination of the biological function of miR-499 identified its regulation of an activator 
of miR-126 transcription (4.3.1). 
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Table 4.4: 26 miRNAs identified from a literature search have roles in heart development and function.  
Chosen miR Role in heart 
miR-1 Inhibits proliferation and promotes differentiation of cardiomyocytes
106
. 
miR-10 Positively affects vasculogenesis and angiogenesis by its effects on VEGF signalling
91,92
. 
miR-15 Inhibition of cardiomyocyte proliferation by inhibition of several cell cycle regulators
106
. 
miR-16 Inhibition of cardiomyocyte proliferation by inhibition of several cell cycle regulators 
106
. 
miR-17 Deletion of the miR-17-92 cluster leads to reduced cardiomyocyte proliferation in mice
98
. 
miR-18 Deletion of the miR-17-92 cluster leads to reduced cardiomyocyte proliferation in mice 
98
. 
miR-19 Deletion of the miR-17-92 cluster leads to reduced cardiomyocyte proliferation in mice 
98
. 
miR-20 Deletion of the miR-17-92 cluster leads to reduced cardiomyocyte proliferation in mice 
98
. 
miR-21 Inhibition of apoptosis of cardiomyocytes
106
. 
miR-24 Inhibition of apoptosis of cardiomyocytes
106
. 
miR-30 Ectopic expression of miR-30 led to excessive angiogenesis in zebrafish embryos
101
. 
miR-31 Negatively modulates cardiac epithelial-to-mesenchymal transition by targeting Isl1
117
. 
miR-92 Deletion of the miR-17-92 cluster leads to reduced cardiomyocyte proliferation in mice 
98
. 
miR-101 Inhibits proliferation of cardiac fibroblasts in adult mice
109
. 
miR-125 Prevents apoptotic signalling and protects the myocardium of adult mice after injury
118
. 
miR-126 Essential for valve formation
110
 and angiogenesis
74
. 
miR-128 Targets Isl1
119
 which is essential for cardiac specification and vasculogenesis
120
, as well as 
cardiac EMT
117
. 
miR-133 Inhibits the proliferation of cardiomyocytes
106
. 
miR-138 Required for regulation of patterning in the looping zebrafish heart
111
. 
miR-143 Reduces proliferation and promotes differentiation of VSMCs
106
, along with miR-145. 
miR-145 Reduces proliferation and promotes differentiation of VSMCs
106
, along with miR-143. 
miR-181 Expression is induced during myogenesis in human heart and skeletal muscle
121
. 
miR-363 Possible role in negative regulation of angiogenesis
122
. 
miR-499 Decreases apoptosis in cardiomyocytes
106
. 
 
The resulting dendrogram (Figure 4.5) was coloured to show the grouping of highly 
correlated miRNAs. Most miRNAs cluster closely, confirming their very similar patterns 
of expression in these samples.  
 
miR-10 and miR-125, both of the miR-10 family, did not correlate well by expression 
pattern (Figure 4.5) and are located on different chromosomes (Chr 1 and Chr7 
respectively). Despite the sequence similarities of these miRNAs across their entire 
hairpins, they have only three matching bases in their seed regions. In addition, their 
known functions in heart development differ greatly (Table 4.4). These data confirm that 
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although miR-10 and miR-125 may have had a common ancestor, they appear not to be co-
regulated in these tissues. 
 
miR-143 and miR-145 correlated closely by fold change expression pattern (Figure 4.5). 
miR-143 has not yet been annotated in the chicken genome, but in the human genome is 
located less than 2 Kbp from miR-145 in an intergenic region of Chr5. In this analysis their 
expression patterns were found to correlate well which indicates that these miRNAs may 
be co-regulated in the chicken, as they are known to be in mice and humans
106
. 
 
miR-363 has not been annotated in the chicken genome but has been identified in this 
screen. In humans, miR-363 is clustered on ChrX with miR-18, miR-19, miR-20 and miR-
92. The closely related expression patterns of miR-363, miR-19, miR-20 and miR-17 
observed here indicates that miR-363 and these members of the miR-17-92 cluster may be 
regulated by the same factors in these samples (Figure 4.5). 
 
Two members of the miR-221 family, miR-221 and miR-222, are clustered together on 
Chr1 and here had similar patterns of expression (Figure 4.5). These miRNAs are known 
to be highly expressed together in endothelial cells and therefore their correlated 
expression patterns in the developing heart confirms previous findings
106
.     
 
The clustering of miR-499 and miR-126 together (Figure 4.5) was noteworthy and, as is 
discussed in 4.3.1, suggests that miR-499 may regulate miR-126 by targeting its 
transcriptional activator, ETS1. 
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Figure 4.5 miRNAs known to be involved in heart development and function from current literature cluster well based on their fold change patterns across 
all samples. A coloured dendrogram of 26 miRNAs known to play a role in heart development and function, clustered based on the fold change in their normalised 
read values over those recorded in the HH5-7 sample. Clustering was done using hierarchical clustering function in the statistical package R. Column two of the grid 
shows which miRNA family each miRNA belongs to. The LNA WISH expression of each miRNA, as annotated on the Geisha ISH web resource, is indicated for each 
time point. HT: Heart tube. So: Somites. Sc: Spinal cord. Ed: Endoderm. SEc: Surface Ectoderm. LB: Limb Buds. AIP: Anterior Intestinal Portal. Nu: Neural Tube. Ao: 
Aorta. PA: Pharyngeal Arches and Clefts. Ep: Epicardium. SV: Sinus Venosus. BV: Blood Vessels. BI: Blood Islands.
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To establish whether the 26 published heart miRNAs (Table 4.4) show average increased 
expression in heart samples, the percentage of the total known miRNA normalised reads 
taken up by these 26 miRNAs were examined across all the samples (Figure 4.6). 
 
 
Figure 4.6: The percentage of the total normalised reads due to miRNAs with known roles in the heart. 
A: The portion of normalised reads from annotated animal miRNAs taken up by 26 known heart miRNAs. B: 
The portion of normalised reads from annotated animal miRNAs taken up by 24 known heart miRNAs, after 
removal of miR-10 and miR-92 reads. 
 
The 26 miRNAs known to function in the heart represented between 64% (HH17-20 H) 
and 79% (HH21-23 NT) of the total reads from all the known miRNAs recorded in the 
samples (Figure 4.6A), and do not appear to be expressed at a higher level in the heart 
tissue samples. However, this domination was largely due to the contributions of two 
miRNAs: miR-92 and miR-10, which comprised more than two thirds of the reads 
recorded in HH5-7 and HH21-23 NT samples respectively. Removal of the reads due to 
these two miRNAs highlighted the increased expression of the remaining 24 miRNAs in 
the heart samples over that detected in the matched non-heart samples (Figure 4.6B).  
 
Table 4.5: Thirteen miRNAs were found to have slightly increased reads in the HH14-16 NT sample 
over that detected in the HH14-16 H sample. Increases ranged from 103% (miR-126) to 489% (miR-1) of 
the HH14-16 H reads. 
miRNAs with slightly increased reads in HH14-16 NT over HH14-16 H 
miR-1 miR-133 miR-17 miR-222 miR-499 
miR-126 miR-143 miR-181 miR-24  
miR-128 miR-16 miR-21 miR-31  
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The reversal of this trend in HH14-16 samples is not due to the effects of any one miRNA, 
but rather from the cumulative effect of 13 out of 24 miRNAs having slightly increased 
fold change numbers in the non-heart sample (HH14-16 NT) over the heart sample (HH14-
16 H) (Table 4.5). The migration of cardiac neural crest is known to depend on miRNA 
expression and miR-21 and miR-181are essential for this migration
123
. Furthermore, miR-
143 is expressed in migrating cardiac neural crest cells that will eventually form vascular 
smooth muscle cells and controls their differentiation into smooth muscle
124
. It is possible 
that the increased read numbers of these miRNAs reflect their expression in the cardiac 
neural crest, which migrates through the dissected area in the HH14-16 NT sample prior to 
their arrival in the outflow tract at HH17 (Table 3.1), which would implicate the remaining 
miRNAs in Table 4.5 as being expressed in cardiac neural crest and possibly having 
important roles during this migration. 
4.2.4 11 Known heart miRNAs correlate well by fold change 
Although all 26 known miRNAs are worthy of further study, analysis of such a large group 
can quickly become cumbersome. The list of 26 known miRNAs evaluated in Figure 4.5 
and Figure 4.6 was narrowed down to eleven miRNAs (Table 4.6) as described below. 
 
Table 4.6: Eleven miRNAs were selected for further investigation based on a list of 26 miRNAs known 
to have roles in heart development and function.  
Chosen miR Role in heart 
miR-101 Inhibits proliferation of cardiac fibroblasts in adult mice
109
. 
miR-125 Prevents apoptotic signalling and protects the myocardium of adult mice after injury
118
. 
miR-126 Essential for valve formation
110
 and angiogenesis
74
. 
miR-128 Targets Isl1
119
 which is essential for cardiac specification and vasculogenesis
120
, as well as 
cardiac EMT
117
. 
miR-133 Inhibits the proliferation of cardiomyocytes
106
. 
miR-138 Required for regulation of patterning in the looping zebrafish heart
111
. 
miR-143 Reduces proliferation and promotes differentiation of VSMCs
106
, along with miR-145. 
miR-145 Reduces proliferation and promotes differentiation of VSMCs
106
, along with miR-143. 
miR-181 Expression is induced during myogenesis in human heart and skeletal muscle
121
. 
miR-363 Possible role in negative regulation of angiogenesis
122
. 
miR-499 Decreases apoptosis in cardiomyocytes
106
. 
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miR-101, miR-125 and miR-181 have not been studied during embryonic development, 
but their effects in adult mice suggested that they may be important during heart 
development
109,118,121
. miR-126 was selected as it is essential for the formation of the 
heart
74,110
, and because it clustered by expression pattern to miR-499. miR-499 is not well 
studied
106
, but is located within an intron of and co-expressed with Myh7b
125
, which is 
essential for normal heart development
126
. Both miR-126 and miR-499 were selected to 
further elucidate miR-499 roles during heart development. miR-128, miR-133 and miR-
145 were selected as they have several interesting roles during heart 
development
106,117,119,120
. miR-138 has not been studied in the chick or well studied in 
general and is essential for looping of the zebrafish heart
111
, and its rapid upregulation 
from the onset of looping (HH11-13, Figure 4.9H) was thought to be noteworthy. miR-
143 was selected because although it is not annotated in the chicken genome, its expression 
pattern correlated highly with that of miR-145 which suggests that these miRNAs may 
function in the chick as they do in mice
106
, during VSMC proliferation and differentiation. 
In addition, miR-130 was consistently detected in the top 10 most highly expressed 
miRNAs in early (HH5-7, HH8-10, HH11-13) and later heart (HH14-16 H, HH17-20 H, 
HH21-23 H) samples (Figure 3.7A, C). As it had not been studied in the context of heart 
development, miR-130 was selected based on its expression in these samples. 
 
The level of correlation between these 11 miRNAs was assessed based on their fold change 
in normalised reads over that recorded at HH5-7 (Figure 4.7). Some of these chosen 
miRNAs, such as miR-126, have well characterised roles in heart development, whereas 
others, such as miR-181, are only suspected of functioning in the growing heart (Table 
4.6). 
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Figure 4.7: An assessment of the extent to which 11 miRNAs with known roles in heart development 
and function correlate based on their fold change patterns across all samples. In order to determine 
whether the fold change patterns of 11 miRNAs with known roles in heart development and function (Table 
4.6) were similar, the correlation of each pairing was assessed. 9 of the 11 were found to have significantly 
similar changes in their read numbers over that detected at HH5-7, when considered over all the remaining 8 
samples.A: A grid displaying the correlation coefficients and the statistical significance of the correlations. 
Correlation coefficients are coloured from low to high in red to green. The top triangle of the grid shows the 
level of significance of the correlations. 0.05 ≥P > 0.01 : *; 0.01 ≥ P > 0.001 : **; 0.001 ≥ P > 0.0001 : ***; P ≤ 
0.0001 : ****. Significance was only observed in pairings with correlation coefficients larger than 0.737. B: 
Schematic diagram indicating the significant correlations between the 11 of 26 miRNAs with known roles in 
heart develoment. C: An indication of the number of known miRNAs that were found to correlate with the 11 
chosen miRNAs, showing that less than 30% of the 412 remaining miRNAs correlated with these chosen 
miRNAs. The numbers are reduced even further when only miRNAs also conserved in humans are 
considered. 
 
Statistically significant correlations were found to exist between 9 of the 11 miRNAs 
chosen for further investigation when examined by fold change in normalised reads 
(Figure 4.7A and B). miR-126 correlated well with six of the 11 chosen miRNAs (miR-
133, miR-138, miR-143, miR-181, miR-363 and miR-499). However, two of the chosen 
miRNAs were found to not be statistically significantly correlated to any of the others: 
miR-128 and miR-145. Control correlations were done with skeletal muscle-specific miR-
206
127
, and chondrogenic miR-140
128
. The fold change patterns of the control miRNAs did 
not significantly correlate with the patterns of the 11 chosen heart miRNAs (Figure 4.7A). 
Despite high levels of correlation between the 9 heart miRNAs observed in Figure 4.7A, 
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these correlations were found to be specific to heart miRNAs and not reflected in the 
overall fold change patterns of all the miRNAs detected in the screen. The 9 miRNAs with 
significant correlations to each other were found have fold change patterns significantly 
similar to less than 30% of the 424 miRNAs expressed in at least two samples (Figure 
4.7C). Only a small number of the correlating miRNAs, ranging from 19 (miR-145) to 58 
(miR-363), were found to be conserved in humans. This analysis suggests that the 
correlations observed may reflect a concerted effect of these 9 miRNAs on heart 
development, and has uncovered a number of conserved miRNAs that also have very 
similar patterns of expression to these heart important miRNAs.  It is conceivable that 
these miRNAs have similar targets or pathways in common, and many of the 26 miRNAs 
involved in heart development and function are known or predicted to target a single gene, 
PTEN, as is discussed in 4.2.5. 
4.2.5 PTEN is an enriched target of most of the miRNAs with functions in the heart 
The phosphatase and tensin homolog gene, PTEN, is known to be essential for normal 
myocardial development in certain parts of the developing heart
129,130
. The 3’ UTR of 
PTEN has 68 target sites for miRNAs conserved among vertebrates, 2 of which have been 
confirmed experimentally (miR-130, miR-182). Despite not being predicted to target this 
gene by TargetScan
131
, more than half (16) of the 26 heart miRNAs shown in Figure 4.5 
have been experimentally confirmed to inhibit PTEN
132
, and a further 6 are conserved 
predicted targeting miRNAs of PTEN (Figure 4.8A). Furthermore, 8 of the 11 selected 
heart miRNAs are known to target PTEN, and only 2 are not predicted to target this gene 
(miR-138, miR-499).  
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Figure 4.8: PTEN is an enriched target of miRNAs known to affect heart development and function, as 
well as of their correlated known animal miRNAs. A: Breakdown of the PTEN-targeting status of 26 
miRNAs described in Figure 4.5. 16 are experimentally confirmed to target PTEN and 6 are predicted to 
target this gene. B: Around 20% of miRNAs with significantly correlated fold change patterns to 11 known 
heart miRNAs are predicted or confirmed to target PTEN. This number increases to between 38% and 56% 
when only miRNAs conserved in humans are considered. The bars outlined in red are miRNAs correlated to 
three miRNAs not experimentally shown to target PTEN to date. 
 
About 20% of the miRNAs significantly correlated to the 11 chosen heart miRNAs are also 
either predicted or confirmed to target PTEN. This number increased to between 30% 
(miR-128) and 56% (miR-133) when only miRNAs conserved in humans were considered 
(Figure 4.8B). PTEN is not a predicted target of either the chondrogenic miR-140 or the 
skeletal muscle-specific miR-206, and is a predicted target of only 5% and 8% of their 
significantly correlated miRNAs respectively. This analysis strongly suggests that one of 
the major functions of the heart miRNAs examined, and of most of their conserved 
correlated miRNAs, is to target PTEN. Furthermore, a “miRNA sponge” pseudogene of 
PTEN, PTEN1, contains multiple binding sites for miRNAs that also target the 3’ UTR of 
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PTEN
133
, in what appears to be a mechanism to further modulate the translation of this 
gene by decreasing the size of the miRNA pool targeting PTEN at any one time. 
4.2.6 Selected correlated miRNA fold change patterns 
In this section the expression patterns of miRNAs found to correlate well to some of the 11 
chosen heart miRNAs (Table 4.6, Figure 4.9) were examined, along with some of the 
implications of these correlations. To determine whether the correlated miRNAs target 
similar pathways, GO terms analysis of their predicted and confirmed target genes was 
performed. 
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Figure 4.9: Normalised reads fold change over levels recorded at HH5-7 for miRNAs that correlate well 
with selected miRNAs with known roles in heart development and function. Dotted lines were used for 
profiles plotted on the secondary axis. A: miR-101 with miR-190 and 19. B: miR-125 with miR-100, miR-99 
and let-7. C: miR-126 and miR-499 with miR-221. D: miR-126 with miR-451. E: miR-130 with miR-10. F: miR-
130 with miR-31. G: miR-138 with miR-126. H: miR-138 with miR-192. 
  
miR-101, miR-19 and miR-190 have very similar fold change patterns across the stages of 
chick development assayed (Figure 4.9A). As both miR-101 and miR-19 are known to 
function in the forming heart
98,109
, the significant correlation of miR-190 expression may 
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indicate a similar role for this miRNA. The predicted and confirmed targets of miR-101, 
miR-190 and miR-19 were found to be significantly enriched for genes involved in the 
development of the nervous system (Table 4.7). 
 
Table 4.7: Significantly enriched common GO terms of the predicted and confirmed target genes of 
miR-101, miR-190 and miR-19.  
Significant GO term P value 
Nervous system development (GO:0007399) 0.4 x 10
-3 
Neurogenesis (GO:0022008) 0.3 x 10
-1 
Neuron differentiation (GO:0030182) 0.2 x 10
-1 
Generation of neurons (GO:0048699) 0.5 x 10
-1 
 
The observed enrichment of targets involved in neurogenesis and neuron differentiation 
suggests that miR-101, miR-19 and miR-190 may ensure that heart tissue remains 
committed to the cardiac lineage (4.3.6).  
 
miR-100, let-7 and miR-125 were found to have very similar changes in expression 
(Figure 4.9B). miR-99, a relatively unstudied miRNA, also correlated well with these 
miRNAs (Figure 4.9B). miR-100 and miR-99 are both members of the miR-99 family and 
have sequences that differ by only one nucleotide (Figure 4.10B). The genomic locations 
of miR-100, let-7, miR-125 and miR-99 are shown in Figure 4.10A. miR-100 expression 
results in the repression of the adult cardiac genes α-myosin heavy chain (αMHC) and 
sarco/endoplasmic reticulum Ca
2+
 - ATPase (SERCA2a) during development
134
. The 
importance of miRNA-mediated downregulation of SERCA2a was recently confirmed 
when miR-25 was shown to inhibit the translation of this gene in humans
135
. However, 
miR-25 is not known in the chick and has not been identified in any of the samples in this 
screen. miR-125, miR-100 and let-7 have significantly correlated patterns of expression, 
suggesting their co-regulation despite miR-100 being located on a separate chromosome. A 
lack of predicted targets of miR-99 and miR-100 proved a frustrating barrier to further GO 
terms analysis of these correlated miRNAs.  
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Figure 4.10: miR-100, let-7, miR-125 and miR-99 are clustered in the chicken genome. A: A schematic of 
the genomic locations of miR-100, let-7, mir-125 and miR-99. B: The mature sequences of miR-100, let-7a, 
let-7c, miR-99 and miR-125 found in the chick. 
 
miR-126, essential for angiogenesis and valve formation
74,110
, has a fold change profile 
very similar to that of miR-499 (Figure 4.9C) and miR-451 (Figure 4.9D). Target 
prediction programmes return very few predicted targets for miR-126, but 131 genes have 
been shown to be affected by this miRNA
132
. Only 16 of the 86 predicted target genes of 
miR-451 are shared with the list of known miR-126 target genes. However, a comparison 
found that 82% of the GO terms of the predicted targets of miR-451 were common to the 
terms from confirmed targets of miR-126, suggesting that despite having few target genes 
in common these miRNAs may be targeting similar pathways during these developmental 
stages. 
 
The fold change patterns of miR-130 and miR-31 were found to be significantly correlated 
(Figure 4.9F). miR-31 is known to target Isl1, a transcription factor that is essential during 
heart development
117,120,136
. In addition, miR-130 represses the translation of a reporter 
construct containing the 3’ UTR of LEF1, a known transcriptional activator of Isl1 (Figure 
4.13C). Together these findings implicate miR-130 as a regulator of heart development, as 
discussed further in 4.3.6. 
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A significant negative correlation between miR-10 and miR-130 was observed (Figure 
4.9E). Not many of the confirmed or predicted targets of miR-130 and miR-10 are shared 
(Table 4.8), and only 25% of the 100 most significant GO terms associated with combined 
confirmed and predicted targets of miR-130 and miR-10 are common to both miRNAs. 
 
Table 4.8: Few of the predicted or confirmed target genes of miR-130 are also predicted or confirmed 
targets of miR-10.  
miRNA Common confirmed targets Common predicted targets 
miR-130 18.5% (13/70) 3.9% (18/462) 
miR-10 16.0% (13/81) 20.6 (18/87) 
 
However, too little is currently known about the functions of miR-130 to allow further 
analysis of this finding (4.3.6). 
 
A significant correlation between the fold change pattern of miR-138 and miR-126, as well 
as miR-138 and miR-192 was observed (Figure 4.9G, H). Cardiac patterning in zebrafish 
requires the expression of miR-138
111
. Furthermore miR-138 translationally repressed the 
expression of a reporter construct containing the 3’ UTR of ZEB2, an activator of PTEN, a 
known target of miR-192 (Figure 4.17). Repression of ZEB2 leads to growth and 
angiogenesis, as is the effect of miR-126 on its target PIK3R2 in the same pathway 
(Figure 4.17). The correlated expression patterns of miR-138, miR-126 and miR-192 may 
reflect their targeting of the PTEN pathway in the growing heart (4.3.5). 
 
Several novel roles for miRNAs correlated to known heart miRNAs were suggested in this 
section, as is discussed further in sections 4.3.5 and 4.3.6. 
4.2.7 Validating targets of miR-130, miR-138 and miR-499 
Three miRNAs and 15 of their target genes were chosen for further investigation. miR-138 
is required for the regulation of patterning in the looping zebrafish heart
111
, and miR-499 is 
associated with decreased apoptosis in cardiomyocytes
106
. miR-130 was selected based on 
its fold change profile as a more speculative miRNA with possible roles in heart 
106 
 
development. Validation was done by luciferase assays of modified pGL3 reporter 
constructs
47
 containing the cloned 3’ UTRs of the target genes, amplified from chick RNA. 
 
The 3’ UTR of the longest transcript of Enabled homolog (Drosophila) (ENAH) contains 
two conserved predicted miR-499 binding sites. ENAH is known to have an essential role 
in intercalated disk function at the interface between cardiac myocytes
137
. This gene has 
nine transcripts, three of which result in protein products
138
. The remaining two transcripts, 
both much shorter, have identical 3’ UTRs that also match to a downstream portion of the 
3’ UTR of the long transcript. This shorter 3’ UTR contains only a single predicted miR-
499 target site. miR-499 was found not to target any of these predicted sites (Figure 
4.11A, B). 
 
The nuclear factor I B gene, NFIB, is predicted to have miR-130 and miR-138 target sites. 
NFIB is thought to direct tissue-specific gene expression during development and is 
expressed in muscle during mouse development and in adult mouse hearts
139
. Although the 
annotated 3’ UTR of NFIB in the chicken genome is 1,800bp long, TargetScan predicted 
miR-130 and miR-138 target sites up to 3,000bp further downstream of the end of the 
annotated 3’ UTR region. Two reporter constructs were prepared with different portions of 
this long UTR. Construct A contained the first 1,700bp of the 3’ UTR of NFIB, with two 
predicted target sites for miR-138. The second construct, B, contained sequence from an 
unannotated region 3,600bp to 5,000bp from the start of the 3’ UTR, as well as single miR-
130 and miR-138 predicted target sites. Neither of the predicted miR-138 target sites in 
construct A was found to reduce the levels of luciferase (Figure 4.11C). Both miR-130 
and miR-138 were found to target construct B (Figure 4.13D). Time constraints lead to 
only a single mutant construct being made, with the miR-130 predicted target site mutated. 
The reporter assay showed that the action of miR-130 on the predicted miR-130 target site 
is responsible for the inhibitory effect of this miRNA on NFIB 3’UTR sensor expression. 
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Figure 4.11: The predicted target sites in the 3’ UTRs of three genes were shown to not be true target 
sites by luciferase reporter assays. A,B: Neither miR-499 nor the control, miR-140, repressed the 
translation of a luciferase reporter constructs containing the 3’ UTRs of the two splice variants of ENAH. C: 
The first 1,700nts of the NFIB 3’ UTR contained two miR-138 target sites, neither of which were responsive to 
miR-138 mimic treatment. D: VANGL2 did not respond to miR-138 or miR-499. One way ANOVA with Tukey 
post test statistical analyses were performed on the results of each construct. 
 
The VANGL planar cell polarity protein 2 (VANGL) mRNA is predicted to contain target 
sites for miR-138 and miR-499. The VANGL gene encodes Vangl2, a transmembrane 
protein that is a component of the Wnt/PCP signalling pathway essential during 
development
140
. PCP signalling is required for OFT formation and cardiac looping, 
although it is dispensable in the CNC
141
. Neither miR-138 nor miR-499 was found to target 
VANGL2 (Figure 4.11D). 
 
TargetScan predicted miR-138 and miR-499 target sites within the Autophagy related 7 
(ATG7) mRNA. ATG7 induces basal autophagy without detrimental effects on cell 
survival, and reduces misfolded protein content in protein misfolding-stressed cells
142
. The 
3’ UTR of ATG7 in the chick has not been annotated and therefore the 2,000bp following 
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the coding region of this gene were cloned into a luciferase miRNA-sensing construct
47
 
and assayed with the two predicted targeting miRNAs, miR-138 and miR-499, either 
individually or together. miR-138 reduced luciferase levels by around 50%, but not when 
the predicted miR-138 target site was mutated (Figure 4.12A). The effects of miR-499 
(Figure 4.12A) were found to not be due to the predicted target site (Figure 4.12B).  
 
 
Figure 4.12: The effects of two miRNAs, miR-138 and miR-499, on luciferase reporter construct 
containing the ATG7 3’ UTR. A: The unmodified 3’ UTR and the 3’ UTR with the miR-138 target site mutated 
were assayed with the microRNA mimics indicated below the graph. B: The miR-499 site and both the miR-
499 and miR-138 sites were mutated and assayed with miRNA mimics as shown. One way ANOVA with 
Tukey post test statistical analyses were performed on the results of each construct. 0.05 ≥P > 0.01 : *; 0.01 
≥ P > 0.001 : **; 0.001 ≥ P > 0.0001 : ***; P ≤ 0.0001 : ****.  
 
Both splice variants of the v-ets avian erythroblastosis virus E26 oncogene homolog 1 gene 
(ETS1) contain single predicted target sites for miR-499 in their 3’ UTRs138. ETS1 is a 
transcription factor that regulates Gata4 and is briefly active in multiple cardiac lineages 
early in cardiac development but restricts to the endocardium where it remains active 
through cardiogenesis
143
. A reporter assay showed that miR-499 translationally represses 
ETS1 (Figure 4.13A), although mutation of two nucleotides in the seed region of the target 
site did not abrogate the repression by miR-499. The online miRNA target prediction tool 
RNAHybrid
144
 predicted a second, more energetically favourable target site for miR-499 
located roughly 100bp upstream of the TargetScan predicted target site (Figure 4.14). This 
predicted target site contains G:U wobble base pairings in the seed region, that have been 
demonstrated not to interfere with miRNA binding
145
. The translational repression of ETS1 
by miR-499 may be a result of interaction with this site, although additional reporter assays 
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on a mutant construct with the extended predicted site mutated would allow further 
elucidation of the binding of miR-499 to this 3’ UTR.  
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Figure 4.13: Reporter assay results of eleven genes found to contain miRNA target sites in their 3’ 
UTRs. In each case the reporter construct is shown on the left (3’ UTR) and the construct with a mutated 
target site, where available, is shown on the right. The miRNA mimics used are indicated below each bar. 130 
TS mutated: miR-130 target site was mutated. 138 TS mutated: miR-138 target site was mutated. 499 TS 
mutated: miR-499 target site was mutated. A: ETS1. B: FZD8. C: LEF1. D: NFIB 3’ UTR from 3,600 – 
5,000bp. The miR-130 target site was mutated. E: NR3C1. F: PPP3CB. G: PRKACB. H: QKI. I: ROCK2. The 
miR-130 target site was mutated. J: TCF12. K: ZEB2 assayed with miR-138. L: ZEB2 assayed with miR-130. 
One way ANOVA with Tukey post test statistical analyses were performed on the results of each construct. 
0.05 ≥P > 0.01 : *; 0.01 ≥ P > 0.001 : **; 0.001 ≥ P > 0.0001 : ***; P ≤ 0.0001 : ****. 
 
 
 
Figure 4.14: The 3’ UTR of ETS1 has a second predicted target site for miR-499. A: The online miRNA 
target site prediction tool RNAHybrid
144
 predicted a second, more energetically favourable target site for miR-
499 in the 3’ UTR of ETS1, with wobble base pairing. B: The 3’ UTR of ETS1 aligned with the miR-499 target 
site predicted by TargetScan indicated by the black arrow. A construct containing the 3’ UTR of ETS1 with the 
third and fifth nucleotide of the target site mutated did not significantly increase reporter levels (). Half of the 
seed region of miR-499 is involved in the RNAHybrid predicted target site.  
 
TargetScan predicted a target site for miR-499 within Frizzled8 (FZD8) mRNA. FZD8 is a 
receptor in the non-canonical Wnt signalling pathway
7
. Although FZD8 does not currently 
have an annotated 3’ UTR138, a predicted target site for miR-499 can be found 
approximately 700bp from the end of the coding region of this gene. This target site was 
responsible for the inhibition of the translation of a luciferase reporter construct containing 
the 1,000bp sequence from the end of the coding region of FZD8 (Figure 4.13B). 
 
The 3’ UTR of Lymphoid enhancer binding factor 1 (LEF1) contains a single miR-130 
putative target site, as predicted by TargetScan. LEF1, a component of the canonical Wnt 
signalling pathway, is required for the formation of major blood vessels in X.tropicalis
146
. 
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The 3’ UTR of LEF1 contains a single miR-130 predicted target site, which was found to 
induce translational repression in a luciferase reporter construct containing the entire 
annotated 3’ UTR of LEF1 (Figure 4.13C). miR-130 has not been detected in the heart by 
LNA ISH from HH19
147
, but northern blot analysis of the developing chick heart showed 
expression of miR-130 from HH5 to HH23 (Figure 4.15). 
 
 
Figure 4.15: Northern blot analysis of miR-130 expression in the developing chick heart. A: Northern 
blot for miR-130 and U6 on RNA purified from HH5-7, HH8-10, HH11-13, HH14-16, HH17-20 and HH21-23 
cardiogenic or heart tissue. A lower amount of HH8-10 RNA was loaded onto the polyacrylamide gel. B: 
Quantification of miR-130 band intensity relative to U6 band intensity performed with ImageJ software
148
 
showed relatively constant levels of miR-130 until HH21-23, where much less miR-130 was detected in the 
embryonic chick heart. 
 
NR3C1, the nuclear receptor subfamily 3 group C member 1, is predicted to have a miR-
138 target site in its 3’ UTR. NR3C1 is a glucocorticoid receptor138. The normal 
development of embryonic organs is fundamentally dependent on glucocorticoids, but 
adult cardiovascular function is negatively impacted by exceptionally elevated levels of 
glucocorticoid exposure during development
149
. The annotated 3’ UTR of NR3C1 in 
ENSEMBL 71 is only 207bp long, but a target site for miR-138 is predicted approximately 
2,000bp downstream of the end of the annotated 3’ UTR. A luciferase reporter construct 
containing the sequence from 1,300 – 2,500bp from the start of the annotated NR3C1 3’ 
UTR is repressed by miR-138 specifically at the predicted target site (Figure 4.13E). 
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The PPP3CB gene encodes calcineurin A, β isozyme, which is predicted to have miR-499 
target sites in both its splice variants. Calcineurin plays a crucial role in the development of 
myocardial hypertrophy
150
. The 3’ UTRs of both PPP3CB splice variants contain a miR-
499 target site in the 500bp their 3’ UTRs have in common. This portion of the 3’ UTR 
was cloned into a luciferase reporter construct, which was targeted by miR-499 at the 
predicted target site (Figure 4.13F). 
 
A miR-130 target site is predicted by TargetScan in the 3’ UTR of the PRKACB gene. 
cAMP-dependent protein kinase catalytic subunit beta of Protein Kinase A (PKA) is 
formed from PRKACB. The signalling molecule cAMP activates PKA which then 
phosphorylates target proteins. miR-130 inhibited a luciferase reporter construct containing 
the first 1,200bp of the 3’ UTR of PRKACB (Figure 4.13G). 
 
The QKI KH domain containing RNA binding protein (QKI), predicted to have two miR-
130 and two miR-499 target sites by TargetScan, is essential for blood vessel development 
but not for heart muscle differentiation or function
151
. None of the splice variants of this 
gene have an annotated 3’ UTR at this time. A construct was prepared containing sequence 
from approximately 1,700bp to 2,300bp after the end of the coding sequence. This 
construct was predicted to contain two miR-130 and two miR-499 target sites. miR-130 
was found to repress the translation of QKI (Figure 4.13H). However, due to time 
constraints a mutant target site of this reporter construct was not prepared and therefore it 
not certain whether the predicted target site of miR-130 is required for the translational 
repression observed. miR-499 was found not to target QKI. 
 
ROCK2, the Rho-associated coiled-coil containing protein kinase 2 gene, is predicted by 
TargetScan to have binding sites for miR-130 and miR-138. ROCK2 negatively affects the 
canonical Wnt signalling pathway by binding to and ensuring the degradation of TGFβ 
type I receptors
152
. ROCK2 has been shown to prevent mesoderm induction by ectopic 
Nodal signals in zebrafish
152
, and has many other known functions including controlling 
VSMC contraction
153
 and inducing endothelial cell differentiation and migration during 
endocardial cushion development
154
. miR-130, but not miR-138, was found to repress a 
reporter construct containing the 50bp 3’ UTR of ROCK2 along with 950bp of downstream 
114 
 
sequence (Figure 4.13I). The repression was shown to require miR-130 binding to a 
predicted target site 780bp downstream of the annotated end of the ROCK2 3’ UTR. 
 
miR-138 was found to repress a reporter construct containing the 3’ UTR of the 
Transcription factor 12 (TCF12) gene via a predicted target site (Figure 4.13J). Canonical 
Wnt signalling induces the transcription of target genes by the interaction of β-Catenin 
with the TCF/LEF family of transcription factors
7
. 
 
A reporter construct containing the 3’ UTR of Zinc finger E-box binding homeobox 2 
(ZEB2) gene was inhibited on transfection with miR-138 (Figure 4.13K). Unfortunately a 
mutant construct was not prepared and therefore it is unknown whether this inhibition can 
be disrupted by mutation to the predicted miRNA binding site. The same 3’ UTR construct 
was repressed to less than 10% of the control level by miR-130 (Figure 4.13L), and 
although mutation of the predicted miR-130 target site did statistically reduce the 
repression, the difference is only 6% and therefore supplementary binding of miR-130 to 
this 3’ UTR is likely.  
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4.3 Discussion 
4.3.1 Few miRNAs have large increases in expression 
Although 423 known animal miRNAs annotated in miRBase release 20 were detected in 
more than one of nine developing chick samples, most had normalised read values equal to 
or less than that recorded in the HH5-7 sample (Figure 4.3). All of the remaining miRNAs 
were found to be upregulated compared to their HH5-7 levels. Most of these show an 
increase of between 1 and 10 fold, and a few increased between 100 and 300 fold over 
HH5-7 in at least one sample (Table 4.1). Six of the fourteen miRNAs upregulated 
between 100 and 300 fold (miR-1, miR-10, miR-126, miR-145, miR-451, miR-499) have 
known roles in heart development and function
74,92,106,110,116
 (Table 4.6), but have varied 
fold change patterns (Figure 4.4). miR-126, miR-451 and miR-499 (Figure 4.4C, E, F) all 
have large increases in expression levels in the HH17-20 Heart sample. Valve formation is 
known to start at this stage as a result of the cardiac neural crest entering the looped heart, 
and therefore the concomitant increased expression of these miRNAs at this stage may 
indicate functions for these miRNAs during this process. Indeed, miR-126 has been 
reported to be required for valve formation by its positive effects on Vascular Endothelial 
Growth Factor (VEGF)
110
, supporting this hypothesis. During valve development VEGF 
signalling is essential in endocardial cells at the outflow tract cushions but not in 
endocardial cells at the atrioventricular cushions
110
. ETS1 is a reported activator of miR-
126 expression
74
 (Figure 4.16A), and has also been found to be a target of miR-499 in this 
study (Figure 4.13A), which suggests that miR-499 might function to limit VEGF 
signalling during valve formation by indirectly reducing the levels of miR-126 in the 
atrioventricular cushions.  
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Figure 4.16: miR-499 is implicated to regulate miR-126 by targeting ETS1.: miR-126 is essential for valve 
formation and angiogenesis, but also increases VSMC apoptosis by repressing FOXO3 (A). B: miR-221 
targets ETS1, the transcriptional activator of miR-126, relieving some of the pro-apoptotic effects of miR-126. 
miR-499 has been found to repress ETS (Figure 4.13A), and may function in a similar way to miR-221 in 
VSMCs. 
 
The fold change patterns of miR-126 and miR-499 have been found to be highly 
significantly correlated (Figure 4.7A, Figure 4.9C), as have the patterns of miR-126 and 
miR-221(Figure 4.9C). miR-221 is known to target ETS1 and has been shown to increase 
SMC proliferation
155
, in contrast to the pro-apoptotic effects of miR-126 on SMCs
156
 
(Figure 4.16B). Inhibition of ETS1 by miR-499 may influence miR-126 levels, and as a 
result valve formation, in a similar way to the interplay between miR-126 and miR-221 in 
SMCs. 
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4.3.2 Creating a profile of miRNAs in Heart by subtraction of NT sample values 
The subtraction of fold change values of miRNAs in the NT samples at later stages (HH14-
16, HH17-20, HH21-23) from their values in the corresponding Heart samples resulted in 
the generation of a profile of miRNA expression in the heart over these stages of 
development (4.2.2). Only 38 of all the known animal miRNAs detected at these time 
points were found to be more than 10 fold higher in Heart samples than in NT samples 
(Table Apx A.6), including 10 miRNAs known to be important for heart development and 
function (Table 4.4). The upregulation of the remaining 28 miRNAs in Table Apx A.6 in 
Heart over NT samples suggests that some of these miRNAs may also have important 
functions in the foetal or adult heart. 
 
miRNAs with fold change profiles, after subtraction of NT reads, that correlate 
significantly with those of 26 heart miRNAs selected from literature (Table 4.4) and miR-
130 were identified (Table 4.3, Table Apx A.7, Table Apx A.8, and Table Apx A.9). 
This analysis revealed networks of miRNAs that have similar NT – H fold change profiles 
to known heart miRNAs and provides an insight into groups of miRNAs that may function 
in concert to regulate heart development and function. 
4.3.3 miRNAs with a role in heart development and function were detected 
Clustering 26 miRNAs known to have roles in heart development and function by their 
fold change in normalised reads over levels at HH5-7 showed that most have broadly 
similar expression patterns in the samples assayed (Figure 4.5). miR-1 and miR-10 did not 
correlate well with any of the others, and are both very highly upregulated in non-heart 
samples (Figure 4.4A and B). As discussed above, miR-126 and miR-499 cluster together 
away from the remaining miRNAs. miR-143 and miR-133 were found to be highly 
correlated and have been shown to have negative effects on the proliferation of VSMCs 
and cardiomyocytes respectively
106
. Furthermore, members of the miR-17-92 cluster (miR-
17, miR-18, miR-19, miR-20 and miR-92) were shown to correlate closely, as did 
members of the miR-15 family (miR-15 and miR-16). 
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The 26 miRNAs with reported functions in heart development and function were found to 
represent between 65% (HH14-16 H) and 85% (HH21-23 NT) of the total reads from 423 
known miRNAs identified in more than one of the nine chick samples (Figure 4.6A). 
However, this was mostly due to the effects of two highly expressed miRNAs with many 
known functions during development: miR-10
157
 and miR-92
158
. Once the reads from these 
two miRNAs were removed, increased expression of the remaining 24 miRNAs in heart 
samples over non-heart samples emerged from HH17-20 (Figure 4.6B). This enrichment 
coincides with valve formation and septation, which takes place in the chick heart at 
HH17-20 and HH21-23 respectively. It is therefore conceivable that these 24 miRNAs may 
contribute to cardiac patterning at these stages.  
 
Further bioinformatic analysis of the targets of these miRNAs might reveal whether they 
share targets in the pathways that control these essential events, giving a starting point for 
further elucidation of the regulation of heart patterning. Eleven of these 24 miRNAs were 
selected for such further analysis, based on criteria shown in Table 4.6, and the results are 
discussed in section 4.3.4. 
4.3.4 11 Known heart miRNAs correlate well by fold change 
Even though nine of eleven chosen heart miRNAs were found to significantly correlate 
with at least one of the others (Figure 4.7A and B), correlations were generally rare with 
less than a third of the remaining 412 known animal miRNAs expressed in more than one 
sample correlating with these eleven miRNAs (Figure 4.7C). Many of the correlating 
miRNAs were found to be poorly conserved (Figure 4.7C), leaving only 68 correlating 
miRNAs that are also conserved in humans (Table Apx A.10, Table Apx A.11). As the 11 
heart miRNAs (Table 4.6) themselves are highly conserved, this small subset of conserved 
miRNAs that correlate to them may have important functions similar to the 11 chosen heart 
miRNAs that have yet to be elucidated. Further analysis of predicted targets and expression 
patterns of these correlated miRNAs should give a good starting point in estimating 
whether these miRNAs are likely to have important biological functions in common with 
their correlating heart miRNAs. 
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4.3.5 PTEN is an enriched target of most of the miRNAs with functions in the heart 
Deletion of the phosphatase and tensin homolog gene, PTEN, in a cardiomyocyte-specific 
manner resulted in hypertrophic growth and reduction in autophagy in mice
129
. However, 
its expression in the endothelium, the layer of cells on the inside of blood and lymphatic 
vessels, is essential for normal development
130
. Many of the 26 miRNAs with reported 
roles in heart development and function (Table 4.4), have PTEN as a confirmed or 
predicted target (Figure 4.8A). The majority (8) of the eleven selected heart miRNAs have 
been experimentally proven to target PTEN, and one more is predicted to target it. 
Surprisingly around 20% of all the sequenced miRNAs significantly correlated to the 11 
heart miRNAs are also either predicted or confirmed to target PTEN (Figure 4.8B). 
Furthermore, a larger enrichment of PTEN-targeting was observed when only miRNAs 
conserved in humans were considered. An effort was made to determine whether the 
enrichment of correlated PTEN-targeting miRNAs to the known heart miRNAs is unique 
by assessing the chondrogenic miR-140 and the skeletal muscle-specific miR-206, along 
with their correlated miRNAs. Neither miR-140 nor miR-206 have been shown or 
predicted to target PTEN, and less than 10% of their correlated miRNAs were PTEN-
targeting miRNAs. A more comprehensive bioinformatic comparison with many more 
miRNAs lacking functions in the heart would more fully test this observation. Although 
the inhibition of this gene is essential for growth in many tissues
159
, a large number of 
miRNAs with expression patterns similar to those with essential roles during cardiac 
development are known or predicted to inhibit the translation of PTEN, suggesting that a 
large network of miRNAs with similar expression patterns in chick heart development 
allow growth by repressing PTEN. A pseudogene of PTEN, PTEN1, has recently been 
discovered that has multiple binding sites of miRNAs that also target PTEN in its 3’ 
UTR
133
. This has lead to the speculation that pseudogenes may function as lures for 
miRNAs, leaving the target less affected. This discovery highlights the very complex 
nature of mRNA regulation by miRNAs, and further supports the study of these ubiquitous 
interactions. 
 
PTEN negatively regulates the powerful PI3K-AKT cascade to limit growth and 
angiogenesis, and it is modulated by miR-21
160
 (Figure 4.17). miR-126 is essential for 
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angiogenesis in the developing heart
74
, and it has been shown to target PI3-kinase 
regulatory subunit-β (PIK3R2), a negative regulator of PI3K and therefore of growth and 
angiogenesis. Interestingly, miR-126 and 54% of its conserved correlated miRNAs are 
predicted or confirmed to target PTEN (Figure 4.8B). Attenuation of the negative 
regulation of the PI3K-AKT cascade allows growth and angiogenesis to take place without 
the risk that a more permanent relief of downregulation would bring. It appears that this 
repressor of growth and angiogenesis is a target of a large number of miRNAs with many 
different expression profiles in the heart, in keeping with the role of miRNAs in “fine 
tuning” the expression of essential targets. 
 
 
Figure 4.17: The attenuation of PTEN, a negative regulator of growth and angiogenesis, by miRNAs. 
PTEN prevents the powerful PI3K-AKT signalling cascade from causing senescence or cancer by directly 
targeting PI3K, thus reducing growth and angiogenesis. Many miRNAs, such as miR-21, miR-26, miR-216 and 
miR-217 are known to directly target PTEN and reduce its negative effects on growth. Other miRNAs have 
been shown to induce growth after indirect reduction in PTEN levels by inhibiting a repressor of miRNAs that 
directly target PTEN (ZEB2, miR-192), or by repressing a negative regulator of growth that targets PI3K 
downstream of PTEN (miR-126, PIK3R2). miR-138 has been found to target ZEB2 in vitro in this study 
(Figure 4.13K). 
 
Zinc Finger E-box binding homeobox 2 (ZEB2) is a DNA-binding repressor of 
transcription known to interact with activated SMADs, factors that induce transcription as 
a result of TGF-β signalling, which are essential during development161. ZEB2 is known to 
repress the transcription of the PTEN-targeting miR-216 and miR-217 (Figure 4.17). 
However, TGF-β induces the transcription of miR-192 which represses ZEB2 and thus 
allows the inhibition of PTEN by miR-216 and miR-217
160
. miR-138 has been shown to 
target ZEB2 in vitro (Figure 4.13K), and has a fold change pattern significantly correlated 
121 
 
to that of miR-192 (Figure 4.9H). This suggests that miR-138 might, along with miR-192, 
allow the inhibition of PTEN by targeting ZEB2 (Figure 4.17). Both miR-216 and miR-
217 were detected in all nine samples assayed in this study, with average normalised reads 
around 70 and 20 reads per million respectively. miR-216 and miR-217 have not been 
studied during chick development, and this analysis provides a starting point for further 
elucidation of their potentially important roles during heart development. 
4.3.6 Selected correlated miRNA fold change patterns 
The fold change patterns of miR-101, miR-19 and miR-190 were found to be significantly 
correlated (Figure 4.9A). miR-101 is known to inhibit the proliferation of cardiac 
fibroblasts
109
, whereas miR-19 not only induces cardiomyocyte proliferation
98
 but also 
decreases neural stem cell differentiation
162
. This suggests that miR-101 and miR-19 may 
function to expand the cardiomyocyte population and ensure commitment to the cardiac 
lineage in these cells. Furthermore, common GO terms significantly associated with the 
predicted and confirmed target genes these three miRNAs were associated with nervous 
system development, neurogenesis, neuron differentiation, and generation of neurons 
(Table 4.7). The extent to which miR-101, miR-19 and miR-190 ensure commitment to the 
cardiac fate may be elucidated by their inhibition in the developing heart. 
 
miR-100 ensures the proper induction of the foetal cardiac gene programme by its indirect 
repression of adult cardiac genes
134
. miR-100, let-7 and miR-125 are clustered within 
10Kbp of each other on the same chromosome and are co-expressed in most animals. The 
human genome contains three such clusters, indicating possible essential roles for all these 
miRNAs
163
. In the chicken genome, miR-125 is still clustered with let-7 but miR-100 is 
present on a separate chromosome, also clustered with let-7 (Figure 4.10A). Interestingly, 
despite being located on separate chromosomes, the expression change profiles of miR-
100, let-7 and miR-125 are still very highly correlated (Figure 4.9B). The conserved 
miRNA miR-99, a member of the same family as miR-100, is clustered with let-7c and 
miR-125 in the chick (Figure 4.10A). Although this miRNA is not part of the miR-100 / 
let-7 / miR-125 cluster in humans, it is located very close to let-7c on another chromosome 
(Chr 21). The only GO term significantly associated with all four miRNAs is very general 
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(GO:0009893, positive regulation of a metabolic process), but this is mainly due to a 
dearth of predicted targets for miR-99 and miR-100. The conservation of all four miRNAs 
suggests that, along with let-7, they may have important functions in higher vertebrates and 
possibly in embryonic heart development. 
 
The possible implications of the correlation between the expression patterns of miR-126 
and miR-499 (Figure 4.9C) were discussed above (4.3.1). 
 
miR-126 negatively regulates the repressors of the VEGF signalling pathway and as a 
result is required for the development of heart valves and blood vessels
74,110
. miR-126 and 
miR-451 were found to have highly correlated patterns of expression (Figure 4.9D). miR-
451 is a known inducer of erythroid maturation
112
. In the chick valve formation begins 
around HH17, and the rapid increase in miR-126 expression in the HH17-20 sample 
confirms its role in this process (Figure 4.9D). Very few of the confirmed targets of miR-
126 were also predicted targets of miR-451, but the majority of GO terms significantly 
associated with the predicted targets of miR-451 were also associated with the confirmed 
targets of miR-126. This suggests that miR-126 and miR-451 may have similar effects 
during development by targeting similar pathways, even if they do not target the same 
genes. It would be interesting to determine whether miR-451 is required for valve 
development or angiogenesis, and whether inhibition of this miRNA recapitulates the 
phenotype observed when miR-126 is absent.  
 
A significant negative correlation between the fold change patterns of miR-130 and miR-
10 was observed (Figure 4.9E). miR-10 is known to have many functions during 
development
157
, and is pro-angiogenic as a result of its effects on the VEGF signalling 
network
92
. However, miR-10 levels were shown to increase rapidly when human 
embryonic stem cells were induced to form neuronal cells following treatment with 
retinoic acid
164
, and miR-10 was found to occupy a larger portion of the total normalised 
reads in non-heart NT samples than in heart samples (Figure 3.7D and F). Furthermore, 
very few of the targets (Table 4.8) and only a quarter of the 100 most significant GO terms 
associated with the predicted and confirmed targets of miR-130 and miR-10 were common 
to both miRNAs. miR-130 may have effects opposite to miR-10 in the developing embryo, 
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but not enough information is currently available on miR-130 functions in vivo to 
substantiate this. 
 
The LIM homeobox transcription factor Islet-1 (Isl1) is required for cardiac 
specification
120
, cardiomyocyte differentiation
136
, vasculogenesis
120
 and cardiac EMT
117
. 
Isl1 is targeted by miR-31, which results in decreased cardiac fibrogenic EMT
117
. The 
expression of Isl1 has recently been shown to be promoted by Wnt signalling via a novel 
TCF/LEF1 binding site, which was identified during early cardiomyocyte 
differentiation
165
. Isl1 is expressed in the chick cardiac crescent and heart tube (HH6-11), 
but its expression becomes limited to the second heart field in the pharyngeal arches later 
on (HH14-24)
17,147
. However, miR-130 and miR-31 were found to have very similar 
changes in expression (Figure 4.9F), and miR-130 targets LEF1 in vitro (Figure 4.13C). 
These results suggest several possible roles for miR-130 in heart development, and further 
studies are required to assess whether the inhibition of miR-130 has functional effects on 
heart development, possibly resulting from its effects on the Isl1 transcriptional activator, 
LEF1. Interestingly, miR-138 was found to target TCF12 (Figure 4.13J), and is known to 
be essential for normal cardiac looping
111
. An investigation of the combinatorial effect of 
dysregulation of miR-130 and miR-138 on Isl1 and therefore on the embryonic chick heart 
may yield interesting results. 
 
miR-138 and miR-126 as well as miR-138 and miR-192 were found to have significantly 
similar fold change profiles (Figure 4.9G, H). The possible related effects of miR-138, 
miR-192 and miR-126 were discussed in 4.3.5 (Figure 4.17). 
4.3.7 Validating targets of miR-130, miR-138 and miR-499 
Three miRNAs and 15 of their predicted target genes were selected for further 
investigation. Luciferase reporter construct assays were used to determine the effects of 
miR-138, known to be essential for patterning in zebrafish during heart looping, and miR-
499, associated with decreased cardiomyocyte apoptosis. miR-130 was assessed in a 
similar way, and was selected based on its presence in the top detected miRNAs in Heart 
but not NT samples (Figure 3.7). 
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miR-138 and miR-499 have been shown to target the 3’ UTR of ATG7 (Figure 4.12) to a 
moderate degree. In zebrafish, the loss of ATG7 leads to defective heart looping and 
malformations in heart structures, amongst other cardiac effects
166
. Although autophagy is 
essential for the development of many heart structures, it is possible that its 
downregulation by these miRNAs is required in other tissues during cardiogenesis, or that 
miR-138 and miR-499 function to ensure ATG7 levels stay within a certain range. The 
knockdown observed as a result of translational repression brought on by treatment with 
miR-138 and miR-499 was not very large. This could also suggest that the targeting of 
ATG7 by these miRNAs is simply a coincidence, with limited functional effects. However, 
both target sites are broadly conserved among vertebrates, although only the miR-138 site 
is retained in humans. Such conservation is often an indication of a functional role for the 
targeting miRNAs, which may be confirmed by overexpression of ATG7 and inhibition of 
these miRNAs in vivo. 
 
miR-130 and miR-138 were found to target a region of sequence approximately 2,000bp 
downstream of the annotated end of the NFIB 3’ UTR, and the predicted miR-130 target 
site was experimentally validated (Figure 4.13D). Expression of NFIB has only been 
detected in adult mouse hearts and is thought to direct tissue specific gene expression 
during development
139
, suggesting that these miRNAs may ensure tissue identity during 
development by translationally repressing this gene. Therefore an upregulation of NFIB as 
a result of miR-130 and miR-138 inhibition may result in a loss of commitment to a 
cardiac fate in developing embryos. 
 
ETS1, a transcription factor that regulates Gata4
143
 and activates the transcription of miR-
126
74
, is a target of miR-499 in vitro (Figure 4.13A). However, the mutation of two 
nucleotides in the predicted target site did not remove the repression. This could be due to 
the presence of another non-canonical target site within the 3’ UTR being responsible for 
most of the inhibition observed, or by miR-499 binding proceeding despite the mutation of 
two nucleotides in the predicted binding site. As miR-126 is intimately involved in 
angiogenesis and valve formation, regulation of its activator by miR-499 adds a layer of 
fine control over these essential processes (4.3.1). 
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Both canonical and non-canonical Wnt signalling is essential at different stages and in 
different tissues during heart development
7
. FZD8 is a receptor for the non-canonical 
WNT-5A
167
, and was repressed by the action of miR-499 on the target site in its 3’ UTR 
(Figure 4.13B). Non-canonical Wnt signalling, via WNT5A, is required in cardiac neural 
crest cells that have migrated into, but not in those still migrating towards, the outflow tract 
for normal septation to proceed. Furthermore, canonical Wnt signalling must be high in the 
endocardial cushions for valve formation to occur normally between HH17 and HH20. The 
levels of miR-499 detected at HH17-20 in the heart sample show a large increase during 
valve formation. It is therefore possible that miR-499 ensures domination of canonical Wnt 
signalling in the endocardial cushions by targeting FZD8, as well as preventing premature 
non-canonical Wnt signalling in migrating cardiac neural crest cells. If so, these actions 
would assure both normal septation and valve formation in the developing heart, which 
may be prevented following inhibition of miR-499 in vivo. 
 
miR-130 levels have been shown to increase during this phase of heart development 
(Figure 4.9E), and miR-130 targets LEF1 in vitro (Figure 4.13C). Although LEF1 is 
required for the formation of major blood vessels in the heart
146
, non-canonical Wnt 
signalling must be high for normal heart looping to occur
7
. miR-130 appears to be virtually 
absent from the heart from HH21 (Figure 4.15), concomitant with increased canonical 
Wnt signalling in the endocardium which is required to support endocardial cell 
proliferation
7
. This implies that the inhibitory effect of miR-130 on canonical Wnt 
signalling is necessary during earlier development, but not during later proliferation. 
Artificially increasing the levels of miR-130 in the heart at HH21-23 may prevent this 
endocardial proliferation in vivo. 
 
A miR-138 target site approximately 2,000bp downstream of the end of the annotated 3’ 
UTR of NR3C1is responsive to miR-138 (Figure 4.13E). The function of the adult heart is 
negatively affected by elevated levels of glucocorticoids during development
149
. As 
NR3C1 is a glucocorticoid receptor, it is conceivable that miR-138 attenuates the levels of 
glucocorticoids cells are exposed to during development, thus preventing poor 
cardiovascular health in adults. Testing the validity of this conclusion would involve in 
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vivo studies on the effects in the adult of reduction of embryonic miR-138 levels, and 
would therefore be quite challenging. 
 
Calcineurin is known to activate glycogen synthase kinase-3β (GSK-3β), a molecule 
intimately involved in canonical Wnt signalling
168
. PPP3CB, the β isozyme of calcineurin 
A, was translationally inhibited by miR-499 in vitro at a predicted target site (Figure 
4.13G). Therefore, translational inhibition of PPP3CB may result in reduced canonical 
Wnt signalling as a result of miR-499 action. miR-499 expression peaks at HH17-20 in the 
heart (Figure 4.9C), a time point which coincides with valve formation. At this time 
canonical Wnt signalling is repressed in cells undergoing epithelial to mesenchymal 
transition (EMT) in the endocardial cushions as part of valve formation
7
. Once the EMT is 
complete canonical Wnt signalling is again upregulated in these cells to induce their 
proliferation. miR-499 may attenuate canonical Wnt signalling in the endocardial cushions 
by repressing PPP3CB, a known activator of GSK-3β, thereby allowing EMT of 
endocardial cells as part of valve development in the chick. However, whether this action 
of miR-499 on PPP3CB is biologically relevant is yet to be determined. 
 
miR-130 was shown to target PRKACB via a predicted target site in its 3’ UTR (Figure 
4.13G). PRKACB is an essential part of PKA, which phosphorylates target proteins. Heart 
failure results when calcium release channels on the sarcoplasmic reticulum of cardiac 
muscle become sensitised to calcium-induced activation following hyperphosphorylation 
of the ryanodine receptor 2 (RyR2) by Protein Kinase A (PKA)
169
. The targeting of 
PRKACB by miR-130 indicates that miR-130 may reduce the PKA phosphorylation of 
RYR2 and therefore protect heart muscle from the negative effects of 
hyperphosphorylation. 
 
Both miR-130 and miR-499 were predicted to target QKI. Although QKI is known to play 
a role during blood vessel development, cardiac function and muscle differentiation 
remains normal when QKI is knocked out
151
. This gene appears to be essential for yolk sac 
vascular remodelling and vasculogenesis in the developing chick embryo.  
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Table 4.9: Many miRNAs with known roles in heart development and function have conserved 
predicted target sites in the 3’ UTR of QKI.  
miRNAs with conserved predicted target sites in 
the 3’ UTR of QKI 
miR-1 miR-20 miR-125 miR-181 
miR-10 miR-24 miR-128 miR-221 
miR-15 miR-30 miR-133 miR-222 
miR-16 miR-31 miR-138 miR-499 
miR-17 miR-92 miR-143  
miR-18 miR-101 miR-145  
 
miR-130, but not miR-499, was found to repress the translation of a QKI reporter plasmid 
(Figure 4.13H). Interestingly, this gene contains conserved predicted target sites for 22 of 
the 26 known heart miRNAs examined previously (Figure 4.5, Table 4.9). Only four 
miRNAs did not have predicted target sites in this gene: miR-126, also known to be 
essential for blood vessel development
74
, and three others, two of which (miR-19, miR-21) 
have fold change patterns significantly correlated to that of miR-126. Although some of the 
predicted target sites are likely to not be true target sites, such an enrichment of heart 
miRNA target sites may indicate an essential need for the repression of QKI during normal 
heart development. It is worth noting that 17 splice variants are annotated for this gene, 
with 15 encoding QKI proteins of various sizes. Despite the large number of splice 
variants, the 3’ UTR of QKI is not currently annotated in the latest chicken genebuild 
(Galgal4
138
). It would be very interesting to determine whether the splice variants have 
unique 3’ UTRs with different predicted miRNA target sites. 
 
A luciferase reporter containing the entire 3’ UTR of ROCK2, along with a 950bp stretch 
of sequence downstream of the end of the annotated 3’ UTR, was inhibited by the action of 
miR-130 on a predicted target site (Figure 4.13I). The ROCK2 gene is known to play 
many essential roles during development, ranging from inhibition of mesoderm 
induction
152
 to VSMC contraction
153
 and endothelial cell differentiation and migration in 
endocardial cushions
154
. It is difficult to suggest what function the inhibition of ROCK2 by 
miR-130 is likely to have, and further validation and examination of this interaction in vivo 
may yield some interesting results. 
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TCF12 expression is repressed by miR-138 (Figure 4.13J) by specifically binding a 
predicted target site in its 3’ UTR. Transcription factor 12 (TCF12) interacts with β-
Catenin to activate transcription as a result of canonical Wnt signalling. However, TCF12 
has two splice variants that generate proteins of different lengths
138
. The shorter protein 
coding transcript has an annotated 3’ UTR 2,300bp long, which contains the miR-138 
target site that has been validated in vitro. The longer protein coding transcript has an 
annotated 3’ UTR only 11bp long, and does not contain any predicted target sites. 
Although it is possible that this difference in UTR may be due to incomplete annotation of 
the newest chicken genebuild, it may be that the second splice variant of this gene escapes 
regulation by miR-130 as a result of a truncated 3’ UTR. The TCF family of transcription 
factors are essential during development
7
 and any investigation into the dysregulation of 
TCF12 is likely to be complex. 
 
The possible role of miR-138 in development as a result of targeting ZEB2 has been 
discussed (4.3.5). miR-130 was shown to greatly inhibit the translation of a reporter 
construct containing the 3’ UTR of ZEB2 (Figure 4.13K). Although miR-130 does not 
have a significantly correlated fold change pattern to miR-192, as is the case for miR-138 
(Figure 4.9H), this miRNA may also be essential for PTEN inhibition leading to growth 
and angiogenesis (Figure 4.17). If both miR-130 and miR-138 are found to target PTEN in 
vivo, it would be interesting to observe the effect on growth and angiogenesis following 
inhibition of both miRNAs at the same time. 
 
Several reporter constructs were found to be translationally repressed by one or more of 
three selected miRNAs. The analysis of this repression in the context of heart development 
and in light of the expression profile of each of the repressing miRNAs has revealed many 
potentially important interactions, as discussed above and in 7.3.3.  
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5 Novel miRNAs 
5.1 Introduction 
In this chapter 3 of 14 putative miRNAs, predicted by Simon Moxon (2.8.4), were 
validated in chicken embryonic tissue. Target sites of the novel miRNAs were predicted by 
searching for 6nt sequences matching the seed region of the novel miRNAs in any of the 
annotated 3’ UTRs of the chicken genome (Galgal4), using custom R scripts written by the 
author (2.8.5). A GO terms analysis was performed on the predicted target genes of the 
novel miRNAs (2.9.2, Table 5.4). 
 
Profiling miRNA expression by NGS has the potential of discovering novel miRNAs, 
which cannot easily be detected by microarray or qPCR methods. Since the advent of small 
RNA deep sequencing the number of miRNAs submitted to miRBase has increased very 
rapidly and attempts are being made to provide a measure of confidence in the miRNAs 
annotated in this repository
170
. 
 
Although 734 precursors and 996 mature miRNAs have been identified in the chick to 
date, 1,872 precursors and 2,578 mature human miRNA sequences are currently annotated 
in miRBase release 20
41,170-173
. This study identified 31 miRNAs known in other animals 
that were detected in the chick samples assayed and that map to the chicken genome 
(Table 3.3), but that are not registered as existing in the chicken. Furthermore, more than 
half of the reads from the miRNA-sized fraction of the HH5-7 sample did not correspond 
to any known animal miRNAs (Figure 3.5A).  
 
The miRNA profile of the developing chick has been assessed by NGS
72,77,174-176
. 
However, an essential step during library preparation for sequencing has been shown to 
favour certain miRNA sequences
64,96
 leading to their over-representation in sequencing 
results and perhaps causing novel miRNAs to be overlooked. Based on the normalised 
reads profile of the known miRNAs identified in this study, it is possible that changes in 
the latest proprietary Illumina workflow may have reduced this bias, which may allow the 
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identification of miRNAs not previously identified. To determine whether any novel 
miRNAs were expressed during the stages of development investigated, bioinformatic 
predictions of possible miRNAs were complemented with experimental validation of the 
predicted structures. 
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5.2 Results 
The UEA Small RNA workbench tool miRCat
42
 was used in collaboration with Simon 
Moxon to identify possible novel miRNAs sequenced in any of the nine chick samples in 
this study. 
 
Table 5.1: The genomic locations and mature sequences of the fourteen potential miRNAs predicted 
by Simon Moxon using miRCat
42
.  
Name Location Mature sequence 
Putative 1 chr1/13939419-13939524(+) CCGAGCGCTGCCCGGGCCGTGG 
Putative 2 chr1/56587108-56587198(-) TTAGAGGACAATGGCCAATACT 
Putative 3 chr1/67350434-67350518(-) TTGAATGCAGGAGCTCCTCCT 
Putative 4 chr10/14163398-14163493(-) CTTGGCTGCTGAGGGACTCTCC 
Putative 5 chr13/16456080-16456166(-) TCATCAGAGAGGCTGGGCTCTGT 
Putative 6 chr14/8505895-8505989(+) TTTCTGGTACAGTGACTCGAGC 
Putative 7 chr15/4870073-4870156(-) GGGGATGTAGCTCAGTGGTAGA 
Putative 8 chr19/147190-147267(-) TGCGCTGCGCTCCCTGCACAG 
Putative 9 chr2/63171551-63171630(+) TTGTGCCTGCATAAACTGACT 
Putative 10 chr4/8488401-8488480(-) TATCTGTCCTTGTGAGCCCCAGA 
Putative 11 chr4_JH375168_random/82858-82942(-) TTCAGGGTGCTGCAGAGAGCA 
Putative 12 chr5/17763791-17763866(+) CTGGCGCGCGTCCGTCCTGGGC 
Putative 13 chrZ/70567939-70568039(-) ATGCAGAAGTGCACGGAAACAGCT 
Putative 14 chrUn_JH376230/1786-1869(-) CGGGGCTGCAGTGGGGCACTC 
 
Fourteen putative novel miRNAs were identified by miRCat (Table 5.1) based on 
annotated miRNAs listed in miRBase release 19
41,171-173
. miRCat predicts sRNAs from 
NGS data in part by assessing the adjusted minimum free energy of the target read, along 
with that of the surrounding sequence in the chicken genome, folded with RNAfold. 
Pooled whole chick embryo RNA was probed for the mature miRNA sequence, and three 
potential miRNAs were confirmed: Putative 14 (Figure 5.1A, D), Putative 10 (Figure 
5.1B, E), and Putative 12 (Figure 5.1C, F). 
 
However, miRBase release 20
41,170-173
 was found to contain an annotated miRNA matching 
perfectly to the sequence of Putative 10 (Figure 5.2B). This miRNA, miR-1462-3p, is only 
known in the chick and is present in intron 1 of the Dachshund2 (DACH2) gene on 
chromosome 4 (Figure 5.5)
138
. 
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Figure 5.1: Novel chick miRNAs identified from sequencing data. The predicted secondary structure, 
generated with miRCat
42
 by Simon Moxon, of Putative 12 (A), Putative 14 (B), and Putative 10 (C). All three 
miRNAs were confirmed by Northern blot. D: Both the pre-miRNA and mature miRNA of Putative 12 can be 
observed. E: Putative 14 was detected in chick samples. F: Putative 10 pre-miRNA and mature miRNA was 
detected (N=3). A U6 loading control band is shown at the bottom of each membrane. Membrane F was 
probed for Putative 10 after probing for Putative 14 and stripping. The same loading control image is shown 
for these blots. 
 
 
Figure 5.2: Assessment to determine whether novel miRNAs have been annotated in miRBase. 
miRBase Blast
41,170-173
 results comparing the putative miRNAs to all known miRNAs. A: Putative 14 has 
limited sequence homology with hsa-miR-1202, but has a large e-value number and is therefore unlikely to be 
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a match. B: Putative 10 matches perfectly to gga-miR-1462-3p. This miRNA is only known in chick in 
miRBase release 20. 
 
Putative 14 has very limited sequence homology with miR-1202 known in humans (Figure 
5.2), and was identified from the JH376230 scaffold of the current chicken genebuild 
(Figure 5.4)
138
. Finally, sequences matching Putative 12 were not found in miRBase 
release 20. This miRNA is positioned 50bp upstream of the coding region of the cell cycle 
associated protein 1 (CAPRIN1) gene in the chicken genome (Figure 5.3). 
 
 
Figure 5.3: Genomic location of Putative 12. Putative 12 is located 50bp upstream from the start of the 
coding region of cell cycle associated protein 1 (CAPRIN1) on chromosome 5
138
. The location is indicated in 
the top panel by a dotted black line and the mature miRNA sequence is highlighted in a black box in the 
bottom panel. 
 
 
Figure 5.4: Genomic location of Putative 14. Putative 14 was identified from the JH376230 scaffold of the 
Galgal4 chicken genebuild
138
, indicated by the dotted line. The mature miRNA sequence is highlighted by a 
black box. 
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Figure 5.5: Genomic location of Putative 10. Putative 10 is located on chromosome 4 in intron 1 of the 
DACH2 (Dachshund2) gene as indicated by the dotted line
138
. The sequence of the mature miRNA is shown 
outlined in black. 
 
Putative 12, Putative 14 and Putative 10 have distinctive expression patterns in the 
embryonic samples sequenced (Figure 5.6). Putative 12 is downregulated as 
embryogenesis proceeds (Figure 5.6A, B), whereas both Putative 14 (Figure 5.6C, D) and 
Putative 10 (Figure 5.6E, F) have sharp increases in normalised reads in the HH14-16 
sample that gradually decreases. 
 
Table 5.2: The seed 6-mer sequences of putative miRNAs used to check for targets in all chicken 3’ 
UTRs. The seed region, nt 2-7, of the predicted mature miRNA sequence was used to generate a 6-mer 
predicted target site which was then checked against all annotated chicken 3’ UTRs for each of the putative 
miRNAs confirmed by northern blot. 
Putative miRNA Seed 6-mer 6-mer target site 
Putative 12  TGGCGC GCGCCA 
Putative 14 GGGGCT AGCCCC 
Putative 10 ATCTGT ACAGAT 
 
A custom R
78
 script was used to identify 6nt target sites, complementary to the seed 
sequence of each putative miRNA (Table 5.2), in all the annotated 3’ UTRs of the chicken 
genome
177
.  
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Figure 5.6: Expression of three predicted novel miRNAs in nine chick embryo NGS samples. The fold 
change in normalised reads over that detected for each putative miRNA in the HH5-7 sample and the 
normalised reads per million for Putative 12 (A, B), Putative 14 (C,D), and Putative 10 (E,F). 
 
Table 5.3: Many possible target sites in a large number of chicken genes with human orthologues 
were identified for the three predicted miRNAs confirmed in chick.  
Putative miRNA Target sites Genes Human orthologues 
Putative 12 189 170 155 
Putative 14 1,088 952 838 
Putative 10 1,821 1,588 1,484 
 
This method identified a large number of possible target sites for each putative miRNA in 
the 3’ UTRs of many chicken genes and their human orthologues (Table 5.3).  
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Table 5.4: Significant GO terms associated with the predicted target genes of three putative miRNAs 
confirmed in the developing chick.  
Putative 12 Putative 14 Putative 10 
Cytoplasm 
(GO:0005737) 
Cell proliferation  
(GO:0008283) 
Generation of neurons 
(GO:0048699) 
 Growth 
(GO:0040007) 
Nervous system development 
(GO:0007399) 
 Developmental growth 
(GO:0048589) 
Neurogenesis 
(GO:0022008) 
 
The GO terms significantly associated with the predicted targets of Putative 12, Putative 
14, and Putative 10 ranged from genes involved with proliferation to components of the 
cytoplasm (Table 5.4). As the custom method of target identification is limited to perfect 
complementarity with the seed region, targets for Putative 10, known as miR-1462, GO 
terms analysis was performed on targets predicted by TargetScan
131
. 
 
The GO terms analysis of Putative 12 returned a very general term, Cytoplasm, as the only 
significant association of the 179 predicted target genes of this miRNA. Repeated analysis 
with slightly different settings did not return any other significant GO term associations. 
Lowering the stringency of the analysis of the predicted target genes to also include non-
significant results showed only six possible associations, all with very general headings 
such as “Positive regulation of cell development”, “Hip dysplasia”, and “Cell cycle 
checkpoints”. The limited nature of basing target predictions solely on seed sequence 
similarity may have led to the inclusion of genes that are not targets, which may be 
obscuring associations of actual targets. 
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5.3 Discussion 
Three of fourteen predicted novel miRNAs were confirmed as true miRNAs by northern 
blot on RNA from chick embryos (Figure 5.1). However, the prediction was based on 
known miRNAs annotated in miRBase release 19, and one of the confirmed novel 
miRNAs, Putative 10  has since been found to match perfectly to miR-1462-3p (Figure 
5.2B) annotated in miRBase release 20. The genomic location of Putative 10 identified by 
miRCat (Table 5.1) was also found to contain an annotated copy of miR-1462 in 
ENSEMBL (Figure 5.5). Therefore Putative 10 appears to be the known chicken miRNA 
miR-1462. This miRNA was detected at quite high levels in three biological replicates of 
RNA from whole chick embryos (Figure 5.1F). However, Figure 5.6F shows that the 
normalised reads of Putative 10 in the sequenced samples were very low. Putative 10 is 
located in intron 1 of DACH2 on chromosome 4 (Figure 5.5). Developing somites express 
DACH2, which functions with EYA2 to control the differentiation of skeletal muscle and is 
expressed in the chick during the developmental stages assayed in the northern blots
178
. 
Many of the genes predicted by TargetScan to be targets of miR-1462 had significant 
association with generation of neurons, nervous system development, and neurogenesis 
GO terms (Table 5.4). Additionally, the predicted conserved targets of miR-1462 showed 
a significant association with the known targets of miR-135. miR-135, via its target 
Smad5, inhibits osteogenesis induced by BMP2 in C2C12 cells
179
. Therefore, miR-1462 
may be functioning in concert with miR-135 to ensure commitment to a skeletal muscle 
fate.  
 
Putative 12 is located 50bp upstream of cell cycle associated protein 1 (CAPRIN1) (Figure 
5.3), and miRBase release 20 does not contain any sequences matching it. Its expression is 
high in the early stages assayed (HH5-13) but drops sharply from HH14 onwards (Figure 
5.6A, B). This may indicate that Putative 12 has functions during the very early stages of 
heart development. Although 155 human genes were identified that corresponded to the 
170 chicken genes containing 189 predicted target sites of Putative 12, these genes were 
associated with a single GO term: cytoplasm (Table 5.4). More than half of the predicted 
targets (54%) of Putative 12 were associated with this GO term. However, this term is very 
broad and further GO terms analyses did not yield any other significant associations of the 
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predicted target genes. The lack of significant associations may be due to inclusion of a 
large number of genes that are not targets of this miRNA which could be obscuring any 
significant associations of real targets of this miRNA. 
 
Putative 14 is present on the JH376230 scaffold and although it has some homology with 
miR-1202 known in humans, it is doubtful that these miRNAs are identical. The 
expression of this miRNA increases sharply in both heart and non-heart tissue in the 
HH14-16 sample (Figure 5.6C, D). Putative 14 is predicted to target genes associated with 
cell proliferation, growth and developmental growth (Figure 5.4). Interestingly, a 
significant association was found between the predicted targets of this miRNA and 
confirmed targets of three miRNAs known to inhibit growth and proliferation. miR-198 
reduces proliferation in lung cancer cells by targeting FGFR1
180
 , miR-593 is thought to 
reduce proliferation of esophageal cancer by its action on Polo-kinase 1 (PLK1)
181
, and 
miR-129 inhibited the growth and migration of thyroid cancer cells
182
. Putative 14 may 
have similar effects on proliferation, especially at the HH14-16 time point which showed a 
rapid increase in Putative 14 expression.  
 
Whole chick RNA was probed for all fourteen predicted novel miRNAs by Northern blot, 
but bands were only detected for the three putative miRNAs shown in this chapter. The 
normalised read counts for all eleven undetected miRNAs were quite low, ranging from 3 
to 188 reads per million and it is possible that these miRNAs do exist but were below the 
limits of detection of the Northern blots performed. Putative 4 and Putative 10 both have 
fewer than 5 reads per million at their peak and both were detected by Northern blot. 
However, whole embryo RNA was used to perform the Northern blots and therefore if a 
putative miRNA is expressed at low levels in a specific tissue, such as the heart, its signal 
may be undetectable without isolating RNA from just the heart for Northern blots. 
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6 The role of miR-1 during early chick heart development 
6.1 Introduction 
In this chapter the biological effects of miR-1 inhibition, as achieved by antagomiR cardiac 
microinjection at HH14, were examined. miR-1 was found to translationally inhibit FZD7 
and RARβ in vivo, and its dysregulation at HH14 resulted in developmental delay of 
embryos. 
 
The cardiac and skeletal muscle-specific
4,5,183,184
 miR-1 is indispensable during heart 
development
5,6,107,108,183,185
. miR-1 inhibits the Wnt signalling receptor FZD7 and the 
Retinoic Acid (RA) signalling receptor RARβ8. Both Wnt and RA signalling are essential 
for cardiogenesis at several stages of development
7,34
, and the effects of miR-1 
dysregulation with respect to these signalling pathways were examined. 
6.1.1 miR-1 
miR-1 has been found to be specifically expressed in skeletal and cardiac muscle, in a 
manner that is evolutionarily conserved
4,5,73,183,184
. The muscle-specificity of miR-1 
expression has been shown by the repression of murine miR-1 sensor constructs in mouse 
hearts, by the in vivo expression of miR-1 LacZ promoter fusion constructs in 
differentiating cardiac and skeletal muscle precursors, as well as by the detection of miR-1 
expression in Zebrafish and D. melanogaster muscle by LNA-probe in situ 
hybridization
108,184
. This microRNA is transcriptionally regulated by MyoD
5
, Myf5 and 
myogenin, myogenic regulatory factors (MRFs)
186
, by members of the myocyte enhancer 
factor 2 (MEF2) transcription factor family, as well as by serum response factor 
(SRF)
5,183,184
. Texel sheep, a very muscular breed popular for its meat, have a G-to-A 
mutation in the 3’ UTR of their myostatin mRNA which allows the closely related miR-1 
and miR-206 mature microRNAs to bind and translationally repress this gene, causing the 
heavy muscularity the breed is known for
6
. Additionally, miR-1 has been associated with 
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myogenesis and with the maintenance of differentiation of muscle cells
107,108,185
, as well as 
with the regulation of key components of the cardiac conduction system
6
. 
 
miR-1 expression in human heart and skeletal muscle was confirmed by Northern blot 
assays
184
. miR-1 has been implicated in cardiac dysfunction with miR-1 expression levels 
decreased in diseased human hearts and in three cardiac hypertrophy models
6,184
, and 
significantly elevated in samples from humans with coronary artery disease (CAD)
185
. This 
microRNA is evolutionarily conserved with a single miR-1 gene being present in both the 
worm and fly genomes and with two miR-1 loci, miR-1-1 and miR-1-2, present in the 
zebrafish, mouse and human genomes
184
. miR-1-1 and miR-1-2 have identical mature 
sequences
114
. The most recent release of the miRBase microRNA database
41,170,171,173
, 
release 20, contains three annotated copies of the miR-1 gene in the chicken genome. 
 
The miR-1a-1 / miR-133a-2 cluster is located in an intergenic region on chromosome 20, 
whilst miR-1a-2 / miR-133a-1 is found on chromosome 2 in an antisense direction within 
intron 12 of the Mib1 gene (Figure 6.1A). A third copy of the miR-1 gene originates from 
the miR-1b / miR-133c cluster within intron 1 of the putative ISG12-1 gene on 
chromosome 23 (Figure 6.1A). The mature sequences of miR-1a-1 and miR-1a-2 are 
identical, whereas miR-1b differs from the miR-1a mature sequence by one nucleotide 
(Figure 6.1B). miR-1a expression is present in the chick embryo heart tube by Hamburger-
Hamilton stage (HH) 11 and in the myotome of the somite from HH14
115
. The Geisha 
chicken embryo gene expression database
17,147
 indicates that miR-1b is expressed in the 
heart from HH13 until at least HH27. 
 
In D. melanogaster SRF is known to regulate the expression of miR-1 in cardiac muscle 
and MEF2 also plays a role in the regulation of muscle-specific miR-1 expression
183
. In 
mice the miR-1-1 / miR-133a-2 cluster is found on chromosome two in a non-coding 
region
4
, whilst the miR-1-2 / miR-133a-1 cluster is positioned in the antisense direction in 
an intron of the ubiquitously expressed Mib1 gene, which is involved in the Notch 
signalling pathway
5
. Both of these clusters have been shown to be expressed specifically in 
skeletal and cardiac muscle
6,114,184
, with expression starting in the ventricular myocardium 
and the interventricular septum from E8.5 and continuing until adulthood
114
. SRF and 
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MEF2 cooperate with the MRFs myogenin and MyoD to induce the expression of miR1-1 
and miR-1-2 in skeletal muscle
4,6
. MEF2 binds to the intronic enhancer within the cluster 
to turn on expression of miR-1 in ventricular myocytes, whereas SRF has been shown to 
direct the expression of miR-1 in ventricular and atrial myocytes
6
. 
 
 
Figure 6.1: Chicken muscle-specific microRNAs. A: The miR-1a-1 / miR-133a-2 cluster is located in an 
intergenic region of chromosome 20, miR-1a-2 / miR-133a-1 resides in intron 12 of the Mib1 gene on 
chromosome 2, and miR-1b / miR-133c is found an intergenic region of chromosome 23. The expression of 
these three clusters is restricted to cardiac and skeletal muscle. The skeletal muscle-specific miR-206 / miR-
133b cluster is sited in an intergenic region of chromosome 3. B: Alignments of the mature microRNA 
sequences that result from the clusters shown in A, with letters in bold indicating sequence differences. The 
skeletal muscle-specific miR-206 is very similar to miR-1. 
 
A 4.6 kilobase (kb) fragment from the genomic region around miR-1-1 and miR-1-2, 
conserved between human and mouse, directed lacZ expression in transgenic mouse 
hearts
108
. This transgene was expressed in the heart from E8.5 and in the myotome from 
E11.5, confirming the cardiac and skeletal muscle-specificity of miR-1 expression
108
. After 
cardiac looping and as cardiomyocyte differentiation progressed, the expression of the 
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transgene became more robust with the strongest expression seen in the less proliferative 
inner curvature of the looping heart tube and atria
108
. 
 
The early expression of miR-1 in embryonic stem cells (ESCs) forced their differentiation 
toward a cardiac fate
6
. The overexpression of miR-1and the closely related miR-206 in 
cultured C2C12 cells advanced myogenic differentiation whereas the knockdown of these 
microRNAs prevented myogenic differentiation
4
. The expression of non-muscle genes is 
repressed in a microarray of HeLa cells transfected with human miR-1, which suggests that 
miR-1 may be responsible for the maintenance of muscle cell identity
184
. Furthermore, 
skeletal myoblasts were forced to differentiate into skeletal muscle cells by the 
overexpression of miR-1 in vitro
5
, and hypertrophic growth of cardiomyocytes was 
inhibited by miR-1 in vitro
6
. Histone deacetylase 4 (HDAC4) is a signal-dependent 
enzyme that causes the repression of MEF2 and leads to the repression of muscle 
differentiation
93
. In C2C12 cells miR-1 was shown to repress the translation of HDAC4, 
leaving MEF2 free to induce myoblast differentiation in conjunction with the MRF 
MyoD
107
. 
 
The injection of miR-1 into Xenopus laevis embryos resulted in increased differentiation 
and decreased proliferation of muscle cells, as well as anomalous heart development
6,107
 
similar to that seen when miR-1 was overexpressed in D. melanogaster embryos
183
. When 
miR-1, controlled by a βMHC promoter which gives high levels of miR-1 expression by 
E9.0, was overexpressed in developing mouse hearts, lethality resulted during mid-
embryogenesis at E13.5, possibly due to heart failure as a result of the observed deficiency 
in cardiomyocytes
108
. It has been suggested that this deficiency of cardiomyocytes is due to 
miR-1 targeting the mRNA of Hand2
108
, a bHLH transcription factor that regulates the 
expansion of the ventricles of the embryonic heart
187
. Postnatal miR-1 overexpression 
confirmed that miR-1 translationally represses Hand2, as significantly reduced Hand2 
protein was detected in transgenic mouse hearts when compared with non-transgenic 
littermate hearts whilst Hand2 mRNA levels remained constant
108
. 
 
Groups of undifferentiated cells along with a general loss of differentiation in some muscle 
was observed when miR-1 was deleted from the D. melanogaster genome
184
. Deletion of 
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miR-1 resulted in a third of mutants dying at embryonic stages, a third dying at hatching 
and the final third dying at larval stages after displaying reduced mobility
183
. Defects in 
cardiac and somatic muscle patterning were seen in the most severely affected embryos 
that died during embryogenesis, and surviving embryos had a loss of cardiac cells in the 
dorsal vessel
183
. 
 
Deletion of miR-1-2 did not result in the upregulation of miR-1-1 expression and it was 
reported that about half of miR-1-2
-/-
 mutants die shortly after birth due to ventricular 
septal defects (VSD)
5
. No difference in Hand2 mRNA levels was detected at E15.5 
between surviving miR-1-2
-/-
 mutants and their wildtype littermates, but Hand2 protein 
levels were four times higher in the miR-1-2
-/-
 mutant animals. As a narrow range of Hand2 
concentrations are required for normal cardiomyocyte development
187
, the dysregulation 
observed in miR-1-2
-/-
 mutants strongly imply that this microRNA plays an essential role 
during heart development by fine-tuning the protein levels of Hand2. In addition, the walls 
of the hearts of the surviving miR-1-2
-/-
 mutants appear thickened, with many myocytes 
apparently undergoing nuclear division
5
. Although mouse cardiomyocytes do undergo 
nuclear and cellular division in the first two weeks of life before permanently exiting the 
cell cycle, a significant increase in mitotic myocytes was found in miR-1-2
-/-
 mutants 
compared to their wildtype littermates
5
. In fact, mitotic myocytes were still found in some 
3-month-old mutant animals
5
. Together with the overexpression studies, these results lead 
to the suggestion that miR-1 has an essential role in inhibiting cell proliferation during and 
following embryonic heart development
5,6
. 
 
Of the surviving miR-1-2
-/-
 mutants, about 15% died of heart and ventricular dysfunction 
by 3 months of age and despite the rest of the animals appearing normal many suffered 
sudden death, leading the researchers to suspect cardiac electrophysiologic defects to be 
the cause
5
. Adult mutant mice were found to have significantly lower heart rates than their 
wildtype littermates and had two-fold higher Irx5 mRNA and 5-fold higher Irx5 protein 
levels than wildtype hearts. Irx5 is a transcription factor that represses a potassium channel 
Kcnd2 and thus regulates cardiac repolarisation. In accordance with the observed increase 
in Irx5 mRNA and protein levels, miR-1-2
-/-
 hearts had lower levels of Kcnd2 mRNA. 
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These results suggest that miR-1 is involved in the regulation of the cardiac electrical 
system by targeting Irx5
5
. 
 
Rats subjected to experimental myocardial infarction (MI), the formation of necrosis 
caused by obstruction of blood circulation, were found to have an increase of about 2.6 
fold of miR-1 expression within the ischemic zone but no increase in the non-ischemic 
zone
185
. Ischemic arrhythmias were increased when miR-1 RNA was injected into the 
infarcted myocardium but were suppressed significantly by the injection of antagomiR-1 
into this region. Further investigation revealed that miR-1 translationally downregulates 
the potassium channel protein Kir2.1 as well as the cardiac gap junction channel protein 
connexin 43 (Cx43), leading to increased arrhythmias in ischemic hearts
185
. When 
antagomiR-1 and siRNA against Cx43 and Kir2.1 mRNA were co-injected, significant 
arrhythmias were induced in ischemic hearts, confirming that these arrthythmias were due 
to the downregulation of Cx43 and Kir2.1 and thus indicating that miR-1 possibly has a 
pathological role in ischemic hearts
185
. 
 
To date miR-1 is intimately involved in both the embryonic development and postnatal 
function of cardiac cells with its effects ranging from differentiation of cardiomyocytes to 
control of components of the conduction system. Microarray assays of adult hearts of miR-
1-2 knockout mice showed significant upregulation of 45 and downregulation of 25 
protein-coding genes
5
, suggesting that many important targets of this microRNA still 
remain unstudied. Previous work done in the Münsterberg laboratory illustrated the 
importance of miR-1 function during somite myogenesis
127
, and miR-1 was shown to 
target the Wnt receptor Frizzled 7 ( FZD7) as well as Retinoic Acid Receptor β (RARβ) in 
vitro
8
.  
 
Like miR-1, miR-133 is known to be expressed specifically in skeletal and cardiac muscle 
under the transcriptional regulation of MyoD, MEF2 and SRF
5,33,183,184
, but unlike miR-1 
this microRNA inhibits the differentiation and stimulates the proliferation of myoblasts
4
. 
Along with miR-1, miR-133 has been found to be involved in the regulation of 
components of the cardiac conduction system and to increase arrhythmias
6
, possibly by the 
repression of a potassium channel protein, KCNQ1
188
. 
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In vitro miR-133 repressed the differentiation and advanced the proliferation of C2C12 
cells by the repression of its targets SRF and polypyrimidine tract-binding protein 
(nPTB)
5,6
, and inhibited ESC differentiation towards cardiomyocytes
6
. Additionally, miR-
133 has been found to repress the translation of the cardiac potassium channel protein 
ether-a-go-go-related gene (ERG), resulting in delayed myocyte repolarization, when it 
was introduced into cardiomyocytes in vitro. The normal hypertrophic response of both 
neonatal and adult cardiomyocytes to agonist stimulation was inhibited by the 
overexpression of miR-133 by an adenoviral vector
6
. Despite the proximity of the 
microRNA genes and their overlapping expression patterns, evidence has been found that 
indicates miR-1, miR-133 and miR-206 can be expressed as independent transcriptional 
units
6
. 
 
In this study miR-1 was detected in all nine samples assayed (Figure 6.2), and was found 
to have a large spike in expression in the HH14-16 NT sample. This large difference 
between the HH14-16 H and HH14-16 NT samples may have been due to contamination of 
the HH14-16 NT sample with material from a developing somite, known to express miR-1 
HH14
115
. 
 
 
Figure 6.2: The fold change pattern of miR-1 over its levels in the HH5-7 sample. miR-1 was found to 
have a very large fold change increase in the HH14-16 NT sample. 
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6.1.2 Frizzled 7 
The Frizzled (FZD) family of 7-transmembrane receptors can bind members of the cystein-
rich, glycosylated Wnt-protein family on the extracellular surface of cells
26
. The Wnt 
signalling pathway is highly conserved and is involved in a large number of biological 
processes during embryogenesis and in adults
25,26
. FZD receptors have been shown to be 
involved in the regulation of the cytoskeleton, cell proliferation, apoptosis induction and, 
in D. melanogaster, receiving polarity signals and transmitting these signals to adjacent 
cells
26
. 
 
After myocardial infarction in rats, myofibroblasts expressed FZD2 whilst migrating into 
the infarct area as well as during their proliferation following migration
26
. Deletion of the 
Dvl1 gene in mice resulted in infarct rupture much more often than in wildtype mice; β-
catenin could not be detected in the hearts of mice that died following infarct rupture 
whereas wildtype hearts had high levels of β-catenin26 showing that Wnt-Fzd signalling is 
essential for wound healing in the heart. Even though the loss of β-catenin abated myocyte-
myocyte interactions by weakening adherens junctions, healthy hearts did not appear 
affected and only once myocardial infarction occurred was the structural integrity of the 
ventricular wall threatened. This suggests that the Wnt-Frizzled signalling cascade is 
essential for healing following a myocardial infarction. Frizzled-associated Wnt signalling 
has been implicated as being involved in angiogenesis, a process which is upregulated in 
ischemic heart disease and results in blood flow being reinstated to the wounded tissue
26
. 
Following induced infarction in rat hearts, the cell adhesion complexes of newly formed 
endothelial cells were disrupted, and concurrently β-catenin was found to be translocated 
to the cytoplasm from the plasma membrane
26
, indicating that Wnt-Fzd signalling is 
involved in the process of vascularisation of the diseased heart. 
 
Foetal, neonatal and overloaded rat hearts have been shown to have higher expression of 
FZD receptors compared to healthy adult hearts
189
. Secreted Frizzled-related proteins 
(sFRPs) antagonise the Wnt / FZD signalling pathway by binding to and therefore 
inhibiting the normal action of either Wnt or FZD
189
. Human adult ventricular 
cardiomyocytes have been found to express sFRPs in the ventricular myocardium of both 
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healthy and diseased hearts
189
. Wnt3A and Wnt8 activity in the cardiogenic mesoderm of 
X. laevis is inhibited by the action of the Wnt antagonists Dickkopf-related protein 1 (Dkk-
1) and Crescent
27
. These findings lead to speculation that Wnt antagonism, in part, initiates 
Nkx2.5 expression, later maintained by the growth factor Bone Morphogenetic Protein 
(BMP), to initiate cardiogenesis
27
. Similarly, in HH8-9 chick embryo explants, Wnt-3a and 
Wnt-1 signals from the neural tube and BMP antagonists noggin and chordin secreted by 
the notochord were found to inhibit cardiogenesis in the anterior paraxial mesoderm
28
. 
When the anterior paraxial mesoderm of chick embryos was exposed to both BMP-4 and a 
Wnt antagonist, the heart was found to become enlarged as a result of the formation of a 
larger pool of cardiac myocyte precursor cells
28
. The migration of mesodermal cells into 
the heart was also stimulated by Wnt antagonists and BMP molecules
28
. Cardiogenesis was 
induced when GSK3β was ectopically expressed in X. laevis ventral mesoderm, indicating 
that heart formation is a result of the disruption of Wnt signalling via the canonical 
pathway
27
. 
 
A member of the FZD family, FZD7, is known to function as part of the canonical Wnt 
signalling pathway
25
. Whole-mount ISH (WISH) on developing mouse embryos showed 
expression of FZD7 to be ubiquitous and comparable to receptors involved in anterior-
posterior patterning in the gastrulating embryo
25
, and in X. laevis FZD7 has been 
implicated in neural crest development by its interaction with Wnt signals
190
. The Geisha 
chicken embryo gene expression database
17
 shows FZD7 expression in chick from HH3, in 
the early mesoderm and primitive streak, up to at least HH10, in the paraxial mesoderm 
and neural tube. In the frog FZD7 is expressed in migrating cardiac progenitor cells 
(CPCs) and in the pericardium and myocardium of the developing heart
189
. 
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Previously, miR-1 expression was reported as skeletal and cardiac muscle-specific
4,5,183,184
 
and essential for both the development and function of the heart
5,6,107,108,183,185
. In vitro 
assays on C2C12 cells have confirmed that miR-1 can suppress sensor constructs 
containing the 3’ UTR of FZD7, at the level of translation8. The inhibition of canonical 
Wnt signalling by Wnt antagonists, along with BMP secretion, is essential for 
cardiogenesis during development
26-28
. The translational suppression of FZD7, a 
transmembrane receptor that binds Wnt
25
, by miR-1 could possibly ensure that FZD7 
receptors are absent and therefore cannot bind stray Wnt signals, and so ensure the 
commitment of the miR-1-expressing cell to the cardiac lineage. In adult hearts the Wnt-
FZD cascade is essential for healing following myocardial infarction in mice
26
, and miR-1 
expression is reported to be upregulated in the ischemic zone following myocardial 
infarction
185
. It is possible that the upregulation of miR-1 following an infarction results in 
the translational suppression of its target FZD7, which leads to a disruption in myocyte-
myocyte interactions and a further weakening of the heart. 
6.1.3 Retinoic acid receptor β 
Retinoic acid (RA), a small lipophilic molecule, directly activates transcription when 
bound to one of three retinoic acid receptors (RARα, RARβ or RARγ). In this signalling 
pathway RA is derived from retinol via retinaldehyde by the action of retinol 
dehydrogenases and retinaldehyde dehydrogenases. The RARs form heterodimers with 
retinoid X receptors (RXRs) and act in the nucleus regardless of whether RA is bound
191
. If 
RA is not bound to the RAR/RXR heterodimer, this complex binds co-repressor complexes 
which repress transcription by keeping the chromatin structure of the target DNA in a 
stabilised state
34
. However, when the agonist binds to the RAR/RXR heterodimer, a 
conformational change leads to the release of the co-repressor complexes allowing co-
activator proteins to become attached, which results in transcriptional activation of the 
gene
34,191
. RA signalling has pervasive roles during development, ranging from early 
dorsoventral axis patterning to the morphogenesis and differentiation of the heart
34
, 
confirmed by the number of abnormalities that resulted when rat and avian embryos were 
deprived of dietary vitamin A
120
. 
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Embryonic stem cells exposed to RA are induced to differentiate into their previously 
specified lineages
34,192
. In vivo experiments on chick embryos have shown that ectopic RA 
causes a large number of heart anomalies, especially when embryos are treated during 
early development (HH3 – HH6)193. Local application of RA to the cardiogenic mesoderm 
inhibited the formation of a fused cardiac crescent and lead to cardia bifida, similar to the 
effects seen when the formation of the cardiac crescent is prevented by the removal of a 
piece of the precardiac mesoderm. A stronger phenotypic effect was seen in embryos 
treated with RA at HH5 than later stages, further indicating that excess RA causes cardia 
bifida by inhibiting the migration of cardiogenic mesoderm
193
. 
 
Mouse mutants lacking either the Rxra or Raldh2 genes died about midway though 
development and had impaired myocardial differentiation and growth
34
. The knockout of 
the genes encoding RARα and RARβ at the same time resulted in many abnormalities, 
including outflow tract and large vessel malformations, and mice died at birth. The heart, 
outflow tract and large vessels were also affected in mice with both the Rarg and Rxrb 
genes deleted; embryonic lethality was observed about halfway through gestation
34
. 
 
The inhibition of RA signalling in vivo lead to an increase in the postnatal size of a 
subpopulation of mouse stem and progenitor cells that contains CPCs, a decrease in the 
number of differentiation markers expressed, as well as an increase in the expression of 
cardiac progenitor markers
192
. Cardiac Fgf8 is necessary for Isl1 expression. As Isl1 
expression defines the second heart field, the inhibition of Fgf8 by RA at the posterior end 
of this region observed in mutant mice limited the size of the cardiogenic region
120
. These 
results suggest that RA negatively controls the size of the cardiac progenitor pool during 
early development in mice. Similarly, the bilateral heart fields expressing Nkx2.5 and 
cardiac myosin light chain 2 became enlarged as a result of the inhibition of RA signalling 
in zebrafish embryos
34
. Further work using zebrafish embryos indicated that lateral 
mesoderm will become specified to a cardiac fate in the absence of RA, providing extra 
support for the suggestion that RA signalling has an inhibitory effect on cardiac 
specification during early development
34
. 
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Epicardial progenitors migrate from the proepicardial organ (Figure 1.2B), over the 
outside of the myocardium and eventually cover the surface of the growing heart
18
 (Figure 
1.2A). The epicardium is responsible for inducing the underlying myocardium (Figure 1.3) 
to grow
18
, though RA signalling is not required during the initial formation and migration 
of the epicardium
192
. Experiments have shown that the growth-promoting effects of the 
epicardium depend on RA
192
, which has been proposed to act on liver cells and result in 
myocardial growth via Epo and Igf2 expression
120
. RA stimulates the secretion of hepatic 
EPO, which in turn fuels IGF2 secretion when it becomes bound to epicardial receptors. 
IGF2 signalling in myocardium induces myocardial growth as a result of IGF2 secretion by 
the epicardium. 
 
Cardiomyocyte differentiation was shown to be suppressed in RA deficient mice
34,192
; this 
phenotype could be rescued by exogenous addition of FGF
192
. FGF signalling, required for 
growth in the heart by recruiting cells to the arterial pole and known to induce 
differentiation of cardiomyocytes, is dependent on RA signalling in murine epicardial and 
proliferating myocardial cells
34,192
. In addition, the migration of neural crest cells is 
disturbed when RA is absent
191
, resulting in a loss of outflow tract septation
34
. It has been 
suggested that a concentration gradient of RA is responsible for the development of the 
segmental units of the hindbrain, possibly due to FGF repressing a RA-metabolizing 
enzyme, Cytochrome P450 26 A1 (CYP26A1), along its own concentration gradient
34
. 
 
In zebrafish embryos miR-138 is expressed in the ventricular chamber during early 
development and in the outflow tract during later development
111
. Chemical inhibition of 
miR-138 caused looping defects, cardiac dysfunction and reduced cardiomyocyte 
differentiation in the vast majority of treated embryos, similar to the effects seen when RA 
signalling was induced in the heart. The expression of miR-138 is reported to be essential 
for normal cardiogenesis during the early stages of cardiac looping
111
. During RA 
signalling retinoic acid dehydrogenase (Raldh2) produces activated RA, and in the 
zebrafish embryo Raldh2 is expressed only in the atrioventricular canal of the embryonic 
heart. The gene encoding Raldh2, aldh1a2, was found to have a conserved miR-138 
binding site, and miR-138 inhibition resulted in upregulated Raldh2 expression in 
ventricular cardiomyocytes as well as cardiac abnormalities
111
. In addition, miR-138 was 
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found to repress the ventricle-specific protein versican. Versican is known to induce valve 
formation and its gene, cspg2, is activated by RA signalling. These results suggest that 
miR-138 plays a role in cardiac development by inhibiting the RA signalling pathway in 
zebrafish ventricular cardiomyocytes
111
. 
 
Retinoic acid receptor β is one of several predicted targets of miR-1, and in vitro 
experiments have shown that miR-1 can repress RARβ at the transcript level8. The size of 
the CPC pool is limited by RA
34,120,192
, and RA signalling is required for FGF-induced 
myocardial differentiation in vivo as well as for myocardial growth stimulated by 
epicardium
192
. 
 
Given the importance of the known roles of miR-1 during heart development, the effects of 
miR-1 inhibition on embryonic development were studied along with the consequences of 
miR-1 inhibition on the translation of FZD7 and RARβ, known targets of this miRNA in 
vitro. Although miR-1 is reasonably well studied, it is very unlikely that most of its roles 
have been discovered and its regulation of FZD7 or RARβ has not been elucidated 
elsewhere.  
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6.2 Results 
6.2.1  FZD7 and RARβ mRNA is expressed in the developing chick heart 
In order to establish an expression profile of FZD7 and RARβ in the chicken embryo, 
WISH assays were performed on embryos ranging from HH4 to HH18.  
 
FZD7 is expressed in primitive streak and the area pellucida of HH4 and HH4+ embryos 
(Figure Apx D.1A, B), as well as in the cardiogenic and paraxial mesoderm at HH8 
(Figure Apx A.1D). FZD7 is still expressed in the cardiogenic mesoderm at HH9 (Figure 
6.3A), and in the heart tube at HH10 (Figure 6.3B, C), HH11 (Figure 6.3D, E), and HH12 
(Figure 6.3F). By HH15 (Figure 6.3G, H) and HH18 (Figure 6.3I, J) however, FZD7 has 
been transcriptionally downregulated in the heart. 
 
The expression profile from HH4 to HH10 established in Figure Apx A.1 and Figure 6.3 
confirms the ISH analysis of FZD7 expression published on the Geisha web resource. In 
addition, the expression of FZD7 was established up to HH18 and FZD7 was found to be 
expressed in cardiogenic and heart tissue from HH4 up to HH14. 
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Figure 6.3: FZD7 expression in the chick during later stages of development. FZD7 mRNA WISH on 
chick embryos. At HH9 FZD7 is expressed in the cardiogenic and paraxial mesoderm (A). B, C: Dorsal (B) 
and ventral (C) views of a HH10 embryo shows FZD7 expression in the neural tube, neural plate, paraxial 
mesoderm and in the heart tube (black arrow). The omphalomesenteric vein (red arrow, C) also expresses 
FZD7 mRNA. D, E, F: FZD7 is expressed in the cardiogenic mesoderm, heart tube (black arrows, E, F), 
omphalomesenteric vein (D), paraxial mesoderm and neural tube at HH11 and HH12. G, H, I, J: FZD7 
expression is not detected in the heart at HH15 (black arrow, G, H) and HH18 (black arrow, I, J). 
 
A very slight RARβ mRNA signal seen in HH10 (Figure 6.4A), HH11 (Figure 6.4B), and 
HH12 (Figure 6.4C) heart tubes. By HH18 RARβ expression appears completely 
downregulated (Figure 6.4D, E).  
 
The expression of RARβ at HH10 seen in Figure 6.4A, B and C mirrors the profile of 
RARβ published in the GEISHA web resource. Information on RARβ expression between 
154 
 
HH11 and HH18 is not available from the GEISHA web resource. RARβ was here found 
to be low at HH11 and absent by HH18.  
 
 
Figure 6.4: RARβ expression in the chick during early stages of development. WISH for RARβ mRNA on 
chick embryos. A, B, C: Ventral view of HH10 (A), HH11 (B) and HH12 (C) embryos with very slight RARβ 
expression seen in the heart tube (black arrows). D, E: By HH18 RARβ expression has been completely 
downregulated in the heart (black arrows). 
6.2.2 miR-1 reduces FZD7 and RARβ protein levels in the heart 
2’-O-methyl modified cholesterol conjugated and fluorescein isothiocyanate (FITC)-
labeled antisense RNAs are known to reduce the levels of endogenous miRNAs and very 
specifically act on just their complementary miRNA
194,195
. The conjugation of cholesterol 
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to these small molecules allows direct movement into cells without the need for damaging 
electroporation. AntagomiR-1 (AM1) inhibits miR-1 expression, whereas an antagomiR 
with a scrambled sequence complementary to miR-206 (Scr206) does not affect miR-1 
levels in ovo
127
. 
 
To assess whether miR-1 translationally inhibits FZD7 and RARβ, AM1 and a control 
antagomiR containing a scrambled miR-206 sequence (Scr206) were microinjected into the 
hearts of HH14 embryos in ovo. Western blot analysis of injected heart tissue showed an 
approximate 38% reduction in FZD7 levels and a 65% drop in RARβ levels (Figure 6.5). 
Three biological replicate assays were performed, a representative of which is shown in 
Figure 6.5A and B. Each biological assay loaded 40μg of protein per lane (2.11), isolated 
from 24 injected hearts. Quantifications of bands for Figure 6.5C and D were performed 
as described in 2.13. 
 
Figure 6.5: miR-1 translationally inhibits FZD7 and RARβ in the developing chick heart. Inhibition of 
miR-1 by antagomiR-1 (AM1) microinjection into HH14 embryonic hearts resulted in increased FZD7 (A) and 
RARβ (B) protein levels compared to the control. An antagomiR with a scrambled miR-206 sequence (Scr206) 
was injected as a negative control and actin was used as a loading control. C,D: ImageJ
148
 quantification 
(2.13) of FZD7 and RARβ Western blot bands, normalised to actin and then to AM1, shows a statistically 
significant increase in protein levels when miR-1 was inhibited with antagomiR-1. N=3, paired t-test. P=0.0002 
(C) and P=0.0005 (D). 
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6.2.3 Reduction of miR-1 impairs embryonic growth 
AntagomiRs are FITC-labelled and therefore embryos successfully injected in ovo can be 
identified by their fluorescence upon harvesting. As expected, injection of antagomiRs into 
the beating chicken heart resulted in widespread distribution throughout the embryo 
(Figure 6.6A, B, C, D, J). AM1 injection is known to result in miR-1 inhibition whereas 
Scr206 does not affect miR-1 levels in ovo
127
.  
 
During preliminary investigations inhibition of miR-1 by AM1 at HH14 resulted in a 
striking developmental delay phenotype, discussed further below, compared to the effects 
of miR-1 inhibition at HH11 (Figure Apx D.2) or HH20 (Figure Apx D.2, Figure Apx 
D.3, Figure Apx D.4). Therefore investigations into the effects of miR-1 dysregulation at 
HH14 were prioritised over further studies at HH11 and HH20. 
 
Embryos were microinjected at HH14 in ovo, after being allowed to cool to room 
temperature to slow the heart rate and minimize damage to the heart during injection, and 
left to develop for 24 hours, which should have resulted in embryos around developmental 
stage HH20. The AM1 and Scr206 embryos from three different experiments were staged 
by counting somites and divided into two groups: those that had reached stage HH20 and 
older, and those that were at or younger than stage HH19. An average of 75% AM1 
injected embryos were found to be younger than HH19, whereas only 9% of Scr206 
injected embryos had not reached HH20 or older at the time of harvest. These results were 
consistent across the three different experiments, and the portion of delayed embryos after 
AM1 injection was significantly different from that after Scr206 injection (Figure 6.6I). 
 
Whole mount in situ hybridisation (WISH) for myosin heavy chain 15 (Myh15) mRNA 
was performed on all injected embryos to visualise the heart (Figure 6.6E, F, G, H, K,  
Figure Apx D.3, Figure Apx D.5). Myh15 is expressed in the heart tube from HH9 and in 
the somites from HH16
17,147
.  
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Figure 6.6 Inhibition of miR-1 by AM1 at HH14 resulted in significant developmental delay not seen 
upon injection with a control antagomiR (Scr206) nor following inhibition of miR-206 by AM206.  
Representative embryos injected with AM1 (A, B, E, F) or Scr206 (C, D, G, H). Most (74%) of embryos 
injected with AM1 were found to be developmentally delayed (I). 26% of embryos injected with AM1, in 
contrast with 91% of embryos injected with Scr206, did not show developmental delay. Inhibition of miR-206, a 
miRNA very closely related in sequence to miR-1, by AM206 at HH14 did not result in the developmental 
delay observed on inhibition of miR-1 (J, K). The expected widespread distribution of the FITC-labelled 
antagomiRs following successful cardiac microinjection (A, B, C, D and E) with the corresponding Myh15 
mRNA expression pattern (E, F, G, H and K) is shown in representative embryos. I: Comparison of the 
fraction embryos found to be at or younger than HH19 after AM1 or Scr206 microinjection at HH14. Inhibition 
of miR-1 with AM1 resulted in an average of 74% embryos younger than HH19, compared with 9% younger 
than HH19 after Scr206 injections. N=3, n=10, P=0.001. 
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6.2.4 Reduction of growth is not seen when miR-206 is inhibited 
miR-1 and miR-206 share several targets, such as FZD7 and RARβ8, which may be 
affected when AM1 is circulated throughout the embryo. miR-206 was inhibited by 
injection with AM206 in order to determine whether the observed developmental delay on 
inhibition of miR-1 at HH14 (Figure 6.6I) may have been due to dysregulation of target 
genes common to miR-1 and miR-206 outside the heart.  
 
The beating heart is essential for development and transfer of nutrients throughout the 
developing embryo. Injection into the heart results in widespread distribution of the 
injected antagomiR, as is apparent by FITC fluorescence (Figure 6.6A, B, C, D, J, Figure 
Apx D.2 and Figure Apx D.4). This resembles the distribution of antagomiR-206 injected 
into the vitteline vein, which resulted in greatly reduced miR-206 levels in the somites of 
chick embryos at 24 and 28 hours post injection
196
.  
 
miR-1 and miR-206 have very closely related sequences that differ by only 5 nucleotides 
in the mature miRNA, and have identical seed sequences (Figure 6.1A). miR-1 is 
expressed specifically in cardiac and skeletal muscle, whereas miR-206 is restricted to 
skeletal muscle only (Figure 6.1A). miR-1 is expressed in the heart from HH11 and in 
somites from HH14
115
, and miR-206 can be detected in somites from HH14
197
. 
AntagomiR-206 (AM206) has a sequence very similar to that of AM1, and in the chick 
embryo AM1 completely inhibits miR-1 but does not affect miR-206 levels
127
. Therefore, 
to assess whether the developmental delay observed as a result of miR-1 inhibition could 
have been due to the dysregulation of target genes common to miR-1 and miR-206 outside 
the heart, miR-206 was inhibited by injection with AM206 (Figure 6.6J, K, Figure Apx 
D.6, Figure Apx D.7). 
 
All AM206 injected embryos had reached at least HH20 at harvest 24 hours after 
microinjection (Figure 6.6J, K and Figure Apx D.7). This confirms that the effect 
observed when miR-1 was inhibited from HH14 was not due to the inhibition of targets 
shared by miR-1 and miR-206 outside the heart. 
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In this chapter miR-1 was confirmed to target both FZD7 and RARβ in vivo, and a 
developmental delay phenotype was observed following inhibition of miR-1 at HH14 by 
microinjection into the heart in ovo. The possible reasons for this delay are discussed 
further in 6.3.  
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6.3 Discussion 
miR-1 is known to target the canonical Wnt receptor FZD7 and the retinoic acid receptor 
RARβ in vitro8. FZD7 is expressed in the heart of chick embryos until around HH15 
(Figure 6.3G, H), and RARβ is absent from the heart by HH18 (Figure 6.3I, J). 
AntagomiR-1 inhibition of miR-1 in developing chicken heart resulted in an average of 
38% and 65% reduction of FZD7 and RARβ protein levels respectively (Figure 6.5). 
 
Microinjection of cholesterol conjugated and FITC labelled antagomiRs into the 
embryonic heart at HH14 resulted in widespread distribution of the antagomiR throughout 
the embryo (Figure 6.6, Figure Apx D.5, Figure Apx D.7 and Figure Apx D.9). When 
HH14 embryos were injected with a known specific inhibitor of miR-1, AM1, 74% of 
embryos were found to be developmentally delayed compared with the 9% of control 
(AM206) injected embryos (Figure 6.6I). Most (91%) of the control injected embryos had 
reached at least HH20, in keeping with the expected development of embryos in 24 hours 
after HH14. 
 
miR-1 and miR-206 have identical seed sequences and are very similar in sequence 
overall, with only 5 nucleotides difference between them (Figure 6.1B). Therefore it is not 
surprising that these miRNAs target many of the same genes, including both FZD7 and 
RARβ8. miR-1 is expressed in skeletal and cardiac muscle, whereas miR-206 is absent 
from the heart (Figure 6.1B). To determine whether upregulation of target genes expressed 
in skeletal muscle that are targeted by both miR-1 and miR-206 was responsible for the 
developmental delay observed, miR-206 was inhibited by antagomiR-206 injection into the 
heart at HH14 (Figure 6.6J, K). After 24 hours embryos were harvested and found to have 
reached the expected HH20 developmental stage, indicating that the developmental delay 
observed when miR-1 was inhibited was not a result of upregulation of target genes in 
skeletal muscle that are also targeted by miR-206. Due to the essential nature of the beating 
heart during embryonic development and the widespread distribution of any material 
injected into the heart throughout the embryo, it is difficult to say whether the 
developmental delay observed when miR-1 was inhibited was due to heart-specific 
upregulation of its target genes or whether other genes normally suppressed by miR-1 in 
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skeletal muscle caused this effect. However, direct injection of AM1 into somites at this 
stage did not result in an obvious effect
127
. 
 
Heart development was observed to be consistent with the overall developmental stage 
achieved by delayed AM1-injected (Figure 6.6A, E), unaffected AM1 injected (Figure 
6.6B, F), and control injected (Figure 6.6C, G) embryos. Canonical Wnt signalling is 
suppressed in cells undergoing EMT
7
, and non-canonical Wnt signalling is thought to be 
essential for epicardial EMT
198
. Epicardial cells undergo EMT and migrate over the 
myocardium at around HH14, forming the epicardium
18
. Growth in the heart at around 
HH12 is mostly from migration, but the forming epicardium induces ventricular 
myocardial cells to become proliferative at HH14 to HH16
18
. As both canonical and non-
canonical Wnt receptors compete for the same ligand, it is feasible that the downregulation 
of canonical Wnt receptors would be essential during times when and in cells where non-
canonical signalling is essential. Therefore, the developmental delay that resulted from 
miR-1 inhibition at HH14 may be due to the loss of FZD7 inhibition allowing this receptor 
to compete for Wnt ligands and therefore reducing the non-canonical signalling essential 
for epicardial EMT and as a result, reducing myocardial growth normally expected at 
HH14 to HH16. Interestingly, preliminary results following antagomiR-1 injections at 
HH11 and HH20 (Figure Apx D.2, Figure Apx D.3, Figure Apx D.4) did not reflect the 
developmental delay observed when miR-1 was inhibited at HH14. This further suggests 
that the delay is a result of a specific event around HH14, and may provide further 
evidence for the initial suggestion that the downregulation of FZD7 is required for 
epicardial EMT. The targeting of FZD7 by miR-1 is essential for cardiomyocyte 
commitment
199
, confirming the importance of the interaction between miR-1 and this 
target. FZD7 overexpression in the HH14 embryonic heart would reveal the effects of 
complete loss of repression of this gene on heart development. Loss of FZD7 
downregulation, such as was achieved in this study by AM1 injection, may affect known 
markers of epicardial EMT
200
 such as platelet-derived growth factor receptor α 
(PDGFRA), sex determining region Y box 9 (SOX9), fibroblast growth factor 1/2/7 
(FGF1/2/7), and Wilms tumor 1 transcription factor (WT1). 
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However, miR-1 is also predicted to target the Snail family zinc finger 2 (SNAI2) 
transcription factor
131
. SNAI2 is a repressor of E-cadherin transcription, which must be 
downregulated for EMT to proceed
201
. SNAI2 is expressed in the primitive streak and 
mesoderm of the chick embryo in cells undergoing EMT during gastrulation. However, 
SNAI2 downregulation did not result in increased levels of E-cadherin or in a discernible 
loss of EMT in gastrulating embryos
201
, which suggests that EMT during gastrulation does 
not depend on E-cadherin downregulation. In the chick SNAI2 is expressed in the 
migrating cardiac neural crest at HH15
17,147
 and in the ventricle at HH21
202
, and is known 
to be required for EMT in the chick heart
203
. It would be interesting to determine whether 
miR-1 targets SNAI2 in vivo and to complement FZD7 investigations by overexpressing 
SNAI2 at HH14 to examine whether miR-1 ensures commitment to a cardiac fate as 
migrating cells move into the heart by repressing both these targets. At HH22-HH23 
apoptosis is increased in the ventricle around the junction with the OFT
18
. The epicardium 
has been implicated as being the source of factors that induce apoptosis in the 
myocardium
18
, and SNAI2 has been shown to have anti-apoptotic activity in 
haematopoietic cells
203
. It may be that its expression in tissue lining the ventricular cavity 
serves to counteract the epicardium-induced apoptosis in this tissue, and that miR-1 
ensures apoptosis in the rest of the ventricle by decreasing the activity of SNAI2 by 
transcriptionally repressing this gene.  
 
Epicardial-induced growth is known to depend on RA signalling
192
 and miR-1 has here 
been shown to reduce the expression of RARβ (Figure 6.5). The genetic knockout of the 
RARβ gene in mice did not result in heart developmental defects and embryos were found 
to be viable
34
, whereas RARα:RARβ null mutants died shortly after birth and displayed 
outflow tract and large vessel malformations
34
. Furthermore, the cardiac neural crest cells 
that migrate into the heart and contribute to septation of the outflow tract require RA 
signalling for their migration
34
. It is possible that miR-1 aids outflow tract septation by 
repressing RA signalling in these cells as they enter the heart and further dysregulation of 
miR-1 and overexpression of RARβ in the heart between HH18-HH20 would test this 
hypothesis. The differences in the observed phenotypes between RARβ and RARα:RARβ 
genetic knockout mice, along with the evidence showing RA signalling is required for 
cardiac neural crest cell migration and resulting outflow tract formation, suggests however 
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that it may be RARα that is essential for this aspect of cardiogenesis. It would be 
interesting to determine whether RARβ competes with RARα, and whether abrogation of 
the effect of AM1 injections at HH14 results by simultaneous reduction of RARβ protein 
levels with a dominant negative form of RARβ. If these receptors do compete for RA 
ligand and this competition results in the observed effect of miR-1 dysregulation, then a 
similar effect should be seen when RARα is inhibited with a dominant negative form of the 
RARα protein by electroporation to the heart.   
 
Furthermore, miR-1 has been shown to target the HAND2 transcription factor which is 
required for cardiomyocyte expansion in the ventricles
108
. When Hand2 was inhibited by 
antisense oligonucleotide injections at HH8 developmental arrest followed 18 hours after 
treatment
204
, and overexpression of miR-1 at E9 in the developing mouse heart also lead to 
developmental arrest (at E13.5)
108
.  
 
Investigating the in vivo functions of miRNAs during development is extremely 
challenging and yet can give invaluable information regarding the roles of a miRNA in a 
complex biological system with multiple targets and many different tissue types. miR-1 is 
known to be essential for cardiogenesis and it is likely to have many different roles during 
development dependent on the specific spatiotemporal effects that result from its 
functional interactions with its many targets, and further study of this fascinating miRNA 
is definitely required. Although this chapter raises more questions than it answers, it does 
give a glimpse into the specific effects of miR-1 dysregulation at HH14 and has led to 
several suggestions for further work. 
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7 General discussion and concluding remarks 
7.1 Study aims 
The aims of this study were: 
1. To generate a miRNA expression profile of the developing chicken heart from 
embryonic stage HH5 to stage HH23. 
2. To explore the functions of miR-1 during chicken embryonic heart development. 
 
A NGS miRNA expression profile was generated for 9 samples from 6 time points (HH5-
7, HH8-10, HH11-13, HH14-16, HH17-20, HH21-23). Bioinformatic analyses of these 
data revealed 31 known animal miRNAs not currently annotated in the chicken genome 
(7.2.1), established that miR-130 is highly expressed at early stages and in later stages in 
heart tissue samples (7.2.2), and showed that three miRNAs (miR-26, miR-30, miR-92) 
were highly expressed in all samples (7.2.3). 
 
A fold change profile of all identified miRNAs over their levels at HH5-7 was generated, 
which revealed 14 miRNAs with increases of expression more than 100 fold over their 
HH5-7 levels (7.3.1). Of these 14 miRNAs, 6 are known to be involved in heart 
development and function. Subtraction of the fold change values of each miRNA in NT 
samples from their values in matched Heart samples generated a Heart miRNA expression 
profile that revealed 38 miRNAs detected at 10 fold higher levels in Heart samples than in 
NT samples (7.3.2). Additionally, 13 reporter constructs were validated to be repressed by 
at least one of miR-130, miR-138, or miR-499 (7.3.3). The most notable of these included 
a regulator (ETS1) of miR-126 expression. miR-126 is essential for valve formation and 
angiogenesis. In addition, miR-138 was found to regulate ZEB2 which affects growth and 
angiogenesis by its effects on the PTEN signalling cascade. Two predicted novel miRNAs 
were confirmed in chicken embryonic tissue (7.4).  
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miR-1 was shown to target both FZD7 and RARβ in vivo (7.5). Finally, miR-1 inhibition by 
antagomiR cardiac injections in ovo at HH14 was shown to result in developmental delay 
of 75% of injected embryos (7.5). 
7.2 miRNA expression profile 
The miRNA expression profile of areas around the forming heart of the chicken embryo 
was established by NGS for nine samples ranging from HH5, when cardiac progenitor cells 
are specified, to HH23, during ventricular septation. 
7.2.1 Known animal miRNAs not annotated in the chicken genome were identified 
by NGS 
Analysis of all the sequences detected within the miRNA-sized fraction revealed the 
presence of 31 miRNAs that map to the chicken genome and are known in other animals 
but not known in the chick (Table Apx A.1). Three of these miRNAs (miR-143, miR-182, 
miR-363) are known to be involved in heart development and function
75,88
, and were found 
to be very highly expressed in the samples assayed (3.2.5). All 31 of these miRNAs will be 
submitted to miRBase for annotation of the chicken genome. 
7.2.2 miR-130 is highly expressed in heart tissue samples 
The normalised expression levels of miR-130 were very high in early samples (HH5-7, 
HH8-10, HH11-13) and in later heart but not NT samples (HH14-16, HH17-20, HH21-23) 
(Figure 3.7). Apart from its dysregulation in diabetic mouse hearts
79
, nothing is known of 
the roles of miR-130 in heart development and function. Interestingly, miR-31 and miR-
130 have significantly correlated patterns of expression (Figure 4.9F). miR-31 is known to 
decrease cardiac fibrogenic EMT by the negative effects on its target Isl1
117
. Is1 expression 
during early cardiomyocyte differentiation has recently been shown to be promoted by Wnt 
signalling via a novel TCF/LEF1 binding site
165
. In this study miR-130 was found to 
reduce the expression of a reporter construct containing the 3’ UTR of LEF1, and a 
reporter construct containing the 3’ UTR of TCF12 was inhibited by miR-138 (Figure 
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4.13C and J). The combined actions of miR-130 and miR-138 during cardiogenesis may 
result in the repression of Isl1 by their effects on the translation of LEF1 and TCF12. 
7.2.3 miR-26, miR-30 and miR-92 were highly expressed across all stages 
All nine samples consistently showed very high levels of three miRNAs: miR-26, miR-30 
and miR-92 (Figure 3.7). More than 40% of the predicted target genes of miR-26 and 
miR-92 were also shared by the other miRNAs, but a large number of the predicted targets 
of miR-30 were found to be unique (Figure 3.9). This high degree of predicted target 
overlap was maintained when only those predicted targets known to be expressed in the 
human heart were considered (Figure 3.10, Table Apx A.3, Table Apx A.4). 
  
miR-10 was the most sequenced miRNA in the older samples and dominates especially in 
the non-heart samples (Figure 3.7). Although all four these highly expressed miRNAs 
share many predicted targets only three GO terms, all related to nerve development, were 
found to be significantly associated with the unique predicted targets of miR-10 (Figure 
3.9). This suggests that miR-10 may suppress nerve development in non-neural tissues by 
counteracting factors promoting the formation of the neural tube, in addition to its known 
roles in angiogenesis miR-10
92
.  
7.3 miRNAs important during heart development 
7.3.1 Finding highly expressed miRNAs by generation of a fold change profile 
The normalised reads recorded for most of the 423 known animal miRNAs detected in at 
least two samples were found to either stay the same as or fall below their levels recorded 
in the HH5-7 sample (Figure 4.3). Most of the miRNAs found to increase as development 
proceeded did so by between 1 and 10 fold over their recorded reads at the earliest time 
point, and only 14 miRNAs were found to increase between 100 and 300 fold over HH5-7 
(Table 4.1). Six (miR-1, miR-10, miR-126, miR-145, miR-451, miR-499) of the 14 
miRNAs found to increase by the largest margin have known roles in heart development 
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and function, which implies that the remaining 8 miRNAs that are upregulated more than 
100 fold may also have important roles in the heart. Large increases in expression of three 
of these miRNAs (miR-126, miR-451, miR-499) were observed in the HH17-20 Heart 
sample (Figure 4.4C, E, F). Valve formation is known to start during these stages and the 
positive effects of miR-126 on VEGF are essential to this process
110
. Interestingly, miR-
499 was found to inhibit a reporter construct containing the 3’ UTR of ETS1, a known 
transcriptional activator of miR-126
74
 (Figure 4.13A), discussed further in 7.3.3. 
7.3.2 Establishment of a heart miRNA expression profile, generated by subtracting 
miRNA fold change values in matched NT samples from Heart samples 
The subtraction of fold change values of known animal miRNAs detected in NT samples at 
the HH14-16, HH17-20 and HH21-23 time points from their values in matched Heart 
samples resulted in the generation of a fold change profile specific to the developing 
embryonic heart (Table 4.2). Fourteen miRNAs were found to be more than 100 fold 
increased in heart over their matched NT values, including 10 miRNAs known to have 
roles in the development or functioning of the heart (Table Apx A.6). Analysis of miRNAs 
with significantly correlated patterns of H – NT values over these three time points 
revealed possible networks of miRNAs that behave in a similar manner to known heart 
miRNAs (Table 4.3). 
7.3.3 Validation of miRNA targets 
Several targets of miR-130, miR-138 and miR-499 were validated in this study following 
analysis of their effects on reporter constructs containing the 3’ UTRs of several genes in 
vitro. 
 
In this study miR-499 was found to target a reporter construct containing the 3’ UTR of 
ETS1 (Figure 4.13A) and the fold change patterns of miR-126, miR-499 and miR-221 
were found to correlate closely (Figure 4.7A, Figure 4.9C). Recently, miR-221 was 
shown to modulate the pro-apoptotic effect miR-126 has on VSMCs by inhibiting the 
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transcriptional activator of miR-126, ETS1
155
. miR-499 may be functioning to attenuate 
the effects of miR-126 in a similar way to miR-221, as described in Figure 4.16. 
 
miR-138 was found to inhibit the translation of a reporter construct containing the 3’ UTR 
of ZEB2, which is known to inhibit two miRNAs (miR-216, miR-217) that target PTEN
160
. 
PTEN is an essential inhibitor of the PI3K-AKT cascade, and is known to have negative 
effects on growth and angiogenesis
160
. ZEB2 is also known to be targeted by miR-192
160
, 
which was found to have a significantly correlated fold change pattern to that of miR-138. 
PTEN is a predicted and confirmed target not only of most of 11 heart miRNAs evaluated 
(Table 4.6, Table 4.8A), but also of many of the miRNAs significantly correlated to each 
of these miRNAs by fold change pattern (Table 4.8B). This suggests that miR-138 might, 
along with miR-192, allow the inhibition of PTEN by targeting ZEB2 (Figure 4.17). 
 
Several predicted target genes with many and varied roles during development were 
validated as targets of three miRNAs, miR-130, miR-138 and miR-499, in vitro. This 
provides a starting point for further investigations into the essential functions of miRNAs 
during development. 
7.4 Novel miRNAs 
Three of thirteen predicted novel miRNAs were identified as a result of this screen, 
although one of these has since been annotated in miRBase as miR-1462-3p. The predicted 
target genes of miR-1462 were significantly associated with neurogenesis, generation of 
neurons and with nervous system development, as well as with the known targets of miR-
135. miR-135 is known to inhibit osteogenesis in C2C12 cells
179
. The dysregulation of 
miR-1462 and miR-135 during the development of skeletal muscle may indicate an 
essential role for these miRNAs. Although the predicted target genes of Putative 12 did not 
have a significant association with any specific cellular processes, its expression is high 
during the early stages of development and further investigation of its expression in the 
developing chick may narrow down its potential roles during chick cardiogenesis, if any. 
The predicted target genes of Putative 14 were found to be significantly similar to the 
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known targets of three miRNAs that negatively affect growth and proliferation: miR-198, 
miR-593, and mir-129
181,182,185
. 
7.5 miR-1 affects growth during early chick heart development 
miR-1 was found to translationally inhibit the canonical Wnt receptor FZD7 as well as the 
retinoid acid receptor RARβ in vivo (Figure 6.5). Inhibition of miR-1 at HH14 by 
microinjection with a cholesterol conjugated antagomiR directly into the heart resulted in a 
significant number of embryos being developmentally delayed (Figure 6.6I). The 
developmental delay was not seen in control injections with antagomiR-206 or scrambled 
206 (Figure 6.6I, J, K). The hearts of AM1 injected embryos were found to be at a 
developmental stage consistent with their overall development, suggesting that miR-1 
inhibition may have resulted in the loss of growth-stimulating epicardium due to a lack of 
epicardial EMT at this stage of development. This effect may have been due to increased 
levels of the canonical Wnt receptor FZD7, normally repressed by miR-1, competing with 
non-canonical Wnt receptors for ligand. Further examination of the observed effects of 
miR-1 inhibition could be made by evaluating epicardial EMT in treated and control 
treated embryos, and by overexpressing FZD7 in the HH14 heart. 
 
However, miR-1 was also shown to repress RARβ in the developing chick heart and 
outflow tract septation is known to depend upon RA signalling in migrating cardiac neural 
crest cells
34
. Genetic knockouts of RARα and RARβ suggest that this RA signalling 
proceeds mainly through RARα. Repression of RARβ levels in these cells may reduce the 
competition for RA ligand, allowing miR-1 to aid outflow tract septation by its repression 
of RARβ. 
 
Although novel miRNAs and several previously unknown interactions of known miRNAs 
and mRNAs were elucidated in this study, much work can still be done to further examine 
the many and varied roles of these miRNAs during cardiogenesis. Furthermore, some of 
the roles of the extremely interesting miR-1 are well known, but many of its functions are 
likely still unexplored and merit further investigation. This profiling study may serve as a 
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guide for future studies of miRNAs involved in heart development and function, and 
several suggestions for future work have been made.  
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Appendix A  
Table Apx A.1: Animal miRNAs sequenced from chicken tissue but not yet formally annotated as 
chicken miRNAs in miRBase. 
miRNA miRNA miRNA miRNA 
miR-7 miR-210 miR-2478 miR-3618 
miR-72 miR-338 miR-2976 miR-3620 
miR-96 miR-363 miR-2984 miR-4454 
miR-141 miR-716 miR-2985 miR-5100 
miR-143 miR-1277 miR-3074 miR-6240 
miR-145 miR-1386 miR-3120 miR-7565 
miR-182 miR-1388 miR-3591 miR-7641 
miR-192 miR-2424 miR-3604  
 
Table Apx A.2: miRNAs detected in a single sample only. 
miRNA Sample Raw 
reads 
miRNA Sample Raw 
reads 
miRNA Sample Raw 
reads 
miR-6545 8-10 3 miR-7476 14-16 NT 1 miR-1579 17-20 NT 1 
miR-6603 8-10 3 miR-1603 17-20 H 2 miR-1601 17-20 NT 1 
miR-6576 8-10 1 miR-1688 17-20 H 2 miR-6647 17-20 NT 1 
miR-1567 11-13 1 miR-3620 17-20 H 2 miR-6712 17-20 NT 1 
miR-6581 11-13 1 miR-1277 17-20 H 1 miR-6594 21-23 H 2 
miR-1554 14-16 H 1 miR-1605 17-20 H 1 miR-7473 21-23 H 2 
miR-1634 14-16 H 1 miR-1642 17-20 H 1 miR-1735 21-23 H 1 
miR-1713 14-16 H 1 miR-1648 17-20 H 1 miR-1759 21-23 H 1 
miR-1741 14-16 H 1 miR-1742 17-20 H 1 miR-6640 21-23 H 1 
miR-7456 14-16 H 1 miR-1760 17-20 H 1 miR-1754 21-23 NT 3 
miR-1683 14-16 NT 5 miR-1813 17-20 H 1 miR-1691 21-23 NT 2 
miR-1768 14-16 NT 3 miR-3591 17-20 H 1 miR-3074 21-23 NT 2 
miR-6629 14-16 NT 3 miR-6567 17-20 H 1 miR-6708 21-23 NT 2 
miR-1574 14-16 NT 1 miR-6571 17-20 H 1 miR-7565 21-23 NT 2 
miR-1588 14-16 NT 1 miR-6650 17-20 H 1 miR-1582 21-23 NT 1 
miR-1675 14-16 NT 1 miR-6706 17-20 H 1 miR-1631 21-23 NT 1 
miR-1718 14-16 NT 1 miR-6695 17-20 NT 4 miR-1637 21-23 NT 1 
miR-3618 14-16 NT 1 miR-6600 17-20 NT 3 miR-1656 21-23 NT 1 
miR-6672 14-16 NT 1 miR-1592 17-20 NT 2 miR-1762 21-23 NT 1 
miR-6681 14-16 NT 1 miR-2984 17-20 NT 2 miR-2976 21-23 NT 1 
miR-6685 14-16 NT 1 miR-1564 17-20 NT 1 miR-2985 21-23 NT 1 
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Figure Apx A.1: Correlation of samples by known animal miRNA normalised reads. A custom R script 
was used to generate a correlation heatmap with manually defined colour breaks. A five colour transition was 
used, ranging from white to black through yellow, orange and red. White: 0 to 0.001 reads per million. Yellow: 
0.001 to 5 reads per million. Orange: 5 to 50 reads per million. Red: 50 to 1,000 reads per million. Black: 1,000 
to 600,000 reads per million. 
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Table Apx A.3: Overlapping predicted targets of miR-26, miR-30, miR-92 and miR-10 that are known to 
be expressed in the human heart.This table contains the first 46 of 92 overlapping genes. Table A4 
contains genes 47 to 92. 
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Table Apx A.4: Overlapping predicted targets of miR-26, miR-30, miR-92 and miR-10 that are known to 
be expressed in the human heart. This table contains genes 47 – 92; see Table A3 for the first 46 
overlapping genes. 
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Table Apx A.5: Diseases significantly associated with predicted overlapping target genes of miR-26, 
miR-30, and miR-92 that are also known to be expressed in the heart. The number of genes found 
associated with each disease is shown in brackets after the disease name. 
Disease (no. genes) P value Disease (no. genes) P value 
Autistic disorder (4) <0.0001 Chronic obstructive airway disease 
(2) 
0.014 
Subarachnoid haemorrhage 
(2) 
0.0003 Heart failure (2) 0.017 
Huntington disease (2) 0.001 Dermatitis (2) 0.030 
Atherosclerosis (4) 0.001 Leukemia (3) 0.034 
Pancreas cancer (3) 0.001 Stomach cancer (2) 0.040 
Drug abuse (3) 0.002 Neoplasm metastasis (2) 0.045 
Retinal disease (2) 0.005 Diabetes mellitus (3) 0.048 
Amyotrophic lateral sclerosis 
(2) 
0.006   
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Figure Apx A.2: Correlation of samples by known animal miRNA fold change over HH5-7. Only miRNAs 
detected in more than one sample were considered. A custom R script was used to construct a correlation 
heatmap with manually defined colour breaks. Correlations were done both by miRNA and by sample. A five 
colour transition was employed, ranging from white to black through green and red. The colour break ranges 
were defined by size of fold change as shown. White: 0, light green: 0.0077 to 1, dark green: 1 to 10, red: 10 
to 100, black: 100 to 300. 
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Table Apx A.6: miRNAs found to have fold change levels greater than 10 fold higher after subtracting 
miRNA reads detected in NT samples from that detected in Heart samples. When fold change levels 
(determined by comparison with the HH5-7 sample) in NT samples from the HH14-16, HH17-20 and HH21-23 
time points were subtracted from the values in the corresponding Heart samples, 38 miRNAs with levels more 
than 10 fold higher in Heart samples were identified. Some of these miRNAs, indicated in yellow, are known to 
have roles in heart development and function. miRNAs that are conserved in humans are indicated in bold and 
underlined. 
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Table Apx A.7: miRNAs found to have significantly similar patterns of expression by fold change 
across the HH14-16, HH17-20 and HH21-23 time points, after subtracting miRNA reads detected in NT 
samples from that detected in H samples. 0.05 ≥P > 0.01 : *; 0.01 ≥ P > 0.001 : **; 0.001 ≥ P > 0.0001 : 
***; P ≤ 0.0001 : ****. Heart miRNAs are shown in yellow. miRNAs conserved in H. sapiens are indicated in 
bold and underlined. 
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Table Apx A.8: miRNAs found to have significantly similar patterns of expression by fold change 
across the HH14-16, HH17-20 and HH21-23 time points, after subtracting miRNA reads detected in NT 
samples from that detected in H samples. 0.05 ≥P > 0.01 : *; 0.01 ≥ P > 0.001 : **; 0.001 ≥ P > 0.0001 : 
***; P ≤ 0.0001 : ****. Heart miRNAs are shown in yellow. miRNAs conserved in H. sapiens are indicated in 
bold and underlined. 
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Table Apx A.9: miRNAs found to have significantly similar patterns of expression by fold change 
across the HH14-16, HH17-20 and HH21-23 time points, after subtracting miRNA reads detected in NT 
samples from that detected in H samples. 0.05 ≥P > 0.01 : *; 0.01 ≥ P > 0.001 : **; 0.001 ≥ P > 0.0001 : 
***; P ≤ 0.0001 : ****. Heart miRNAs are shown in yellow. miRNAs conserved in H. sapiens are indicated in 
bold and underlined. 
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Table Apx A.10: Conserved miRNAs found to correlate significantly to 11 known heart miRNAs. 68 
miRNAs conserved in humans were found to correlate significantly by fold change pattern to 11 selected heart 
miRNAs. This table shows correlating miRNAs 1 to 34. 
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Table Apx A.11: Conserved miRNAs found to correlate significantly to 11 known heart miRNAs. 68 
miRNAs conserved in humans were found to correlate significantly by fold change pattern to 11 selected heart 
miRNAs. This table shows correlating miRNAs 34 to 68. 
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Appendix B  
B.1 Oligonucleotide sequences 
B.1.1 Illumina adapter sequences 
RNA 3’ adapter: 5’TGGAATTCTCGGGTGCCAAGG 
Library RNA 5’ barcoded adapter 
HH5-7 5’CAAGCAGAAGACGGCATACGAGATCGTGATGTGACTGGAGTTCCTTGGCA
CCCGAGAATTCCA 
HH8-10 5’CAAGCAGAAGACGGCATACGAGATACATCGGTGACTGGAGTTCCTTGGCA
CCCGAGAATTCCA 
HH11-13 5’CAAGCAGAAGACGGCATACGAGATGCCTAAGTGACTGGAGTTCCTTGGCA
CCCGAGAATTCCA 
HH14-16 
H 
5’CAAGCAGAAGACGGCATACGAGATTGGTCAGTGACTGGAGTTCCTTGGCA
CCCGAGAATTCCA 
HH14-16 
NT 
5’CAAGCAGAAGACGGCATACGAGATCACTGTGTGACTGGAGTTCCTTGGCA
CCCGAGAATTCCA  
HH17-20 
H 
5’CAAGCAGAAGACGGCATACGAGATATTGGCGTGACTGGAGTTCCTTGGCA
CCCGAGAATTCCA 
HH17-20 
NT 
5’CAAGCAGAAGACGGCATACGAGATGATCTGGTGACTGGAGTTCCTTGGCA
CCCGAGAATTCCA  
HH21-23 
H 
5’CAAGCAGAAGACGGCATACGAGATTCAAGTGTGACTGGAGTTCCTTGGCA
CCCGAGAATTCCA 
HH21-23 
NT 
5’CAAGCAGAAGACGGCATACGAGATCTGATCGTGACTGGAGTTCCTTGGCA
CCCGAGAATTCCA 
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B.2 AntagomiR sequences 
AntagomiR-1 
5'.Fl.mU.*mA.*mC.mA.mU.mA.mC.mU.mU.mC.mU.mU.mU.mA.mC.mA.mU.mU
.*mC.*mC.*mA.3'-Chl3' 
 
AntagomiR-206 
5'.Fl.mC.*mC.*mA.mC.mA.mC.mA.mC.mU.mU.mC.mC.mU.mU.mA.mC.mA.mU
.mU.*mC.*mC.*mA.3'-Chl3' 
 
Scrambled-206 
Fl.mC*.mA*mU.mC.mC.mA.mU.mC.mA.mC.mU.mC.mA.mC.mU.mC.mC.mA.mU.
*mC.*mA.*mU.3'-Chl 
B.3 Primers for amplifying 3’ UTR fragments of predicted target genes 
Target 
gene 
Forward primer Reverse primer 
ATG7 ATAGATCTTGAACTGTGTTGCTGCC
TTT 
ATGCTAGCTCAGAGAATCAAAGATT
GCAGAA 
ENAH A ATCAGATCTGCCGATGTGACTCTTT
AACTTG 
TCGCTAGCCAAAAATGTCCACATGC
ATAAA 
ENAH B ATAGATCTACCAATAGCGTTCAGCC
AAT 
ATGCTAGCTTTTGTGAACTGAACTT
ACACACATC 
ETS1 ATCAGATCTTGAAGAGCTTATGGGA
CTTCATC 
TCGCTAGCATCCGTTTGTTAATATT
TTTCCTAGCC 
FZD8 ATCAGATCTGGCAAGACCCTCGAGT
CC 
ATCGCTAGCCCCTCACTGGTGAGAA
CCAC 
LEF1 ATCAGATCTGCATGGTGGGAAAAGA
AATG 
ATCGCTAGCAATTCAAGTGCTGGGC
TTTT 
NFIB A ATAGATCTAAAGAAGGAAGACGGGA ATGCTAGCAAAAGCACTACCTACAT
194 
 
TGG AGGCAAAA 
NFIB B ATAGATCTGAGGGAAGATGGATGGC
TTT 
ATGCTAGCAACAAAAGACCTTGACA
GGATCA 
NR3C1 TAAGATCTCCGACTGCTTCACCCTT
TT 
TAGCTAGCAGAGCCATTCCCAAGCA
CT 
PPP3CB ATCAGATCTCCACGTCAACTTCTGG
TTTACTC 
TCGCTAGCCAGCCTCAGAAATTTTA
AGACCA 
PRKACB ATAGATCTAGGAGTAAGAGGACAAG
ATGACA 
ATGCTAGCCCAGAATAAAACTTGGC
AATAACC 
QKI ATAGATCTCAGGTGGCTTATCTCCT
ATGG 
ATGCTAGCCAAAACCCAAAACCACA
AACA 
ROCK2 ATCAGATCTTTAAGGGCTAACCGCT
TTCC 
TCGCTAGCTTTTCATAGCACTTAAT
GAGGGTTAAT 
TCF12 ATCAGATCTGGTGACCTTTCTTCAC
AAGGA 
ATCGCTAGCAAAAAGATGGCACATT
TATTGCT 
VANGL2 ATCAGATCTGTCGTGCAGGTCCCTG
AG 
ATCGCTAGCTGCAGTAAAACAACCC
CAAA 
ZEB2 ATCAGATCTCCTGCTTGAAAAACAC
TGCT 
ATCGCTAGCATGTAAGCAGGCTTGG
GTGT 
B.4 Mutagenesis primers for generation of mutant reporter constructs 
with nucleotides in the predicted target site mutated 
Primer Sequence 
ATG7 138 Mut Fwd CCTTAAAAGCAAGGATACCATGGGCTCCTATATTCCCATCATA
AAAGAAGACTCACTGAA 
ATG7 138 Mut Rev TTCAGTGAGTCTTCTTTTATGATGGGAATATAGGAGCCCATGG
TATCCTTGCTTTTAAGG 
ATG7 499 Mut Fwd GAAGTTAAGAGAATGTTCTACTATGTAGATCTAATTGCTTTGA
GGATGAATCATTGATTC 
ATG7 499 Mut Rev GAATCAATGATTCATCCTCAAAGCAATTAGATCTACATAGTAG
195 
 
AACATTCTCTTAACTTC 
ETS1 499 Mut Fwd GCTTCTTTGGGTGAGATTCTGAGATCTAAGAAAGCCAGAAAAA
TGTAGCTCACTTTA 
ETS1 499 Mut Rev TAAAGTGAGCTACATTTTTCTGGCTTTCTTAGATCTCAGAATC
TCACCCAAAGAAGC 
FZD8 499 Mut Fwd TGCCTTATAACAGACTGAATCAAAACAAAGCTTAATTATACAC
CCCAGATAAATACGGGT 
FZD8 499 Mut Rev ACCCGTATTTATCTGGGGTGTATAATTAAGCTTTGTTTTGATT
CAGTCTGTTATAAGGCA 
LEF1 130 Mut Fwd GCTTTTGTCTTCACTCCACCTCTGCCTAGATCTCTTAAGCCCT
CGTCTCATCTGTGTCCA 
LEF1 130 Mut Rev TGGACACAGATGAGACGAGGGCTTAAGAGATCTAGGCAGAGGT
GGAGTGAAGACAAAAGC 
NFIB B 130 Mut Rev AGGAGGCCAGAGACTGGATTTGGATCCTCAATGTTATCTTAAT
CTTTTGACTGCTGAGC 
NFIB B 130 Mut Fwd GCTCAGCAGTCAAAAGATTAAGATAACATTGAGGATCCAAATC
CAGTCTCTGGCCTCCT 
NFIB B 138 Mut Rev CCTTGACAGGATCATATAAACTATATTGGATGTAGATCTTGGG
ACCTTACTGCCAGCA 
NFIB B 138 Mut Fwd TGCTGGCAGTAAGGTCCCAAGATCTACATCCAATATAGTTTAT
ATGATCCTGTCAAGG 
NR3C1 138 Mut Rev ACCTACGCTCTGTATTTACATAAAGCTTGTACCTGTATGCATA
TTATTGCCCA 
NR3C1 138 Mut Fwd TGGGCAATAATATGCATACAGGTACAAGCTTTATGTAAATACA
GAGCGTAGGT 
PPP3CB 499 Mut Fwd CATGAAATGTCTTTAAAACAATAGATTAGAATAAGCTTAAAAT
TTCTGAGGCTGGCTAG 
PPP3CB 499 Mut Rev CTAGCCAGCCTCAGAAATTTTAAGCTTATTCTAATCTATTGTT
TTAAAGACATTTCATG 
PRKACB 130 Mut Rev GTCTCAGCTCCACCTCATCTGTTAACAGCTAGCAAAGATCCCA
ATGTGAGCCCT 
PRKACB 130 Mut AGGGCTCACATTGGGATCTTTGCTAGCTGTTAACAGATGAGGT
196 
 
Fwd GGAGCTGAGAC 
ROCK2 130 Mut Fwd TGCTTTGTGGCAGAAAAAATAGAGATCTATTTTTACACCTAGT
AGGTATATCAATGTCAA 
ROCK2 130 Mut Rev TTGACATTGATATACCTACTAGGTGTAAAAATAGATCTCTATT
TTTTCTGCCACAAAGCA 
TCF12 138 Mut Fwd GCTGATAAACCTTTCCAACCAGATCTAAGAAGTTCAAAAACTT
TCTGTCAATGTAACA 
TCF12 138 Mut Rev TGTTACATTGACAGAAAGTTTTTGAACTTCTTAGATCTGGTTG
GAAAGGTTTATCAGC 
ZEB2 130 Mut Rev TTTTAAGTTTGTAGTGATATATAAGTCGGATCCAATTCGTACA
ATTTACTAGTTTGTG 
ZEB2 130 Mut Fwd CACAAACTAGTAAATTGTACGAATTGGATCCGACTTATATATC
ACTACAAACTTAAAA 
Amp GA 1 Fwd CAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGA
AGCT 
Amp GA 1 Rev GGAGCTGAATGAAGCCATACCAAACGACGAGCGTGA 
 
B.5 Northern blot oligos 
Anti miR-130 
TGCCCTTTTTTTGCCTG 
 
Anti U6 
GCTAATCTTCTCTGTATCGTTCC 
 
Anti Putative 1 
5'-CCACGGCCCGGGCAGCGCTCGG 
 
Anti Putative 2 
5'-AGTATTGGCCATTGTCCTCTAA 
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Anti Putative 3 
5'-AGGAGGAGCTCCTGCATTCAA 
 
Anti Putative 4 
5'-GGAGAGTCCCTCAGCAGCCAAG 
 
Anti Putative 5 
5'-ACAGAGCCCAGCCTCTCTGATGA 
 
Anti Putative 6 
5'-GCTCGAGTCACTGTACCAGAAA 
 
Anti Putative 7 
5'-TCTACCACTGAGCTACATCCCC 
 
Anti Putative 8 
5'-CTGTGCAGGGAGCGCAGCGCA 
 
Anti Putative 9 
5'-AGTCAGTTTATGCAGGCACAA 
 
Anti Putative 10 
5'-TCTGGGGCTCACAAGGACAGATA 
 
Anti Putative 11 
5'-TGCTCTCTGCAGCACCCTGAA 
 
Anti Putative 12 
5'-GCCCAGGACGGACGCGCGCCAG 
 
Anti Putative 13 
5'-AGCTGTTTCCGTGCACTTCTGCAT 
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Anti Putative 14 
5'-GAGTGCCCCACTGCAGCCCCG 
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Appendix C  
C.1 Cloned 3’ UTR sequences 
The portion of 3’ UTR of each target gene that was amplified is shown, with the primers 
used to amplify the 3’ UTR shown underlined. In each case the position of the predicted 
miRNA target site is indicated. 
C.1.1 ATG7 3’ Region with miR-499 (green) and miR-138 (pink) target site 
TGAACTGTGTTGCTGCCTTTTATCTGTTATTCGACAAGTTAATGATTGCTTACCCATTCTG
ACTGCCATGAATATGAACAATTTAAATCACATACTGGCATGAATATCTTCACTGTAAAAGC
AGTCATTTCTGGATATAACTCTTCGTATTTTCATTTTCATTATGTAAATAACCAAAGTAAT
GTGGTTATGTTTAAATCTTATTCCCTTTTTTTTTCCCTCCATTTTCTTAATGAGACATACA
TAAAATTTGCTGCTTTAGTGAACTTTGGTATTTCATTTGTTCCATTTTTTATTTTGCTTGT
AAGCAGACATGTCTAAGCAGCATCTCTAAATGCTTTTTCTTCATCTTTCCAACACTTGTGT
ACCTTTACTTAGAGTTCATTATTAAGTTGAGAATATTCTTCTGTTGGGAAATAAACTGCAT
TCTTATTTACAGGAGAGCAGGAGTAGGTTAAAAACCTACACTTGCAGTGTATATCATGTTG
CTTTCTATTTCAAAGTAAATATTTATAGTACAATTGATTCCCTTTTCTTTATTATGGTATG
ATTGTTCTTACCTGTGTCAACGGAGAAATTATTCTCTGTAAAGATTTCATAATTTCATTCT
ATGGAAGAAATGTGGTTTGACTTATATTTACACAGGAAAGACCAAAATGGATCTGTATCAT
ACTCTCTGCTGAAGTTAAGAGAATGTTCTACTATGTAGTTAAAATTGCTTTGAGGATGAAT
CATTGATTCACTAAAAAGTTGTAGTTAAATGTATTACCAAAATAAGAAATTGATTTTCTAA
CTGTGCCATTCTTGGTTGCTGTTGTGTATTTCTTTACAGGTGTTAAACACCGATTCTGATT
TTCATTTTGGCTGGTGTTTAAGTATTTCAATTTCTGCAGCATCAGGAATGGCTTCAGATAT
TATGGCTGATACTGTGAGAATCTTTGGGTTCTCAAGGATTTGTAAAAATGGATTTGTAAAA
TATCAAAGTAACTTACTACAAAACTGAAAGCAAATCTATTGTTTTTTGTCTTGCAATAGGT
TTTAGAAGTATAATTGAAATTCATTTTAAGGCTTTATATTGTGGAGATTATGGACTAACTT
GCTCAGAAAAGAAGGCAGAATTGCTTTATTTGGCAACCAGTCTTTATTTCTATTATACATT
ATGAAAATTAGTTGACCAACTAGTCAATCCAATTAATTTAGTTTGGTTTACTTCCTTTAAC
ATAAGCTCTGAATATCTGGTGCAGATAATTTCACAGCTTCTCTCTTAGACCACATCAGAGG
ATGTTCTGTCGGGTCAAATTCACCTTAAAAGCAAGGATACCTGCAGCTCCTATATTCCCAT
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CATAAAAGAAGACTCACTGAAACATGTTGAGGTTAGCATTAGTTGTTATGTCTATTTCTTT
TTGTGATCACTAAAGTAGATTTAAGTTTTAAAGTCCTGTTTAGCTAACTTCATTGTAATAT
ATATATCTGAATTAAATATATTTTTTGATAGGAAACTGATCTTTTGGTGGTCAGGTAATGA
TCAATAAGATTGATAACATGTGATATACATTTTTAAGTAGTTTATTAACATACAGCATTAC
CTATGAGCTGTGTGATTTGCATGCTGTAGTTCTTCTGGAATCGCGTATCGGTAGTGGGTAG
TTTAAAGGGAAAGACTCGCATTTTTATCTTTTGGAATTGCTGAGTGTAAAAGTCTTCTGCA
ATCTTTGATTCTCTGA 
C.1.2 ENAH A 3’ Region with miR-499 target site 
GCCGATGTGACTCTTTAACTTGGTATAAAACTGACTACGTTTGTGAGCTGTTAGAAGAAAA
TGGAAACAGACACTTGGAAGGAGGGAGAAACATCATATTCTGAAAAGCTTCAGACGCATCA
CTCTGGTGATATGCTATTTTCCCTCCTGGTTTGCAGCTTTTTTCTGACCTTTACAGCAGGG
TGGAAAAGAGTCTTAAGGTTACTGTAATGATTGTGCAGAAATTCCTACACCTTTCAGACAA
GATCACAGTGCTTTGAAGTATACTCATGTCAAAATAAAATTGCACATGTTTCAGAATTTGT
TGTTTAAAAAAAAAAACAAACAGGGAAAAGCTTGGGAAGGCTTTTCAGAGAGGTTTTCTTT
ATTAATGAAGGATTTAGCAAGTTATACTGTTGTACTTCAAATGTAACTCAGGTTTGTCTTC
CTATCATATCTGATGTTTCCATGAATAATTTAAAAGATCAGATGTGTGTAAGTTCAGTTCA
CAAAATATGAAACAATTAGAAATATGTACTTTTAAAGGGCAATATTTGTAAGTGAATGACC
TAGACAGTGTTCACATGTCAAGATTTTGGGATTTTATGATAGGAAGCCTCTCTAGTTAGCC
TTCATGCAATTTTATAGGAAAAAAAAGAAAAGCAATTGCAGTCCAGAGTTTAAAGATGTAG
ATGCCTTCCTACATTGTTACAATGCTTTACCAAATCTAAGACTTCTACATAATGCGAATCA
GCAGTCAAATGTAAATCATTAGTATGTTGTAGATTTACGGTAGATTTTTGGGCTTTTTTTA
GATTTATGCATGTGGACATTTTTG 
C.1.3 ENAH B 3’ Region with two miR-499 target sites 
ACCAATAGCGTTCAGCCAATGGCTGTTTCCACCTTCTACACTTCTCATGCTCAGTCTTGAA
CAGAAGATTCAGATAAAAGAACGTTCACAATGTTTAGTTTTCAACAGAAGATACTGAGTGG
TCTTCTGTAGTCATGGGAAATTATTTAGAAAGAGTATTTCATGCATCCATGAATCAAGAAG
TAAATGAAACTACATGTAAGCTGTTACGGGTGTTTTTTTAACACCTTAGTGTAGATTTCTT
TTTACTTGTGGAATATACCAAAGCTGAGTATGAAAAAGGTCTTTTGCTGTGCTGATAAAAT
201 
 
AGCAAATATCCGTCAGCTGATGTGGTAGAACGAGTTGACTGGTGTGGGGCAATAGTGCAGT
GTCATCCCATATACTTCAGACACTAACTGTTTAATAAAAGTTTTTTTTCTCTATTAATATA
TTCACTACGCTGCTTACTCCAGCCGAATGGACAATATGATGCAAATAATGTGCAGCCCAGA
GGCTCTCCTTAAACTAAAACCGAGTGAGCCCACACACATGCCACTTGATATCTCCAGCAAG
TCCACCATTGAGATACGGGATGGAAAAATAAAACATTAATGAAGACTACAGAGGGGAGAAG
GGCACTGCCTAGCTCAGAATTACACACGTCTTTAACCTAGTGAAGCTACGTTATGTGTGAT
TATTCACTTTCTGTGACTGTTTTAGAAGGCTGAGCTTTCTTTTGGGGGCTAGTTATGTATG
CTGGCTTTCTTCCTTGTTTTAAAATGTATGATTTGTTTATTTCTCTTTCTCTGTAGCTATC
AGGCAGGAACTGAGCAAGTCGAATACTGCATAGAAAGACTAGTACTAAGCCGATGTGACTC
TTTAACTTGGTATAAAACTGACTACGTTTGTGAGCTGTTAGAAGAAAATGGAAACAGACAC
TTGGAAGGAGGGAGAAACATCATATTCTGAAAAGCTTCAGACGCATCACTCTGGTGATATG
CTATTTTCCCTCCTGGTTTGCAGCTTTTTTCTGACCTTTACAGCAGGGTGGAAAAGAGTCT
TAAGGTTACTGTAATGATTGTGCAGAAATTCCTACACCTTTCAGACAAGATCACAGTGCTT
TGAAGTATACTCATGTCAAAATAAAATTGCACATGTTTCAGAATTTGTTGTTTAAAAAAAA
AAACAAACAGGGAAAAGCTTGGGAAGGCTTTTCAGAGAGGTTTTCTTTATTAATGAAGGAT
TTAGCAAGTTATACTGTTGTACTTCAAATGTAACTCAGGTTTGTCTTCCTATCATATCTGA
TGTTTCCATGAATAAT]TTAAAAGATCAGATGTGTGTAAGTTCAGTTCACAAAA 
 
C.1.4 ETS1 3’ Region with miR-499 target site 
TGAAGAGCTTATGGGACTTCATCTTTTTTTTTTTTTTTTTTTTTGCTTTTTTTTTCGTTAT
TTTTTTGTTAGAGAGCAACTCAGATTTGATGCTTTGAGGATGTTGGGAGAGAGGGTGGAGG
GCGAGTCAAACTTCTGGTTGGAATAACCTCCAGAGTTTGGTTCAGAGAAGGATGAGCCTTT
GTTTGCTGAGAGCTCCAGGACAGGCTTCTTTGGGTGAGATTCTGAGTTTTAAGAAAGCCAG
AAAAATGTAGCTCACTTTAAAAAGAAAAAAGAAAAAAAAAAGAAAAAAGCAAACAGGAAAA
CCTCCCCGTCCCTCGCTGGCTAGGAAAAATATTAACAAACGGAT 
 
 
202 
 
C.1.5 FZD8 3’ Region with miR-499 target site 
GGCAAGACCCTCGAGTCCTGGAGGGCCCTCTGCACCCGCTGCTGCTGGGCCAGCAAAGGTG
CTGCCGTGGCCGGGGGTGCTGGAGCAGGAGCGGGCGGGCAGACCGCTATCGCTGCTGCTGG
AGGACTTGGGGCTGGTGGAGGCGGCTCCCTGTACAGCGATGTCAGCACCGGCCTGACGTGG
AGGTCTGGCACTGCCAGCTCCGTCTCCTACCCCAAGCAGATGCCTCTGTCTCAAGTGTGAG
GAGGGGGAAAAGAGGCCATAGGTTAGGGAATGAGGGACACTGGCCTGCCTGAAATGCCCCC
TCACTGTTTGGTGCCATTAATGAACCACTAATGGTCCTTATTAGCCACAGCTTGTATAGAA
CAATGCAGCTGGCAGAGGCCCCAGGCTCCAGCCCCCTCCTCCTTCCCCTCCATTCATATGC
AGGGAGCATGTACTTCAAGGAGCCAGCATATTATTTTGCTGGCGGAGGAAGGCAGGGGCTC
ACCCGTGTCTTGCAGAGGGCAAGGCAGAGCGGCTCCTGATTTACTTTGGACTAACGGCAGC
TCGTGGGAGGGAGGGTCTTCCTCCCCCATCCCAAAGCGGGAGTCTGCTGGAACTACAGGTT
TTTGGGATATAGATGACCAGGCAAATGCCTTATAACAGACTGAATCAAAACATGTCTTAAT
TATACACCCCAGATAAATACGGGTTTCCTACATTAAAGGATGTATTTATATAATTATTTGT
TACCTTGTACAGATGTGTAAAATATGTATATATCCAAAGCTATACAGTCTGTAAATTTTTT
TGTAAAAAAGTTTAGAGGCTACCCCTGTAAGAGCAAATATGAGTATTCTATTTTGTCAATA
AAATGACTTTTGATAAATGACTTCTTCAAGCTTTTCCCCTACTCCTGCCCTGGTTACTGCA
GCAGCTGTGTCCCTGGGTGGTTCTCACCAGTGAGGG 
 
C.1.6 LEF1 3’ Region with miR-130 target site 
GCATGGTGGGAAAAGAAATGCTTTCTCAACTTGCAAAGCAAAGGCGGCGACACCAGGACCC
CTGCTGGAGATGGAAGCTTGTTAAACCCTAGGTGTGTCCTTCATCCACACAGACCACCCCC
AAGGAGTCTGTCTAGGATGTCATTCACCCTGATGTCACTGCTAAAGACACTGAATCATAAA
GACAATCACTGCCAAAATCCTTCACTATCACGAGGTCCAGCCCTGATATAAATAGAGCGAA
TAAGCTCCTGGGTCAGCAGAGCAGCTTTTGTCTTCACTCCACCTCTGCCTTGCACTCTTAA
GCCCTCGTCTCATCTGTGTCCATGTTGAGTCAGCAAACAAAGTAGCGTGGCTGTCTCTGCC
TGCTTCAGCCAACAGAGTAACTTAGAGCACCGCTGCCCATACAGCACATCGAGGAATGGAA
TTTGCCTGGACCAGGATGACACACTCAAAACTTCTTTTTATTTAATGGTGCGACAGGATCA
ATTTTGGTTTTAGCTTTTTTAAGAAACTTGAATGCTTTTGTATTTTAACTTTTAGTTTGTA
ATTTCCTTGGTGTATATTTTACTAGGTATGAGCTTTTAAACAACTGTCAAAAATCTGAACT
203 
 
ACTTTTTAAATAATGGGGTTTATTTTCCTTTTTTTTTTTTTTTTTTTCTCTCCTGCCAGAG
GAAAAGCCTGTATGGAAAAAGGTGGCTTTTTTTGTTAAACTACTTGTAACAAATAGTGGCC
TCTCAGTCTATATAATACAGTGTCATATAGAACTAAATAAATGTAACAACAGTCAGCTGGT
CAGTAGCCATGTCAGTCTTGCATCACCTCCTCTGTAAACATAAGCAATACATCCAGCAAAT
CTGACTGCAGTGAGTTCTCCTTCTTACCCATCGCCCTTCTCCTTGTAAAAAGCCCAGCACT
TGAATT 
 
C.1.7 NFIB A 3’ Region with two miR-138 target sites 
AAAGAAGGAAGACGGGATGGGAGAAGAAACTGAAGAACGAAGAATAAATAGACCAGCAATT
GCAGCACTTACAATCACTAATTCCCTTATGGTCGAAACTGAAATGACATACAAAGGGTCGA
TGATATTTCACTGATGGGTAGAACGCAGCTCCTGCTAAGTAGCCTTTGTTATATGAAGTCC
GCTGGGAAATAGATGTTCTGTCTCTGACAATATATTTTAACTGACTTTCTAGATGCCTTAA
TATTTGCATGATAAGCTAGTTTTATTGGTTTAGTATTCTTGTTGTTTACGCATGGGATCAC
TATTCCTGGTTATCTCACAAAACAAAGGCTAGGCAGCAGCAGCAGATTTGCAGGAGGACAA
GGGCTGTAAGCCAGCCGTTTTCTCAACACTCTGATTTCTAAATGTTTAAAAAAGAAAAAAG
AAAAAAAAAAGCTCTGTAGCCTTTAGTTATCAGTATGGATTTATTAAACTTTGGCCCTTGA
CTCAGCCTTTTCTAGTGTGTTACCCAGCTTGAAATTTTCAATCAGAATGAACACACACGCT
CTATGTAAGAGATGCCTCTATGTAGGTGAAAGTGTTATCTTTTCATGCAACAGTAAAAAAA
AAAAAGAAAAAAAAGAAAAAAAAACCATACAAACTACAAACTTTTTACCCACTAAAGAAAC
ACTTAGAGAGGCAAGTGCAATTTAAAAGTTGTATCAAAGGGGTCATCATTATAAGTCCTTC
AGCCCTTGGACTCTAAATTGAGGGGATTAAAAAAAGGAATTAAAATTTACTTTGAACAAAT
TTATTTTTCCCCTCAGTTTTTGAGGGCATTAAAAGGCATTACATCAAGACAAATCATGTCC
TTGAGAAAAATAAATCAATGAAAACACAGCACTTATGTTGGTTTAGCTGCTGCCTCCACAA
AGGGGTAGAATTTATTTATTTAAAGTTACTGGTTGCATCAAGAACCCATAGGGTTTATATT
TTTCTGTATAATCTGCATCATAGAGACAAAGAGATAGGCAAATCCATGCCAAAAGGGCAAA
GCTTACTGTTTACAAACTGGTAATACCAGGATGGGGATAAGATTTATTTAAATAATGCACT
CTCTAAGTCTAATTACAGGGTGCTGAAAACTTGCATGGTGCTTTCAGAAGTTAGCCTTGTT
CAACAGATTTCACATATTGACAGAAATATAATGTGCATGGGCAGACATTTTGCCTCTGTGT
CTCTTAAAAAGTAATTAATTAAAATACTCTTTCCAGTAATCCCGATTTGCACGAAAATATA
ATGTCCACATTACGTGCCTTGCCTTGAAATCTAAAAAATGAAAAAAAAAAACAACAAAAAA
204 
 
ATACAAAAAATCCACAAAAACAAACAAAAAAAAAATTGACATCACTACACTTGTTTTGCTG
CATTTATTATCATTTAAATCTTTACCATTTTTATGACAAAATATTTTGTACTCCAGATGGG
AAAAAAAGTGTGACATCATGGATTTTTTAGACAGTTATATCTTTATCTCACATTTATAAAG
CATATCATGGCTGTGTATAATTGCCGCTTAAGAATTGTAATCGACCAGCAATATTTTCAGT
ATTTTGGTGTTTTTTCTATTAACCTTTCATGTTTTTCATCTTCCAATTAATATTGGGGGGG
GGAGGGGGGGAGGGGGTTCAAATTTATACGAATTATGCAATACCAAGTTTTGCCTATGTAG
GTAGTGCTTTT 
 
C.1.8 NFIB B 3’ Region with miR-130 (blue) and miR-138 (pink) target sites 
GAGGGAAGATGGATGGCTTTATGCGAGCTTTTCTGTTATCTCTGACCTCTTGTATGAAAAA
AAAAAAAAAAAAAAAAAGAAGAGCTTGCAGATGTGATATTTTTAAAAGCAGATTCCTTCCA
TGCGAATGAATTGGTTTTGTTAAGCAACTGTGGGTTTTTTCACACGTGCCTCTCTGATAGA
AAAGTCTGGTTGGAAGAAAACACACTTTTCATTTATGTTTTTGTTTGTTTGTTTTTGAAGC
TCAGCAGTCAAAAGATTAAGATAACATTGAGAACTCAAATCCAGTCTCTGGCCTCCTCCTT
CACCAGGAAGTGTATTCTGACTAAATCAAGCCACCCCGTTCTATGTGCACTGTTCTGCCTT
TATTAAGTTGCTTTGCAGCCCTGGCCTCATGGCTGTGCCACTGAAGTGTGTTCCCCCTGGA
GTGACATGAACGTTTGAGGCTTGACTATGGAAAAAAAAAAAAAAAAAAAAAAGGCAGTGAA
GGAGACTGTACATAAAGACATGGCAAAAATATTAATTATAGCAATATAGTTGTGGGGTGAT
GTTCAGGTGGGCAGCTCCATTGAAAATATGTGAATGGATTTGTGAAGCTGCAAGTAGCGAG
AAGAAAGGAGGATTTTCTGAATGAACCGCCTACCTTGTAGACAGTAATTTGTACACTGTAT
AGTTTTGTTAAGATTTTTTTTTTTTTAATTAAAATACCCTTGTTTGTAAAGCTAACTTTTT
AACAATTATAATGGAAATATATGTCATTTCCATTTTTAAAGTAAACAAGAATATTCCTTGT
TTGGAAGCTGGACTTGGGTTAAAACTCTCCAGTTTCTTAATTTATGTGTTAAAAAAAAAAA
TAAATAAAAAATTTGTCCATGTTAGCAGATATTTCACAGATTCCTGTGCTTGAAAAGCATA
GGTTACTAATCCTTTAAAAATGTAAATGGAGAAAAGTTATATTTTATGAAGGTTATTTTGT
TGTATTTAGTATTGGAAAAGTTGGTTTTCAGAGCATTTCAAAATGTTGGAAGCACCACTGT
CTTTTTATTAGTATATATGGCCTTTAGCAAAAGTTTTTGTGATTGTTACATGATGGTATTT
AAGATTAGGTTCACAGAGCAATTCAGGATAGGCAGAGAATAAAAACAGTACTTATGTCTCA
CATAGCTGTGTCCTCAGGGAGCAGAATTTTGGATTTGCAACTTGTAGCTTCATAAGGACTT
AATGAAAGAGATTGCACAAGGACATACTCAGCTGTGACACCGGGGTGTGTTCTGTACCTAA
205 
 
ATCTAAATTATATTTACTGTGTGAGGTTATGAAGGCTGCAGAAAGTTATCCCATATTCAGT
GTACAGTATTCACTTTTAATGAAACAACTCTTTAATGTTGCTGGCAGTAAGGTCCCAAGCA
TGACATCCAATATAGTTTATATGATCCTGTCAAGGTCTTTTGTT 
 
C.1.9 NR3C1 3’ Region with miR-138 target site 
CCGACTGCTTCACCCTTTTCCTCGGGAGCAGGAGAGCTCCGCTGCCGGCTTCGTGATCTTA
GAGGTGTACGTCCACCCTTGTCTTTGTACGGCTGCATCCCTTCCTATCGAGTGACTAGCGT
GCCATAAATCTGCCATAGGTCTCGTGAATTTCTCCTCGTTGCCATGGGTAGCTGTATTTTA
AAACGTTTAGAAGCTGTAGTAGCCTTTTCTACCTGCACCTTAACGATTTTCTTTATCTCGA
AATTGAAATATTTACCAAGCCACTCTAAAATTTATTTGTACTGAAAGTGGCCCGATTATTT
GTGTAATAACGATGAGAAAAATCATCTGGGAAGATACAAAACCTAATATATTTTTGTATTT
AGTTATAGTTTCCAATATGTATAATCGGTATATTCGCTGATCTGAGAAAAGAAGGGAAGGG
CTACTGCAGCTTTAAAAGCAATTTATTAATGACTGTAAAATAGCTTGTATAGTGTATAATA
AGGATGATTTTTAGATGACAGATTGCTTTATCATGATACATGTAATTATATTTTTTGTAGG
GGTCACGGATATGCTGAATGGTAACCCGTGCCAGCCGTGCTTTGTCTGGAGGTAGTGCTGA
AGGCACTGACATTCAGCATCCAAAGAAGTACTCTGTTAGAAAGAAAAACAAAAAAACAAAA
CCTGTGTTCAGTGGCTGTTTTTAAGGTTGAATTTGCATTTCTCCTATCACTGTGTCAAAGC
GCAAGTCGGACCTTGGATGGAACGCTCCCCTCCGTGCCTCCGCCTGAGCGGATGGGTTCCC
TTCGTAGACAGCCGCACGAGCCGCAGCAAAAGCAGCTGGAAACATTGGGCAATAATATGCA
TACAGGTACCAGCAATATGTAAATACAGAGCGTAGGTTGTTCACAACACACCAGTACCTTT
CTGCCATGCAGCAGAAGTTCGTTTCCGAGCGAGACAGGAAACTAAATTTTCATCCTTTCTT
AAATCTTTTTGAATGTTATACCTATTAAAGCAAAAGATACTATATTCAGTACTTTGGAGTA
AAATATCATCTTTAATAAAAAAAAATACTCGTTCTCTTCTCTTTGAATAATCTGTACAAAA
TACGTACGTTTCATGGCAGTTCAGGTGCCCTTCAGTGCTTGGGAATGGCTCT 
 
C.1.10 PPP3CB 3’ Region with miR-499 target site 
CCACGTCAACTTCTGGTTTACTCACTTATGTCTTGCCTGAGAATTCCTAGATTACTGCTTT
TTGATGTGACAACAGACGAAATAGCCAGGGGGGTCAGCGAGGTGACTGCTTATCGGGAGGT
206 
 
GGAACGCCATCTGCCTGACCCTGCTGAAGAACAGCGCCGTGCTTTGAGACAACAGCCCCTC
TCTTCACGCGGCGACCGACCTCCTGGGAGCACCCTTCGTGTATTCAGGCTGCTGCGACTGC
AGAAGAGCTGGGAGGAAGGAAGCGGGCTGTTATCACTAAAGCACCCCTAGACTAGCATCTT
ATGCCTGTTGTTGTCAACACTTGACGTTTACAAATGGGATTTTTCTTTCGGTAGAGGTAGC
TTGTTTGTTTGTTTGTTTTTTAAATCAGACTTTCAAATACGACCCTAAGAGCTAACTATTT
ATTAATGGACATCGGTTTCATGAAATGTCTTTAAAACAATAGATTAGAATGGTCTTAAAAT
TTCTGAGGCTG 
 
C.1.11 PRKACB 3’ Region with miR-130 target site 
AGGAGTAAGAGGACAAGATGACATCAGGGCTCACATTGGGATCTTTGCACTCTGTTAACAG
ATGAGGTGGAGCTGAGACCATCATATGTCAAAACAGTTACCTAGTTACTTCATTCCACAAA
GCTGACTGAGGTCTTTATTGCCATCTTCCATGTGTGCGGTTTGCACCAACCCTTCTAACTA
GGCACAATTAAGCAAGCACTGTTTGTGCAGTAACACAGAATAATAGACCACTTTCCTACTT
AACTTTGGTTTCTGTCGTTCTTTGTTTCTGTGTATTGTTCATTTTTCCCCTTTAAAATGAA
GTAGTTTTTTACCCAAGAATGCTCCATTTTATTTTGAATAATGTATTATTTGTGTGAGTGA
AATGGAAGGTGTTGCGGCTAGTGTGATTTAGACTGAAGTGAAAGGTAAATGTTGCTTCTAG
TCTGTGCCAGCCAATAATTCTTGTCTGTCTCGTGTCTGATGCTACAATTTATAATAATAAT
TTTTTAGTAGCTCAGACTAAACCTAGCCAACATTTTTAGCGTTTTTGAAGGTAGTATTTAT
CGCCATATAAATGTCTGCTAAATTAACTTAAAAATGTTTCTTCCTGGAGACTGACCAAAAT
TCAGTAGAATCAATTGGATGGCTTAAGTAGGAAGACAGTAGCTAGACCCCGTGCCTTGGTT
TTCTACATCCCTGCGATTTTCGTCACTGCCTCCTTCCTTTGTATTTCCACCTAGGCAGTAG
GTCAATTGCCATAGCCAGACTGTACCACGGAAAGCTTACAGTCTCAAGAGAGGGAGTAATT
CCACCTGGTCTGGATTTTGGACCATATTTAACCAAGTCAACTTACCGGCATTTCAGTTGGC
CATATGAAATGACTTTTAAGAACATTAACCCTAAACTCTTAAAGGAAGTTTTGGTCAGTAT
TGTAGAGAATGACTCATCTTGTTTTTGGTTTGTTTTTTTTTTTAATGTTTTTTAGCCAATA
TTTGGGCTCCCGAAGTATTCCTTGTTTCAAGCCTTTTTTGATTTATTTTTTTTTAAAGGCA
TCCTTTGAAAAAAAAGTAAATAGAAAATGATGTTAAAGCGAAAAACCACAAAAAGTAAAAT
GTGCTGTGCCATTGGCTTGTGAAAAGCAAATGGTATAGCAAATGCAAAATAATGTTCTAGA
TGCATTGCTGGATGAACACGGTTATTTTTTGTTAGCTGTTAAGAATAAGAGGTTATTGCCA
AGTTTTATTCTGG 
207 
 
 
C.1.12 QKI 3’ Region with miR-130 (blue) and miR-499 (green) target sites 
CAGGTGGCTTATCTCCTATGGAGTAAGTCATGTATACCTCTATCTGTCTGCATGAAAACCA
TGCTGAGATTTCAGGTAAACATTGTTTTACTTTCATCTAAACAACACCGGTGTTGTCTTAA
GAATTGTACATGAAATAAACTTTACAACTTTATTTCATTTTATTCTGACTCCAAAATCCTA
GATTATCCCCGGCCCGGCAGTTTCAACAGTTTTGCAAAAGGCTTTGAAAAGCATTGTTCAG
GAATGAAACAGATTCTTGAACATGTTAAAGTTATGTTGTAGAATTAAAATTCTAAGTATTT
ATCATACTCATTGAGTTGTTCAATCACTGATACACTTCCGTAGCTATGGCCATGAAAAACA
ATGTCAGCAAACCGAAATATATATATTTTTTTCAATGCAGAAATGTTTTTTACGTGGTTAA
ATGTTGCTAAAACTATGTTTGCATTCACTGGGTCTAAAGTTTTTTGTTGTTGTTTTTGTTT
TTGTTTTTTTTTTTTTTTAATTCTAAATCGATTTTCAGATGACTTGGTAGTACTACTGCAT
TCACTTTTTAAGTAGGTTTTTACTCTTTGCATAGGTTTTTTTTTAGAGATAAGCACTGCAT
TTAAAGCAAGAATCCCGGAATGTGTAAATGTTTTTTACTCTTTACAACTAAGCATTTAGAA
TTGGTGAAGGGTTGAAAAATGTAGCTCATTTTAACTAAGAATAAAACCCCAGTTTATAAAT
AATACAAAATTGAATTTGATGCATATAACAGAGAGACTGACTGATTTAATTGTAATAAACT
GTAAATGGTGTTGCACAGTTGACAAACCTGTGTGTACTGTAGAAGGCCAGAGACATGGCAG
AGGATGTATCACAGGTGTACTGGTATTTTTAAAAGGTAGCTTGCTTTGGTTATAAACTCCA
CAAGAAATAATAATGCTCAGAATATTCTTGAATGTTATATCCAAACCAACTGTCACATAAT
TTATATATAAATTTTAATACAGTTTAATCAAAATTGTAATCAGTATCAAAATGCTTTAAGA
GTCTGTGTTTCTAGTATACCTGTAAAGTGGTGAGATTGTGCCACATAAATATTTATTTTTA
GTTTTTGCTTATTTTTGAAACAGCCGTTTTAATTTAAACAAATCCCAGTTAGCATGATTCT
GAAAAATATCAGGGAGCACGTGGTCTCATTTATGCTACAGTAGTCATTTTTTTTAAGTGTT
TATGAACTGTATCCTAAATGATAGGCCATTTTTGTTATGTGAAGGTAAATCAACCCATGAG
AATGATTGCTAAGTCGATGCTATCTGTGAATATTACACCTACTGGACTTCATTTGAATGAA
ATGGCACAAATCTGACTTTGCACTGAATACCTTTCTCACTTTCATCTCCTCTGCCTTAGTC
AAAATGGCAACAGTACAAAAACTTTATCAACCTCAGAATTTATTAGCTATGATTAAGCTGT
TGAATGAGTCTTAAAAAATAAAAATTAAAAAAAAAAATCATACTACTGTTAAGTGGACCAA
GTTTGGTGAAGGAGAATGTGAGAGAATGATTAAAGAAGGAACAGCTCAAGAACATTGGGAA
TGATAACTTTCCACTTGAGAATTTTTTTTTATGTTTTACTGTAATTTGTTTGTGGTTTTGG
GTTTTG 
208 
 
C.1.13 ROCK2 3’ Region with miR-130 (blue) and miR-138 (pink) target sites 
TTAAGGGCTAACCGCTTTCCATGAACACAGACACAACTCAAGGTGATAATTTTCTTCCTGT
TACAGCAAGACTGAAACATATCCCAAAATATATTAAAAATATATATTTTCCTGAGAGATTG
TGCTATATATATCAGAGGTTTACATTTTTGCTGCAATATAAATTACTAATCTCTGAGGGTT
TTCCTGTATTCCCCCGAGTGACTGATCAAACGAGGAATGGCTGGTAAATAGTAAAAGGATA
TGTTAGGTAACCTTTTAAGTTCTGTTCCACAAAAGCTTTCTCGGCAAGACACATACACTAC
ATTTCATAAAAGGATTGAGAGGAATGAATATTTAAACTGAAGAAAGTGACTTCTCAGCTTT
CATAAAGATGCCACCAGCATGCCTGCGAGAACAGGAGGACGATCCATCATAGTGATATAGA
CTGCATCTGTAAGAAGTGACCATTATACTGTGTATATATATTGTACTGTAATACTGCAAGA
GGGTTTTAAAAATCTTTCCACTTTATTTTTTTATGCTTATTAATCAGATACCGTTACTTAT
TGCAGTTGCAACTATGCACTTGTATAAAGCCATAATGTTGAAGTTTATATCATTCATACAT
GTCTATCAAAAGCTGCATGTCAGTGTTCAGCAGCTAGTTCGAAGTATATGCTAGTTTCAGC
TGCGTCATCATGGGCAGTCCTGTTTTACCTGTCTAATTGCCTTAATTTAATTTTTTTTTTG
AGTTTTTTTTTTGCCCATTCTCTGTATTTAAGGAAAAAAGGTTTACCAGCTCTTAGGATGC
AATTTTGCTTTGTGGCAGAAAAAATAGTGCACTATTTTTACACCTAGTAGGTATATCAATG
TCAACTTACTTTGAATGTATATCGACTGGTTTTGAGGGTGGAGAAGTGTTGGTTACAAAAA
CAATGTCTGATAAGAATGGACTTACTAGACCATGTGCTTATACATGTAACTGCTCATCCAG
CCCTTCTTACAAACCTCAATATAGTTATTGACTTATATTAACCCTCATTAAGTGCTATGAA
AA 
 
C.1.14 TCF12 3’ Region with miR-138 (pink) and miR-499 (green) target sites 
GGTGACCTTTCTTCACAAGGACACAGACAACTAACATTATATGAAGACACAAACCTGACAG
GAGAAAACACTTGAAGCAAGAAACCCAAATGCAATCTTATGATCAAAGCTACTGGTCAACA
CCTGCATCAGGATTGAAGATAGAGGATCTTCAGATAGAATTTCAGCCCATGAAATACTCTG
AACATATCATTCTGTTGCAAGCAGTGTGTCGCTTCTGCACAATCAGAGACTGTTGTGATCT
CTCCACTCATTGTGGAAGTTGCCTTGTGCCTAAACTGAATTGACAAATGCATTGTAACTAC
AAATTTTATTTATTGTTATGGAACTGTAAAGGTCTACATATAAAGGGAAAAGTTAACATGT
TAAAAGCTGATACAATTTCAGCTGGATGCCAGCATTTATTAAAGCTGTTCACATTCAGAGA
ACAAAGCAGTGACAACCGTCGACCCGTAGCATTCCCAGCATACCTATTAGTGTCTTAAAAA
209 
 
AGGAAGGGAAAAGTCTTTTGTTGTCCTTTCCTCTCCTTTTGCCATATGACTAGTGTTTTCC
ACGCAATAGGAAACTATTCCTTGGTATAGCTTTTTTTATGTTATTTTTGGTCTCTGGTAAT
CTGAACAGTTATGGTCATAGTTACCCTTCCATACTGAGCTCCGTGTTTCAGGCCGGTAAGG
GGCCTCCTGAGCAGGCTCCAGGCAGGAGCAGTACTGTGACCATAACATTTCGTAGATTTAA
AAATTGATTTTTATTTTCCCTCAGACTTTCCTCAAATGTTTTTTTTTCTAATTATAAACAA
AACCTTTTTAGGCTTCTAGGCTTCATAGTAAAGCTTGTAACGTGAAGTGTAAATTGGGTGG
GGAGAATCTACTTTGTTAGAGTTGCTTTGTTTTCCGAGCAGTAAGTACTACATATAGTACA
TGTAAAGTGTTAGCTGTATGTAAGCACAAAATGCATTAAAATACAAAGGAGATTTTTTTCA
GGCTGTATTTTTGGTGAATAGTAAAATCCTAAATTCACCGTGGCAGGTAGTGTGATGACAT
AGCCACCAGTAAGGTGGGCTTACTTACCTAATGGAATATAAGAGCAATGGTCACCAGTTTT
TCCTTACTGTATCCATCAGTTATCTTGTCATTTTTGTATGGCTTGTCAGTGGAGAAAAATC
AGTGTGAATCAAATGCAAACAAATGACCCCTCCCAAGCCATATCAACATTAAACAATTAAA
TGTTTCTCCACCAGAACAGTGTCCATAAGTATTCCTTTGTCACAAATGTGTTGAGATGGTT
AAAATCCCTTTGAACTTCCATGGAAACTGTCTTCCACTGCAATGACCATGGGAGGAAACTT
CCTAAGCCAAGGTTGTCTGAGCTATTGTTTATATAGTGCATCTTTCATTACTGGTAATTGG
TTCACCGTACAAAACAGGAACAAAACAGTACTTTTTATGAAGTCATTTAATTTGAAAGAAC
AAAAGCTGGATCGTTAAAATAAACTAATGAATTTAAGCTCACGTTTGCAATGGTTCCTAAC
AGAACAGTTTGTGAAAATAGTGGACTCATTTCTGTTACTTTAATTTGCATATACCATCAGA
TAACACCTGATTATATCTGTGGCCTTGTTCTTCATTTCAGTGTTTATTGGCTAAACAAATT
TGTTGCTTATGACGTGTGAAAGTGATCACGTGCCACTGCCTGGCCTTTTTCCTTCTAAGCT
TGTTGTCTTTTTGGCTATATTAGACTTTGCAGTATGCCCAGAAGCTTTCCTTCATAAAATA
GAAAGAAAAAAACATTTGGCTTATTTTTCACTGTAGCTAGTCTTTTATACAATAATCTTGT
AAGAAAATTTCTTGAATTCTAAATATTACTCTTTCTAGATTTTTGAAATCGAAAAAGTTTT
CAGTAAAAAGTTTCTTACTTTATTTTACTATATTAGGTAGTAAAAATGTAGGGTTATTTAC
CATAACCTGTTCATTAATATCAGAAATTTACAATAGCATTGTAAGACCATAGTAGGGTTCT
AGCATACCGTGTAGTACCTATGGAGTATTGTAAGAGCTAATTGTCCGAGATGAATTGCTTC
TCATCTTGTTCTCCAGTTTCCATTGTTGGTTTATTGCAGATTTGTACCCTGTGTCAAATTT
CAAGGTATTGCTGATAAACCTTTCCAACCAGCAGCAAGAAGTTCAAAAACTTTCTGTCAAT
GTAACAGAAAACACTATGTATATAACATTTATGTAGCAATAAATGTGCCATCTTTTT 
 
210 
 
C.1.15 VANGL2 3’ Region with miR-138 (pink) and miR-499 (green) target sites 
GTCGTGCAGGTCCCTGAGCACCAAGCCCCATCCCCGGCACGAGGCCGCTCGGTGCCCGTCC
CCACGCTCCCACACCCAGCTCCTCGCAGCCATCCCCAGGAGGCACTGCCAGCACAGCACAG
TGTCACAGCCGGACGGGCAGCATCTCAGTGCCATCCCCTCAAGGGCTGACCTTCGGCTGAG
TTCTCTGCACCAGCAGCCTCGCTCGTGGCCAGGTCTGAAGCATCTCCTGCGTCTTCCTCTT
CTGCTGCGACCCGCTGCGTCTCCGGTCTTAAAGCACCACCTGTGTCTGGACTGGTTGGTAA
TAACGACACTTTGGGAGTGTTTTGCAAACCCCTGTGATCTGAGGCTGCTATGGAACCTTCC
CTCCGCCCCACGGCCGGGGCAGACCCCACAGGCACTGTCCTGCTGCCATGGGAGACCCTCA
GCTCCCTGCTGCTTTGCATGCAGAGCTCCTCACAGAAGCAGGAGGAGGTCTGATGATGAAG
CTGAGAAACATCCCAGCGATGTGGGTGCCCCAACCCACCCCCAGTTCCCAGCACACCCCTC
ACATAGGGCCCGTTGCCCCTATTCCAACGTGTGCTGGCTGCCAGAACCACAGAATCACTGA
GATTGGAAGAGATCATTGAGTCCACCCATCTGTCATCGCCACCAACGGGGCTGGTGAGGGG
CTGTGGGATTTGGGGTGCAGCACCCCGTGGCTTGCAGTGAGGCAGCCCAAAGCACACCCAG
GCCCTGGTGCTGGCTCCAAAGGGCTTCTTCATGGAGACCATGCTCTGTGGGCTCCTCAGCT
CCTGTCCCATGGAGGTAGTGATGCAGTGACCCCCCCCAGGGGTGCAGAGCAGGGGGACCCC
AACACTCAGGGCTGCAGCACAGCTTCTGCCTTCCCTCGGCTCTGTGAGGGCTGCCAATACC
TCGTGGGGGTTCCTGTATTTATCCATTTTTTTATGCTGGGGGTCACCCCAAGCCGGGTTTG
GGCTTCCTTGGCCCTGAGAGCTGCCAAACCTTATCACTGTGACACACACATCCCCCCCCAC
CCGAGGGGCTGTGGGGGCTTCCCAGTAAGCACCAGTAGCAGAAAACAGATCCAAGTGGATC
TCAAGGGCTTTCCCAGCACAAAACGGGTGGGATGTAGTGTGTGTGTGGGGGGGGGGGGACA
CCGTCCCAAATTCCCAGGGGTTTTTCTGGAAATCTCTTCTATTTTCCAGACTTTCCGTGGC
TTTGTGACCCCGCTCAGCCCTGTGCAGCTTCCAGTCCCGTTTACACACGCAGCCCTTTGGG
GCTGGTGCCGACAGGAGCCCAATTTGGGGTTGTTTTACTGCA 
C.1.16 ZEB2 3’ Region with miR-130 (blue) and miR-138 (pink) target sites 
CCTGCTTGAAAAACACTGCTGTGTTAAGCTGTTCATGCACGTGCCTGATGCTTCCAGGAAG
CCTGTAGAGATGGACTAAAGGGGCAGTTCAGCCAAGACAGAATTAGATGGAGTTTGAGCTG
GGTATTGTTAAGAACTGCATTATGCAAAATTTTTGTACAGTGTTAAGGCCTAAAAACTGTG
TGGTTCAGAGACTAAATCCTGTGTTTAATAGCATTTATACTTTAAGCACAAACTAGTAAAT
TGTACGAATTGCACTCGACTTATATATCACTACAAACTTAAAAAAAAAAAAAAGATATGTC
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TAATTTATATTAATACATTTTAAAAAGGTGCCCGCACTACCATACATCAGTATTATTATTA
TTATTATTCCTTTTTAATTTAATGTGCTCGCACTACAGTACATCAGTATTATGACTCCTCT
GTACTTTCCTTTGCTATTCATACGTTTCCCAGTTTTCAGCCTAAGTAACCACACAATTTTA
GGCCTCGATTTTTATTTTATTTTTCTGTGAAGGAACTTGAAGTGATGCATGTGTGAATTTA
AGATACCGAAGTCTTAAAGTGACCTGGACGTGAAGGAAAAAGTAAGATGAGAAATAAAGAA
AGCCTTTGTAAGGTGGTTTTAAAAGCCTTATATGCAAACCTTTTAATCTGTGTGTTTCTGC
AAGTGCCATCCTTGTATAGTGTTAAGGGGGTAACGTGTGTTACCTTTGCACCAGCTTCAGT
GTTAAGCTCACCCTGTTCTTTGAAGCACCCATGTCAGTATTAGAAGAATAGGCAGCAGTTC
CTTAGTTTACATATGTTTGTGCAATTTTTTTCTGTACTTTTTTGTTCATTAATTTTGTCAG
TATTACACCAAACCTTTTTTTTTTTTTTTTTTCCAACAAAAATTTTTTGCATTCATTTAAT
TTTAGGTCAAATAACATTTTATTTATGTGGCTCATTTTATATTTCCTAATTTTATTTATTT
CATACTGTAGTGTACAGTATTATAGTTCTTCAATATATAGATATATTTTAGTAAAAAAGGA
ACATGACGTTGATCATTTGGGCAAATTTTACGTAAAGAGAAGAGCATTTATTGTGTTTTGG
AACATTAATTGTGAGATGGGATTTTTCAATTTTATTATTTTATTTTTGTTTTTTCCAATTA
CTGGAAATTCCAAATTTGGGAACTTTTGATACGATCTTGTGAAAACACTGTATTTTCGACT
GAAAATTCCACTTTCTTCATCTTGTTTTT 
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C.2 Mutated target sites 
The predicted target sites of genes were mutated as shown in red. In each case the 
predicted target site is shown above, with the mutant site below. 
C.2.1 ATG7 miR-138 mutant 
 
C.2.2 ATG7 miR-499 mutant 
 
C.2.3 ETS1 miR-499 mutant 
 
C.2.4 FZD8 miR-499 mutant 
 
C.2.5 LEF1 miR-130 mutant 
 
C.2.6 NFIB B miR-130 mutant 
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C.2.7 NFIB B miR-138 mutant 
 
C.2.8 NR3C1 miR-138 mutant 
 
C.2.9 PPP3CB miR-499 mutant 
 
C.2.10 PRKACB miR-130 mutant 
 
C.2.11 ROCK2 miR-130 mutant 
 
C.2.12 TCF12 miR-138 mutant 
 
C.2.13 ZEB2 miR-130 mutant 
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Appendix D  
D.1 Expression of FZD7 mRNA during early stages of chicken 
development 
 
Figure Apx D.1: FZD7 expression in the chick during early stages of development.  FZD7 mRNA whole 
mount in situ hybridization (WISH) of chick embryos at stage HH4 (A), HH4+ (B), HH5 (C) and HH8 (D). FZD7 
is expressed in the primitive streak posterior to Hensen’s node at HH4 and HH4+ (A, B), and also in the lateral 
plate mesoderm at HH5 (C). By HH8 FZD7 is expressed in the cardiogenic and paraxial mesoderm (D). 
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D.2 Exploration of miR-1 dysregulation during heart development 
 
Figure Apx D.2: AM1 and Scr206 injections into the HH11 and HH20 heart in ovo did not result in a 
developmental delay as observed when miR-1 was inhibited at HH14. A, B: Microinjection into the HH11 
chick heart with AM1 (A) or Scr206 control (B) did not appear to have a delaying effect on embryo maturation. 
However, due to the heart being positioned between the rest of the embryonic body and the yolk very few 
embryos were successfully injected with AM1 or Scr206 at this stage (N=3, n=3). C, D: Embryos injected with 
AM1 (C) or Scr206 (D) at HH20 developed at the same rate. 
216 
 
 
Figure Apx D.3: AM1 cardiac microinjections at HH20 did not result in developmental delay. AM1 
microinjection into HH20 hearts in ovo resulted in embryos that all appeared about the same stage, but with 3 
embryos (A - C) much smaller than the remaining seven embryos (D - J). All pictures show the entire field of 
view at 1.6x magnification and were taken immediately after harvest to confirm that antagomiR had 
successfully been injected into the embryonic heart. After injection embryos were left to develop for 24 hours. 
 
Figure Apx D.4: Scr206 microinjections at HH20. Three embryos (A – C) were found to be at a similar 
developmental stage to the majority (D – J) despite their smaller size, following Scr206 microinjections in 
HH20 hearts in ovo. Pictures were all taken at 1.6x magnification and the entire field of view is displayed. 
Embryos were left to develop for 24 hours after injection and the imaged immediately upon harvest to confirm 
successful injection of the FITC-labelled antagomiR. 
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Figure Apx D.5: AntagomiR-1 distribution in ovo. AntagomiR-1 is conjugated to a FITC tag and successful 
microinjection into the beating heart in ovo results in the wide distribution of the miR-1 inhibitor. All pictures 
show the entire field photographed at 3.2x magnification and therefore size differences seen in this grid 
between smaller embryos (A – H) and larger embryos (I, J) is not due to magnification differences and reflect 
actual size differences between embryos. 
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Figure Apx D.6: Developmental delay was observed following inhibition of miR-1 at HH14. AntagomiR-1 
microinjected embryos (Figure Apx D.2) were probed for Myh15 mRNA. The majority of miR-1-inhibited 
embryos were found to be at or younger than HH19. Embryos were injected in ovo at HH14 with 0.5mM 
antagomiR-1 and left to develop for 24 hours. Only two embryos (I, J) had reached the expected 
developmental stage (HH20) or older stages, with the remaining embryos developmentally delayed (A – H). 
 
 
Figure Apx D.7: Wide distribution of the control antagomiR, Scr206, was seen after in ovo 
microinjection into HH14 chick hearts. The antagomiR is FITC labelled and embryos were imaged 
immediately after harvesting to confirm successful injection. All pictures show the entire field photographed at 
3.2x magnification and almost all the embryos appear of a similar size (A – I) apart from one (J).  
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Figure Apx D.8: Scr206 injected embryos did not display developmental delay. MyH15 WISH was 
performed on control (Scr206) microinjected embryos (Figure Apx D.7). Almost all the embryos were found to 
be at or older than HH20 (A – I), apart from one (J). In ovo injections with 0.5mM control antagomiR (Scr206) 
were performed at HH14 and embryos were left to develop for 24 hours. 
 
 
Figure Apx D.9: Microinjection with FITC labelled antagomiR-206 (AM206) into HH14 hearts in ovo 
resulted in a distribution of the antagomiR throughout the embryos. Embryos were imaged as soon as 
they were harvested to confirm successful injection of AM206. The photographs were taken at 3.2x 
magnification and the entire field of view is displayed, giving an indication of relative embryo size. All embryos 
appear to be broadly similar in size (A – J). 
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Figure Apx D.10: Inhibition of miR-206 at HH14 did not result in developmental delay. AM206 
microinjected embryos (Figure Apx D.9) were probed for MyH15 mRNA. The embryos were all found to have 
reached at least HH20 (A – J). The 0.5mM AM206 antagomiR was microinjected into the heart at HH14 and 
embryos were incubated for a further 24 hours following this treatment.  
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Appendix E  
Table Apx E.1: Hamburger Hamilton stages of chicken embryo development. 
HH 
stage 
Age (hours) HH stage Age 
1 5 hrs 15 50 – 55 hrs 
2 6 – 7 hrs 16 51 – 56 hrs 
3 12 – 13 hrs 17 52 – 64 hrs 
4 18 – 19 hrs 18 3 days 
5 19 – 22 hrs 19 3 – 3.5 days 
6 23 – 25 hrs 20 3 – 3.5 days 
7 23 – 26 hrs 21 3.5 days 
8 26 – 29 hrs 22 3.5 – 4 days 
9 29 – 33 hrs 23 4 days 
10 33 – 38 hrs 24 4.5 days 
11 40 – 45 hrs 25 4.5 – 5 days 
12 45 – 49 hrs 26 5 days 
13 48 – 52 hrs 27 5 – 5.5 days 
14 50 – 53 hrs 28 5.5 – 6 days 
 
